pmid
stringlengths 5
8
| title
stringlengths 17
342
| abstract
stringlengths 1
4.53k
| all_entity_list
listlengths 2
73
| label
sequencelengths 1
80
| intra-sentence
sequencelengths 1
80
| head_gene_entity
listlengths 1
80
| tail_diease_entity
listlengths 1
80
| head_name
sequencelengths 1
80
| tail_name
sequencelengths 1
80
|
|---|---|---|---|---|---|---|---|---|---|
10319897 | Novel exon 3B proteolipid protein gene mutation causing late-onset spastic paraplegia type 2 with variable penetrance in female family members. | Spastic paraplegia type 2 (SPG2) is allelic to Pelizaeus-Merzbacher disease (PMD), with both conditions resulting from mutations in the proteolipid protein gene (PLP). We report an SPG2 family in which 3 male members and a heterozygous female member were affected with spastic paraplegia characterized by relatively late onset and mild clinical manifestations. A unique H147Y mutation in exon 3B of the PLP altering the proteolipid protein (PLP) but not the alternatively spliced DM20 isoform was identified as the cause of this distinct disease phenotype. Cellular pathology studies of SPG2 mutations offer an explanation for the paradoxical finding that mutations associated with the mildest phenotype in male family members also affect female carriers. | [
{
"begin_idx": "413",
"end_idx": "431",
"entity_id": "C536857",
"entity_type": "Disease",
"text_name": "spastic paraplegia"
},
{
"begin_idx": "67",
"end_idx": "92",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "spastic paraplegia type 2"
},
{
"begin_idx": "144",
"end_idx": "169",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "Spastic paraplegia type 2"
},
{
"begin_idx": "171",
"end_idx": "175",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "SPG2"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "SPG2"
},
{
"begin_idx": "731",
"end_idx": "735",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "SPG2"
},
{
"begin_idx": "191",
"end_idx": "219",
"entity_id": "D020371",
"entity_type": "Disease",
"text_name": "Pelizaeus-Merzbacher disease"
},
{
"begin_idx": "221",
"end_idx": "224",
"entity_id": "D020371",
"entity_type": "Disease",
"text_name": "PMD"
},
{
"begin_idx": "67",
"end_idx": "92",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "spastic paraplegia type 2"
},
{
"begin_idx": "144",
"end_idx": "169",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "Spastic paraplegia type 2"
},
{
"begin_idx": "171",
"end_idx": "175",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "SPG2"
},
{
"begin_idx": "306",
"end_idx": "309",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "PLP"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "SPG2"
},
{
"begin_idx": "547",
"end_idx": "550",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "PLP"
},
{
"begin_idx": "585",
"end_idx": "588",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "PLP"
},
{
"begin_idx": "731",
"end_idx": "735",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "SPG2"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
true,
true,
true
] | [
{
"begin_idx": "67",
"end_idx": "92",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "spastic paraplegia type 2"
},
{
"begin_idx": "67",
"end_idx": "92",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "spastic paraplegia type 2"
},
{
"begin_idx": "585",
"end_idx": "588",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "PLP"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "5354",
"entity_type": "Gene",
"text_name": "SPG2"
}
] | [
{
"begin_idx": "191",
"end_idx": "219",
"entity_id": "D020371",
"entity_type": "Disease",
"text_name": "Pelizaeus-Merzbacher disease"
},
{
"begin_idx": "413",
"end_idx": "431",
"entity_id": "C536857",
"entity_type": "Disease",
"text_name": "spastic paraplegia"
},
{
"begin_idx": "731",
"end_idx": "735",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "SPG2"
},
{
"begin_idx": "171",
"end_idx": "175",
"entity_id": "D015419",
"entity_type": "Disease",
"text_name": "SPG2"
}
] | [
"spastic paraplegia type 2",
"spastic paraplegia type 2",
"PLP",
"SPG2"
] | [
"Pelizaeus-Merzbacher disease",
"spastic paraplegia",
"SPG2",
"SPG2"
] |
10320038 | Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases. | A recent study has shown mutations in CLN2 gene, that encodes a novel lysosomal pepstatin-insensitive proteinase (LPIP), in the pathophysiology of late-infantile neuronal ceroid lipofuscinosis (LINCL). We have measured the LPIP activities in brains from various forms of human neuronal ceroid lipofuscinoses (NCL), canine ceroid lipofuscinosis and other neurodegenerative disorders with a highly sensitive assay using a tetrapeptide Gly-Phe-Phe-Leu-amino-trifluoromethyl coumarin (AFC) as substrate. Brain LPIP has a pH optimum of 3.5 and an apparent km of 100 microM for the crude enzyme. The enzyme activity is totally absent in LINCL patients. Pronounced increase in the LPIP activity was seen in patients suffering from infantile (INCL), juvenile (JNCL) and adult (ANCL) forms of neuronal ceroid lipofuscinoses. LPIP activity was also found to be increased about two-fold in Alzheimer's disease when compared with normal or age-matched controls, while in globoidal-cell leukodystrophy (Krabbe's disease) it was similar to the normal controls. Although mannose-6-phosphorylated LPIP is increased 13-fold in brains of patients with JNCL, this form of LPIP did not have any enzyme activity. The mechanism by which LPIP activities are increased in a wide range of neurodegenerative diseases is unknown, although neuronal loss, followed by gliosis are common characteristics of these diseases. | [
{
"begin_idx": "848",
"end_idx": "852",
"entity_id": "C564953",
"entity_type": "Disease",
"text_name": "INCL"
},
{
"begin_idx": "992",
"end_idx": "1011",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "1452",
"end_idx": "1459",
"entity_id": "D005911",
"entity_type": "Disease",
"text_name": "gliosis"
},
{
"begin_idx": "1072",
"end_idx": "1101",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "globoidal-cell leukodystrophy"
},
{
"begin_idx": "1103",
"end_idx": "1119",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "Krabbe's disease"
},
{
"begin_idx": "1425",
"end_idx": "1438",
"entity_id": "D009410",
"entity_type": "Disease",
"text_name": "neuronal loss"
},
{
"begin_idx": "260",
"end_idx": "305",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "late-infantile neuronal ceroid lipofuscinosis"
},
{
"begin_idx": "307",
"end_idx": "312",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "390",
"end_idx": "420",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "neuronal ceroid lipofuscinoses"
},
{
"begin_idx": "422",
"end_idx": "425",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "NCL"
},
{
"begin_idx": "428",
"end_idx": "456",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "canine ceroid lipofuscinosis"
},
{
"begin_idx": "744",
"end_idx": "749",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "865",
"end_idx": "869",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "JNCL"
},
{
"begin_idx": "897",
"end_idx": "927",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "neuronal ceroid lipofuscinoses"
},
{
"begin_idx": "1247",
"end_idx": "1251",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "JNCL"
},
{
"begin_idx": "85",
"end_idx": "111",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative diseases"
},
{
"begin_idx": "467",
"end_idx": "494",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative disorders"
},
{
"begin_idx": "1377",
"end_idx": "1403",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative diseases"
},
{
"begin_idx": "151",
"end_idx": "155",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
},
{
"begin_idx": "865",
"end_idx": "869",
"entity_id": "1201",
"entity_type": "Gene",
"text_name": "JNCL"
},
{
"begin_idx": "1247",
"end_idx": "1251",
"entity_id": "1201",
"entity_type": "Gene",
"text_name": "JNCL"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
false,
true,
true,
true
] | [
{
"begin_idx": "151",
"end_idx": "155",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
},
{
"begin_idx": "151",
"end_idx": "155",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
},
{
"begin_idx": "1247",
"end_idx": "1251",
"entity_id": "1201",
"entity_type": "Gene",
"text_name": "JNCL"
},
{
"begin_idx": "1247",
"end_idx": "1251",
"entity_id": "1201",
"entity_type": "Gene",
"text_name": "JNCL"
}
] | [
{
"begin_idx": "992",
"end_idx": "1011",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "260",
"end_idx": "305",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "late-infantile neuronal ceroid lipofuscinosis"
},
{
"begin_idx": "260",
"end_idx": "305",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "late-infantile neuronal ceroid lipofuscinosis"
},
{
"begin_idx": "744",
"end_idx": "749",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "LINCL"
}
] | [
"CLN2",
"CLN2",
"JNCL",
"JNCL"
] | [
"Alzheimer's disease",
"late-infantile neuronal ceroid lipofuscinosis",
"late-infantile neuronal ceroid lipofuscinosis",
"LINCL"
] |
10323252 | Changes at P183 of emerin weaken its protein-protein interactions resulting in X-linked Emery-Dreifuss muscular dystrophy. | Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked recessive muscular dystrophy characterized by early contractures of the elbows, Achilles tendons and spine, slowly progressive muscle wasting and weakness, and cardiomyopathy associated with cardiac conduction defects. The emerin gene has been mapped to Xq28 and encodes a 34-kDa serine-rich protein, emerin, which has been localized to the nuclear envelope in a wide variety of tissues, including skeletal and cardiac muscle. Mutations spanning the emerin gene have been identified in patients with EDMD. We present here the effect, on emerin protein expression, of two missense mutations identified in unrelated EDMD patients. These alterations predict the replacement of a proline residue at position 183 with either a histidine or a threonine. Biochemical analysis has demonstrated that the mobility and expression levels of the mutant forms of emerin are indistinguishable from that of wild-type emerin, but that they have weakened interactions with nuclear lamina components. In comparison with the usual EDMD phenotype, patients with P183 missense mutations have a later age at onset of first symptoms, elbow contractures, ankle contractures, upper limb weakness and lower limb weakness, but there is no difference for the age at onset of cardiac involvement. This is the first report of protein studies on patients with missense mutations resulting in the clinical features of EDMD. These studies demonstrate the importance of proline 183 for the proper structure/function of emerin. | [
{
"begin_idx": "370",
"end_idx": "396",
"entity_id": "C562490",
"entity_type": "Disease",
"text_name": "cardiac conduction defects"
},
{
"begin_idx": "231",
"end_idx": "285",
"entity_id": "D003286",
"entity_type": "Disease",
"text_name": "contractures of the elbows, Achilles tendons and spine"
},
{
"begin_idx": "1289",
"end_idx": "1307",
"entity_id": "D003286",
"entity_type": "Disease",
"text_name": "elbow contractures"
},
{
"begin_idx": "1309",
"end_idx": "1327",
"entity_id": "D003286",
"entity_type": "Disease",
"text_name": "ankle contractures"
},
{
"begin_idx": "306",
"end_idx": "320",
"entity_id": "D009133",
"entity_type": "Disease",
"text_name": "muscle wasting"
},
{
"begin_idx": "170",
"end_idx": "207",
"entity_id": "D009136",
"entity_type": "Disease",
"text_name": "X-linked recessive muscular dystrophy"
},
{
"begin_idx": "339",
"end_idx": "353",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "cardiomyopathy"
},
{
"begin_idx": "325",
"end_idx": "333",
"entity_id": "D018908",
"entity_type": "Disease",
"text_name": "weakness"
},
{
"begin_idx": "1329",
"end_idx": "1348",
"entity_id": "D018908",
"entity_type": "Disease",
"text_name": "upper limb weakness"
},
{
"begin_idx": "1353",
"end_idx": "1372",
"entity_id": "D018908",
"entity_type": "Disease",
"text_name": "lower limb weakness"
},
{
"begin_idx": "79",
"end_idx": "121",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "X-linked Emery-Dreifuss muscular dystrophy"
},
{
"begin_idx": "123",
"end_idx": "156",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "Emery-Dreifuss muscular dystrophy"
},
{
"begin_idx": "158",
"end_idx": "162",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "EDMD"
},
{
"begin_idx": "679",
"end_idx": "683",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "EDMD"
},
{
"begin_idx": "793",
"end_idx": "797",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "EDMD"
},
{
"begin_idx": "1190",
"end_idx": "1194",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "EDMD"
},
{
"begin_idx": "1564",
"end_idx": "1568",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "EDMD"
},
{
"begin_idx": "19",
"end_idx": "25",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "158",
"end_idx": "162",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "EDMD"
},
{
"begin_idx": "402",
"end_idx": "408",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "480",
"end_idx": "486",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "629",
"end_idx": "635",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "679",
"end_idx": "683",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "EDMD"
},
{
"begin_idx": "716",
"end_idx": "722",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "793",
"end_idx": "797",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "EDMD"
},
{
"begin_idx": "1028",
"end_idx": "1034",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "1080",
"end_idx": "1086",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "1190",
"end_idx": "1194",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "EDMD"
},
{
"begin_idx": "1564",
"end_idx": "1568",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "EDMD"
},
{
"begin_idx": "1663",
"end_idx": "1669",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "19",
"end_idx": "25",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "emerin"
},
{
"begin_idx": "1564",
"end_idx": "1568",
"entity_id": "2010",
"entity_type": "Gene",
"text_name": "EDMD"
}
] | [
{
"begin_idx": "79",
"end_idx": "121",
"entity_id": "D020389",
"entity_type": "Disease",
"text_name": "X-linked Emery-Dreifuss muscular dystrophy"
},
{
"begin_idx": "1353",
"end_idx": "1372",
"entity_id": "D018908",
"entity_type": "Disease",
"text_name": "lower limb weakness"
}
] | [
"emerin",
"EDMD"
] | [
"X-linked Emery-Dreifuss muscular dystrophy",
"lower limb weakness"
] |
10323455 | Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. | OBJECTIVE: To investigate whether the pathogenesis of rheumatoid arthritis (RA) is associated with the functional chemokine receptor CCR5, which is the primary CC chemokine receptor expressed by T cells in rheumatoid synovium, and its nonfunctional receptor, delta32CCR5, which is generated by the homozygous 32-basepair deletion (delta32) in the CCR5 gene. METHODS: The frequency of the CCR5 genotype was compared among 673 patients with RA, 113 patients with systemic lupus erythematosus (SLE), and 815 control subjects. The CCR5 genotype was studied by polymerase chain reaction amplification of the region flanking the delta32 deletion (delta32CCR5). RESULTS: Frequencies of the wild-type CCR5 alleles (0.929, 0.907, and 0.942, respectively) and delta32CCR5 alleles (0.071, 0.093, and 0.058, respectively) in controls, SLE patients, and RA patients did not differ significantly. However, none of the RA patients had the homozygous delta32CCR5 genotype, compared with a frequency of 0.009 in controls (P = 0.014 by Fisher's exact test; chi2 = 4.12 with Yates' correction, P = 0.042) and 0.027 in SLE patients (P = 0.003 by Fisher's exact test; chi2 = 11.63 with Yates' correction, P = 0.0006). CONCLUSION: The results suggest that the CCR5 receptor plays an important role in RA and may be a suitable target for therapy. | [
{
"begin_idx": "15",
"end_idx": "35",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "134",
"end_idx": "154",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "156",
"end_idx": "158",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "519",
"end_idx": "521",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "921",
"end_idx": "923",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "984",
"end_idx": "986",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "1359",
"end_idx": "1361",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "541",
"end_idx": "569",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "571",
"end_idx": "574",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "903",
"end_idx": "906",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1179",
"end_idx": "1182",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "74",
"end_idx": "78",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "194",
"end_idx": "217",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "chemokine receptor CCR5"
},
{
"begin_idx": "427",
"end_idx": "431",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "468",
"end_idx": "472",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "607",
"end_idx": "611",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "773",
"end_idx": "777",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "1318",
"end_idx": "1322",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "194",
"end_idx": "217",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "chemokine receptor CCR5"
},
{
"begin_idx": "194",
"end_idx": "217",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "chemokine receptor CCR5"
}
] | [
{
"begin_idx": "15",
"end_idx": "35",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "903",
"end_idx": "906",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
}
] | [
"chemokine receptor CCR5",
"chemokine receptor CCR5"
] | [
"rheumatoid arthritis",
"SLE"
] |
10329380 | A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. | The human dopamine D4 receptor gene (DRD4) is an important candidate gene for schizophrenia. We identified a novel -521C>T polymorphism in the 5'-promoter region of DRD4. A transient expression method revealed that the T allele of this polymorphism reduces the transcriptional efficiency by 40% compared with the C allele. This polymorphism is of interest because of reported elevation of D4-like sites and DRD4 mRNA in the postmortem schizophrenic brain. The C allele frequency was significantly higher in 252 Japanese schizophrenics (0.48) than in 269 Japanese controls (0.41) (p = 0. 02) [odds ratio = 1.35 (95% confidence interval 1.05 - 1.72)]. Although the association is weak and should be considered tentative until other studies replicate it, this polymorphism provides a tool with the potential to examine whether DRD4 is related to susceptibility to and neuroleptic response in schizophrenia. | [
{
"begin_idx": "85",
"end_idx": "98",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "178",
"end_idx": "191",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "535",
"end_idx": "548",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenic"
},
{
"begin_idx": "989",
"end_idx": "1002",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "49",
"end_idx": "53",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "110",
"end_idx": "130",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "dopamine D4 receptor"
},
{
"begin_idx": "137",
"end_idx": "141",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "265",
"end_idx": "269",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "507",
"end_idx": "511",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "924",
"end_idx": "928",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "110",
"end_idx": "130",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "dopamine D4 receptor"
}
] | [
{
"begin_idx": "85",
"end_idx": "98",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
}
] | [
"dopamine D4 receptor"
] | [
"schizophrenia"
] |
10330339 | Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. | The late-infantile form of neuronal ceroid lipofuscinosis (LINCL) is a progressive and ultimately fatal neurodegenerative disease of childhood. The defective gene in this hereditary disorder, CLN2, encodes a recently identified lysosomal pepstatin-insensitive acid protease. To better understand the molecular pathology of LINCL, we conducted a genetic survey of CLN2 in 74 LINCL families. In 14 patients, CLN2 protease activities were normal and no mutations were identified, suggesting other forms of NCL. Both pathogenic alleles were identified in 57 of the other 60 LINCL families studied. In total, 24 mutations were associated with LINCL, comprising six splice-junction mutations, 11 missense mutations, 3 nonsense mutations, 3 small deletions, and 1 single-nucleotide insertion. Two mutations were particularly common: an intronic G-->C transversion in the invariant AG of a 3' splice junction, found in 38 of 115 alleles, and a C-->T transition in 32 of 115 alleles, which prematurely terminates translation at amino acid 208 of 563. An Arg-->His substitution was identified, which was associated with a late age at onset and protracted clinical phenotype, in a number of other patients originally diagnosed with juvenile NCL. | [
{
"begin_idx": "211",
"end_idx": "216",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "344",
"end_idx": "348",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "CLN2"
},
{
"begin_idx": "475",
"end_idx": "480",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "515",
"end_idx": "519",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "CLN2"
},
{
"begin_idx": "526",
"end_idx": "531",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "558",
"end_idx": "562",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "CLN2"
},
{
"begin_idx": "722",
"end_idx": "727",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "790",
"end_idx": "795",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "57",
"end_idx": "102",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "late-infantile neuronal ceroid lipofuscinosis"
},
{
"begin_idx": "179",
"end_idx": "209",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "neuronal ceroid lipofuscinosis"
},
{
"begin_idx": "124",
"end_idx": "150",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal storage disorder"
},
{
"begin_idx": "256",
"end_idx": "281",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative disease"
},
{
"begin_idx": "323",
"end_idx": "342",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary disorder"
},
{
"begin_idx": "344",
"end_idx": "348",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
},
{
"begin_idx": "515",
"end_idx": "519",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
},
{
"begin_idx": "558",
"end_idx": "562",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "344",
"end_idx": "348",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
},
{
"begin_idx": "515",
"end_idx": "519",
"entity_id": "1200",
"entity_type": "Gene",
"text_name": "CLN2"
}
] | [
{
"begin_idx": "211",
"end_idx": "216",
"entity_id": "C566857",
"entity_type": "Disease",
"text_name": "LINCL"
},
{
"begin_idx": "179",
"end_idx": "209",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "neuronal ceroid lipofuscinosis"
}
] | [
"CLN2",
"CLN2"
] | [
"LINCL",
"neuronal ceroid lipofuscinosis"
] |
10330340 | Calpainopathy-a survey of mutations and polymorphisms. | Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal recessive disorder characterized mainly by symmetrical and selective atrophy of the proximal limb muscles. It derives from defects in the human CAPN3 gene, which encodes the skeletal muscle-specific member of the calpain family. This report represents a compilation of the mutations and variants identified so far in this gene. To date, 97 distinct pathogenic calpain 3 mutations have been identified (4 nonsense mutations, 32 deletions/insertions, 8 splice-site mutations, and 53 missense mutations), 56 of which have not been described previously, together with 12 polymorphisms and 5 nonclassified variants. The mutations are distributed along the entire length of the CAPN3 gene. Thus far, most mutations identified represent private variants, although particular mutations have been found more frequently. Knowledge of the mutation spectrum occurring in the CAPN3 gene may contribute significantly to structure/function and pathogenesis studies. It may also help in the design of efficient mutation-screening strategies for calpainopathies. | [
{
"begin_idx": "0",
"end_idx": "13",
"entity_id": "C535895",
"entity_type": "Disease",
"text_name": "Calpainopathy"
},
{
"begin_idx": "1148",
"end_idx": "1163",
"entity_id": "C535895",
"entity_type": "Disease",
"text_name": "calpainopathies"
},
{
"begin_idx": "76",
"end_idx": "93",
"entity_id": "D009136",
"entity_type": "Disease",
"text_name": "dystrophy type 2A"
},
{
"begin_idx": "109",
"end_idx": "137",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "55",
"end_idx": "66",
"entity_id": "D049288",
"entity_type": "Disease",
"text_name": "Limb-girdle"
},
{
"begin_idx": "263",
"end_idx": "268",
"entity_id": "825",
"entity_type": "Gene",
"text_name": "CAPN3"
},
{
"begin_idx": "479",
"end_idx": "488",
"entity_id": "825",
"entity_type": "Gene",
"text_name": "calpain 3"
},
{
"begin_idx": "791",
"end_idx": "796",
"entity_id": "825",
"entity_type": "Gene",
"text_name": "CAPN3"
},
{
"begin_idx": "982",
"end_idx": "987",
"entity_id": "825",
"entity_type": "Gene",
"text_name": "CAPN3"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "479",
"end_idx": "488",
"entity_id": "825",
"entity_type": "Gene",
"text_name": "calpain 3"
},
{
"begin_idx": "982",
"end_idx": "987",
"entity_id": "825",
"entity_type": "Gene",
"text_name": "CAPN3"
}
] | [
{
"begin_idx": "1148",
"end_idx": "1163",
"entity_id": "C535895",
"entity_type": "Disease",
"text_name": "calpainopathies"
},
{
"begin_idx": "55",
"end_idx": "66",
"entity_id": "D049288",
"entity_type": "Disease",
"text_name": "Limb-girdle"
}
] | [
"calpain 3",
"CAPN3"
] | [
"calpainopathies",
"Limb-girdle"
] |
10331110 | Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. | BACKGROUND: Obsessive-compulsive disorder (OCD) is a common and severe psychiatric illness that affects 1-3% of the population and presents a well-established co-morbidity with major depressive disorder (MDD). Twin and family studies have suggested a genetic component in the etiology of OCD, although the mode of inheritance is unknown. Pharmacotherapy of the disease implicates both serotonergic and dopaminergic pathways. Previously, guided by the 22q11 microdeletion-related psychiatric phenotype, we provided evidence for a sexually dimorphic association between OCD and the gene for catechol-O-methyltransferase (COMT). In this report, we use 110 nuclear OCD families to analyze the inheritance of variants of COMT and monoamine oxidase-A (MAOA), another gene modulating monoamine metabolism. METHODS: A sample of 110 nuclear OCD families was collected, and lifetime diagnoses were ascertained using the Diagnostic Interview for Genetic Studies (DIGS). DNA was genotyped for functional variants of the COMT and MAO genes, and allele inheritance was examined using the Transmission Disequilibrium Test (TDT) and Haplotype-based Haplotype Relative Risk (HHRR) test. RESULTS: We provide evidence supporting the previously reported sexually dimorphic association between low COMT enzymatic activity and OCD. We also provide evidence for a similar sexually dimorphic association between OCD and an allele of the MAOA gene, previously linked to high MAO-A enzymatic activity. In agreement with the well-established action of MAO-A inhibitors as antidepressants, this association is particularly marked among male OCD probands with co-morbid MDD, who represent more than 50% of our male OCD sample. CONCLUSIONS: Our analysis indicates that variants of two genes modulating monoamine metabolism contribute significantly to OCD susceptibility. Most importantly, an unexpected sexually dimorphic pattern of genetic susceptibility to OCD is revealed and suggests the possibility that profound gender differences in genetic predisposition may exist not only for other OCD susceptibility genes, but for an array of other psychiatric disorders as well. | [
{
"begin_idx": "217",
"end_idx": "228",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric"
},
{
"begin_idx": "625",
"end_idx": "636",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric"
},
{
"begin_idx": "2260",
"end_idx": "2281",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric disorders"
},
{
"begin_idx": "323",
"end_idx": "348",
"entity_id": "D003866",
"entity_type": "Disease",
"text_name": "major depressive disorder"
},
{
"begin_idx": "350",
"end_idx": "353",
"entity_id": "D003866",
"entity_type": "Disease",
"text_name": "MDD"
},
{
"begin_idx": "1787",
"end_idx": "1790",
"entity_id": "D003866",
"entity_type": "Disease",
"text_name": "MDD"
},
{
"begin_idx": "115",
"end_idx": "144",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "obsessive-compulsive disorder"
},
{
"begin_idx": "158",
"end_idx": "187",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "Obsessive-compulsive disorder"
},
{
"begin_idx": "189",
"end_idx": "192",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "434",
"end_idx": "437",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "714",
"end_idx": "717",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "807",
"end_idx": "810",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "978",
"end_idx": "981",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "1451",
"end_idx": "1454",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "1534",
"end_idx": "1537",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "1759",
"end_idx": "1762",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "1832",
"end_idx": "1835",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "1967",
"end_idx": "1970",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "2075",
"end_idx": "2078",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "2208",
"end_idx": "2211",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
},
{
"begin_idx": "72",
"end_idx": "76",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "735",
"end_idx": "763",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "765",
"end_idx": "769",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "862",
"end_idx": "866",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "1154",
"end_idx": "1158",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "1423",
"end_idx": "1427",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "81",
"end_idx": "85",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
},
{
"begin_idx": "871",
"end_idx": "890",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "monoamine oxidase-A"
},
{
"begin_idx": "892",
"end_idx": "896",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
},
{
"begin_idx": "1559",
"end_idx": "1563",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
},
{
"begin_idx": "1596",
"end_idx": "1601",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAO-A"
},
{
"begin_idx": "1671",
"end_idx": "1676",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAO-A"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "735",
"end_idx": "763",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "81",
"end_idx": "85",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
}
] | [
{
"begin_idx": "115",
"end_idx": "144",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "obsessive-compulsive disorder"
},
{
"begin_idx": "2075",
"end_idx": "2078",
"entity_id": "D009771",
"entity_type": "Disease",
"text_name": "OCD"
}
] | [
"catechol-O-methyltransferase",
"MAOA"
] | [
"obsessive-compulsive disorder",
"OCD"
] |
10331951 | Bestrophin gene mutations in patients with Best vitelliform macular dystrophy. | Best vitelliform macular dystrophy (VMD2) is an autosomal dominant dystrophy with a juvenile age of onset. Mutations in the Bestrophin gene were shown in patients affected with VMD2. In a mutation study, we made three new and interesting observations. First, we identified possible mutation hotspots within the gene, suggesting that particular regions of the protein have greater functional significance than others. Second, we described a 2-bp deletion in a part of the gene where mutations have not previously been reported; this mutation causes a frameshift and subsequent premature termination of the protein. Finally, we have evidence that some mutations are associated with variable expression of the disease, suggesting the involvement of other factors or genes in the disease phenotype. | [
{
"begin_idx": "127",
"end_idx": "155",
"entity_id": "D003317",
"entity_type": "Disease",
"text_name": "autosomal dominant dystrophy"
},
{
"begin_idx": "43",
"end_idx": "77",
"entity_id": "D057826",
"entity_type": "Disease",
"text_name": "Best vitelliform macular dystrophy"
},
{
"begin_idx": "79",
"end_idx": "113",
"entity_id": "D057826",
"entity_type": "Disease",
"text_name": "Best vitelliform macular dystrophy"
},
{
"begin_idx": "115",
"end_idx": "119",
"entity_id": "D057826",
"entity_type": "Disease",
"text_name": "VMD2"
},
{
"begin_idx": "256",
"end_idx": "260",
"entity_id": "D057826",
"entity_type": "Disease",
"text_name": "VMD2"
},
{
"begin_idx": "115",
"end_idx": "119",
"entity_id": "7439",
"entity_type": "Gene",
"text_name": "VMD2"
},
{
"begin_idx": "256",
"end_idx": "260",
"entity_id": "7439",
"entity_type": "Gene",
"text_name": "VMD2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "115",
"end_idx": "119",
"entity_id": "7439",
"entity_type": "Gene",
"text_name": "VMD2"
},
{
"begin_idx": "256",
"end_idx": "260",
"entity_id": "7439",
"entity_type": "Gene",
"text_name": "VMD2"
}
] | [
{
"begin_idx": "43",
"end_idx": "77",
"entity_id": "D057826",
"entity_type": "Disease",
"text_name": "Best vitelliform macular dystrophy"
},
{
"begin_idx": "127",
"end_idx": "155",
"entity_id": "D003317",
"entity_type": "Disease",
"text_name": "autosomal dominant dystrophy"
}
] | [
"VMD2",
"VMD2"
] | [
"Best vitelliform macular dystrophy",
"autosomal dominant dystrophy"
] |
10332047 | Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. | Psoriasis is an inflammatory skin disease of unknown origin, but with a clear genetic component. The strongest genetic association has been found with the major histocompatibility complex (MHC) region, and specifically between susceptibility to familial early onset psoriasis and human leukocyte antigen (HLA)-Cw6. The basis of this association of the HLA-C locus with disease pathogenesis is, however, not clear, and it is possible that other genes, or a combination of genes, in the HLA region are of functional importance. The MHC S gene is expressed specifically in keratinocyte differentiation and, being located 160 kb telomeric of HLA-C, is a plausible candidate gene. We analysed the allelic distribution of two polymorphisms in the MHC S gene (at +619 and +1243) in a case-control association study. We could confirm a significant association between psoriasis and HLA-Cw6 [odds ratio (OR) = 7.75]. No association was found between disease (or any subtypes) and the MHC S gene polymorphism at position +619, despite its close proximity to HLA-C and the strong linkage disequilibrium between the loci. However, a significant trend with the rarer allele at MHC S (+1243) and psoriasis was detected in the overall data set (OR = 2. 66; P = 2 [times] 10(-)9). This effect was most pronounced in the type 1a (early onset) psoriatics (OR = 3.43). Furthermore, homozygosity for the associated allele at MHC S (+1243) increased the risk of disease over that for carriage of HLA-Cw6 alone (OR = 9. 38), suggesting that allele 2 of MHC S (+1243) provides an additional risk in psoriasis susceptibility. The strong association found here, coupled with the biological involvement of the MHC S gene product corneodesmosin in skin physiology, implicates this locus (or a haplotype across HLA-C and MHC S ) in the impaired desquamation characteristic of psoriasis. | [
{
"begin_idx": "88",
"end_idx": "97",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "365",
"end_idx": "374",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "959",
"end_idx": "968",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "1281",
"end_idx": "1290",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "1675",
"end_idx": "1684",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "1947",
"end_idx": "1956",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "38",
"end_idx": "59",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "corneodesmosin (MHC S"
},
{
"begin_idx": "629",
"end_idx": "634",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "840",
"end_idx": "845",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "1074",
"end_idx": "1079",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "1263",
"end_idx": "1268",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "1504",
"end_idx": "1509",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "1630",
"end_idx": "1635",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "1783",
"end_idx": "1788",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "1802",
"end_idx": "1816",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "corneodesmosin"
},
{
"begin_idx": "1892",
"end_idx": "1897",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "MHC S"
},
{
"begin_idx": "385",
"end_idx": "412",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "leukocyte antigen (HLA)-Cw6"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "38",
"end_idx": "59",
"entity_id": "1041",
"entity_type": "Gene",
"text_name": "corneodesmosin (MHC S"
},
{
"begin_idx": "385",
"end_idx": "412",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "leukocyte antigen (HLA)-Cw6"
}
] | [
{
"begin_idx": "88",
"end_idx": "97",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "1947",
"end_idx": "1956",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
}
] | [
"corneodesmosin (MHC S",
"leukocyte antigen (HLA)-Cw6"
] | [
"psoriasis",
"psoriasis"
] |
10333056 | Variants in the sulphonylurea receptor gene: association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians. | AIMS/HYPOTHESIS: We have analysed to what extent two previously reported single nucleotide polymorphisms in the sulphonylurea receptor gene (SUR1) are associated with Type II (non-insulin-dependent) diabetes mellitus in The Netherlands. Furthermore, we estimated haplotype frequencies in control and diabetic populations, including data extracted from three other studies. METHODS: Subjects with Type II diabetes (n = 388) and normoglycaemic subjects (n = 336) were randomly selected from two population-based studies, the Hoorn and Rotterdam studies. DNA was typed for variants in exon 16 (-3c-->t variant in the splice acceptor site) and exon 18 (Thr759Thr, ACC-->ACT). RESULTS: The genotype frequencies in both populations were similar. We observed an association of the exon 16-3t variant with Type II diabetes (allele frequencies 0.41 % vs 0.48 % in NGT and Type II diabetes, respectively, p = 0.01). There was no association between Type II diabetes and the variant in exon 18 or the combination of both variants (p > 0.5). A strong linkage disequilibrium between the exon 16 and exon 18 variants was observed in the diabetic groups but not, or less pronounced, in the control groups from the different studies. Haplotype estimation shows that several different risk haplotypes exist in different Caucasian populations. CONCLUSION/INTERPRETATION: The exon 16-3t allele of the SUR1 gene is associated with Type II diabetes in the Netherlands. Based on estimated haplotype frequencies in different Caucasian populations we conclude that multiple haplotypes on the SUR1 gene seem to confer a risk for developing Type II diabetes in Caucasians. | [
{
"begin_idx": "435",
"end_idx": "443",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
},
{
"begin_idx": "1258",
"end_idx": "1266",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
},
{
"begin_idx": "88",
"end_idx": "113",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes mellitus"
},
{
"begin_idx": "302",
"end_idx": "351",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II (non-insulin-dependent) diabetes mellitus"
},
{
"begin_idx": "531",
"end_idx": "547",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "933",
"end_idx": "949",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "998",
"end_idx": "1014",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "1074",
"end_idx": "1090",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "1546",
"end_idx": "1562",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "1750",
"end_idx": "1766",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "276",
"end_idx": "280",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "1517",
"end_idx": "1521",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "1703",
"end_idx": "1707",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "276",
"end_idx": "280",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
},
{
"begin_idx": "1517",
"end_idx": "1521",
"entity_id": "6833",
"entity_type": "Gene",
"text_name": "SUR1"
}
] | [
{
"begin_idx": "302",
"end_idx": "351",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II (non-insulin-dependent) diabetes mellitus"
},
{
"begin_idx": "1258",
"end_idx": "1266",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
}
] | [
"SUR1",
"SUR1"
] | [
"Type II (non-insulin-dependent) diabetes mellitus",
"diabetic"
] |
10333087 | Missense variants in the human cholecystokinin type A receptor gene: no evidence for association with early-onset obesity. | [
{
"begin_idx": "114",
"end_idx": "121",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obesity"
},
{
"begin_idx": "31",
"end_idx": "62",
"entity_id": "886",
"entity_type": "Gene",
"text_name": "cholecystokinin type A receptor"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "31",
"end_idx": "62",
"entity_id": "886",
"entity_type": "Gene",
"text_name": "cholecystokinin type A receptor"
}
] | [
{
"begin_idx": "114",
"end_idx": "121",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obesity"
}
] | [
"cholecystokinin type A receptor"
] | [
"obesity"
] |
|
10335546 | Possible association between schizophrenia and a CAG repeat polymorphism in the spinocerebellar ataxia type 1 (SCA1) gene on human chromosome 6p23. | The gene for spinocerebellar ataxia type 1 (SCA1) is a potential candidate gene for schizophrenia because of previous positive linkage findings in this region (6p22-24), and because the reported correlation between SCA1 onset and the number of CAG repeats suggests anticipation. To test the involvement of this gene in the development of schizophrenia, we examined genotypes of the SCA1 CAG repeat polymorphism for 49 Caucasian patients with schizophrenia, and 88 Caucasian controls. We found a significant association between the frequencies of alleles of this gene and schizophrenia (chi 2 = 18.40, df = 8, P = 0.018). Among 13 alleles, one allele (31 trinucleotide repeat) was significantly more frequent in patients with schizophrenia than in controls (chi 2 = 9.57, df = 1, P = 0.002). This association was sustained after applying a Bonferroni correction for multiple testing (P = 0.05/13 = 0.004), and the chi-square results were shown to be robust through Monte Carlo simulation. We observed no allelic association with three flanking microsatellite markers (D6S288, D6S1605, and D6S337), suggesting that our result was not due to population stratification. Further studies of this locus are needed to confirm this finding, and to determine a potential role for this gene in the development of schizophrenia. | [
{
"begin_idx": "29",
"end_idx": "42",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "232",
"end_idx": "245",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "486",
"end_idx": "499",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "590",
"end_idx": "603",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "719",
"end_idx": "732",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "873",
"end_idx": "886",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "1450",
"end_idx": "1463",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "80",
"end_idx": "109",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "spinocerebellar ataxia type 1"
},
{
"begin_idx": "111",
"end_idx": "115",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "SCA1"
},
{
"begin_idx": "161",
"end_idx": "190",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "spinocerebellar ataxia type 1"
},
{
"begin_idx": "192",
"end_idx": "196",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "SCA1"
},
{
"begin_idx": "363",
"end_idx": "367",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "SCA1"
},
{
"begin_idx": "530",
"end_idx": "534",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "SCA1"
},
{
"begin_idx": "80",
"end_idx": "109",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "spinocerebellar ataxia type 1"
},
{
"begin_idx": "111",
"end_idx": "115",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "SCA1"
},
{
"begin_idx": "161",
"end_idx": "190",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "spinocerebellar ataxia type 1"
},
{
"begin_idx": "192",
"end_idx": "196",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "SCA1"
},
{
"begin_idx": "363",
"end_idx": "367",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "SCA1"
},
{
"begin_idx": "530",
"end_idx": "534",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "SCA1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "80",
"end_idx": "109",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "spinocerebellar ataxia type 1"
},
{
"begin_idx": "363",
"end_idx": "367",
"entity_id": "6310",
"entity_type": "Gene",
"text_name": "SCA1"
}
] | [
{
"begin_idx": "29",
"end_idx": "42",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "111",
"end_idx": "115",
"entity_id": "D017827",
"entity_type": "Disease",
"text_name": "SCA1"
}
] | [
"spinocerebellar ataxia type 1",
"SCA1"
] | [
"schizophrenia",
"SCA1"
] |
10338091 | Two novel mutations of the FMO3 gene in a proband with trimethylaminuria. | The mammalian flavin-containing monooxygenases catalyze the NADPH-dependent N-oxygenation of nucleophilic nitrogen-, sulfur-, and phosphorus-containing chemicals, drugs, and xenobiotics, including trimethylamine. The FMO3 gene encodes the dominant catalytically active isoform present in human liver. We have identified two missense mutations in the coding region of the gene in a proband with trimethylaminuria (TMA): M66I and R492W. Whereas two mutations (P153L, E305X) accounted for TMA in our eight unrelated previously documented Australian families of British origin, the present report is the first evidence of compound heterozygosity for two rare mutations in a proband with this disorder. This suggests that other rarer alleles, also causing TMA, will be found in the same populations. | [
{
"begin_idx": "55",
"end_idx": "72",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "trimethylaminuria"
},
{
"begin_idx": "468",
"end_idx": "485",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "trimethylaminuria"
},
{
"begin_idx": "487",
"end_idx": "490",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMA"
},
{
"begin_idx": "560",
"end_idx": "563",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMA"
},
{
"begin_idx": "825",
"end_idx": "828",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMA"
},
{
"begin_idx": "27",
"end_idx": "31",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
},
{
"begin_idx": "291",
"end_idx": "295",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "27",
"end_idx": "31",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
}
] | [
{
"begin_idx": "55",
"end_idx": "72",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "trimethylaminuria"
}
] | [
"FMO3"
] | [
"trimethylaminuria"
] |
10339581 | Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. | Hyaluronan (HA), a large glycosaminoglycan abundant in the extracellular matrix, is important in cell migration during embryonic development, cellular proliferation, and differentiation and has a structural role in connective tissues. The turnover of HA requires endoglycosidic breakdown by lysosomal hyaluronidase, and a congenital deficiency of hyaluronidase has been thought to be incompatible with life. However, a patient with a deficiency of serum hyaluronidase, now designated as mucopolysaccharidosis IX, was recently described. This patient had a surprisingly mild clinical phenotype, including notable periarticular soft tissue masses, mild short stature, an absence of neurological or visceral involvement, and histological and ultrastructural evidence of a lysosomal storage disease. To determine the molecular basis of mucopolysaccharidosis IX, we analyzed two candidate genes tandemly distributed on human chromosome 3p21.3 and encoding proteins with homology to a sperm protein with hyaluronidase activity. These genes, HYAL1 and HYAL2, encode two distinct lysosomal hyaluronidases with different substrate specificities. We identified two mutations in the HYAL1 alleles of the patient, a 1412G --> A mutation that introduces a nonconservative amino acid substitution (Glu268Lys) in a putative active site residue and a complex intragenic rearrangement, 1361del37ins14, that results in a premature termination codon. We further show that these two hyaluronidase genes, as well as a third recently discovered adjacent hyaluronidase gene, HYAL3, have markedly different tissue expression patterns, consistent with differing roles in HA metabolism. These data provide an explanation for the unexpectedly mild phenotype in mucopolysaccharidosis IX and predict the existence of other hyaluronidase deficiency disorders. | [
{
"begin_idx": "161",
"end_idx": "185",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis IX"
},
{
"begin_idx": "509",
"end_idx": "547",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "congenital deficiency of hyaluronidase"
},
{
"begin_idx": "674",
"end_idx": "698",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis IX"
},
{
"begin_idx": "1019",
"end_idx": "1043",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis IX"
},
{
"begin_idx": "1921",
"end_idx": "1945",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "mucopolysaccharidosis IX"
},
{
"begin_idx": "1981",
"end_idx": "2015",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "hyaluronidase deficiency disorders"
},
{
"begin_idx": "838",
"end_idx": "851",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
},
{
"begin_idx": "141",
"end_idx": "159",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal disorder"
},
{
"begin_idx": "956",
"end_idx": "981",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal storage disease"
},
{
"begin_idx": "13",
"end_idx": "18",
"entity_id": "3373",
"entity_type": "Gene",
"text_name": "HYAL1"
},
{
"begin_idx": "1222",
"end_idx": "1227",
"entity_id": "3373",
"entity_type": "Gene",
"text_name": "HYAL1"
},
{
"begin_idx": "1359",
"end_idx": "1364",
"entity_id": "3373",
"entity_type": "Gene",
"text_name": "HYAL1"
},
{
"begin_idx": "1739",
"end_idx": "1744",
"entity_id": "8372",
"entity_type": "Gene",
"text_name": "HYAL3"
},
{
"begin_idx": "478",
"end_idx": "501",
"entity_id": "8692",
"entity_type": "Gene",
"text_name": "lysosomal hyaluronidase"
},
{
"begin_idx": "1232",
"end_idx": "1237",
"entity_id": "8692",
"entity_type": "Gene",
"text_name": "HYAL2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "13",
"end_idx": "18",
"entity_id": "3373",
"entity_type": "Gene",
"text_name": "HYAL1"
},
{
"begin_idx": "13",
"end_idx": "18",
"entity_id": "3373",
"entity_type": "Gene",
"text_name": "HYAL1"
}
] | [
{
"begin_idx": "509",
"end_idx": "547",
"entity_id": "C563209",
"entity_type": "Disease",
"text_name": "congenital deficiency of hyaluronidase"
},
{
"begin_idx": "838",
"end_idx": "851",
"entity_id": "D006130",
"entity_type": "Disease",
"text_name": "short stature"
}
] | [
"HYAL1",
"HYAL1"
] | [
"congenital deficiency of hyaluronidase",
"short stature"
] |
10340396 | Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. | Prolactin (PRL) is a neuroendocrine hormone that influences immune and hematopoietic development. The mechanism of action of this hormone in vivo remains unclear; therefore, we assessed the effects of PRL on hematopoiesis in vivo and in vitro. Normal resting mice were treated with 0, 1, 10, or 100 microg of recombinant human prolactin (rhPRL) for 4 consecutive days and euthanized on the fifth day for analysis of myeloid and erythroid progenitors in the bone marrow and spleen. Both frequencies and absolute numbers of splenic colony-forming unit granulocyte-macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-e) were significantly increased in mice receiving rhPRL compared to the controls that had received saline only. Bone marrow cellularities were not significantly affected by any dose of rhPRL, but the absolute numbers and frequencies of bone marrow CFU-GM and BFU-e were augmented by rhPRL. These results suggest that rhPRL can promote hematopoiesis in vivo. Because rhPRL augments myeloid development in vivo, we examined the potential of the hormone to reverse the anemia and myelosuppression induced by azidothymidine (AZT). Mice were given rhPRL injections concurrent with 2.5 mg/mL AZT in drinking water. rhPRL partially restored hematocrits in the animals after 2 weeks of treatment and increased CFU-GM and BFU-e in both spleens and bone marrow. The experiments with AZT and rhPRL support the conclusion that the hormone increases myeloid and erythroid progenitor numbers in vivo, and they suggest that the hormone is clinically useful in reversing myelosuppression induced by AZT or other myeloablative therapies. | [
{
"begin_idx": "1212",
"end_idx": "1218",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "1438",
"end_idx": "1454",
"entity_id": "D007960",
"entity_type": "Disease",
"text_name": "increased CFU-GM"
},
{
"begin_idx": "0",
"end_idx": "9",
"entity_id": "5617",
"entity_type": "Gene",
"text_name": "Prolactin"
},
{
"begin_idx": "126",
"end_idx": "135",
"entity_id": "5617",
"entity_type": "Gene",
"text_name": "Prolactin"
},
{
"begin_idx": "453",
"end_idx": "462",
"entity_id": "5617",
"entity_type": "Gene",
"text_name": "prolactin"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "0",
"end_idx": "9",
"entity_id": "5617",
"entity_type": "Gene",
"text_name": "Prolactin"
},
{
"begin_idx": "126",
"end_idx": "135",
"entity_id": "5617",
"entity_type": "Gene",
"text_name": "Prolactin"
}
] | [
{
"begin_idx": "1212",
"end_idx": "1218",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "1438",
"end_idx": "1454",
"entity_id": "D007960",
"entity_type": "Disease",
"text_name": "increased CFU-GM"
}
] | [
"Prolactin",
"Prolactin"
] | [
"anemia",
"increased CFU-GM"
] |
10341858 | Novel DAX1 mutations in X-linked adrenal hypoplasia congenita and hypogonadotrophic hypogonadism. | OBJECTIVE: Mutations of the DAX1 gene (Dosage-sensitive sex reversal-Adrenal hypoplasia congenita critical region on the X chromosome gene 1), which encodes a novel orphan nuclear receptor, have been identified in patients with X-linked adrenal hypoplasia congenita (AHC) and hypogonadotrophic hypogonadism (HHG). We have investigated two kindreds with AHC and HHG for DAX1 mutations. METHODS: Two kindreds with five affected males, four carrier females and four unaffected males were investigated. The gonadotrophin deficiency in three of the boys was observed to be partial until mid-puberty. DAX1 mutations in the entire 1413 bp coding region were sought by DNA sequence analysis. RESULTS: Two DAX1 mutations, situated within exon 1, were detected. These consisted of an insertional mutation at codon 183 that led to a frameshift and a premature Stop at codon 184, and a missense mutation Leu278Pro that involved a highly conserved leucine residue within the proposed ligand binding domain. Co-segregation of these mutations with the disease in each family, and their absence from 107 alleles in 73 (39 males and 34 females) unrelated control individuals, was demonstrated by allele specific oligonucleotide hybridization (ASO) analysis for the insertional mutation, and by Ban I restriction endonuclease analysis for the missense mutation. CONCLUSIONS: Two novel DAX1 mutations have been detected in two families with adrenal hypoplasia and hypogonadotrophic hypogonadism. The finding of partial gonadotrophin deficiency in the affected males from these families is notable and an early recognition of such a possibility in a patient, which may be facilitated by DAX1 mutational analysis, may help to prevent the sequelae of delayed androgen replacement therapy. | [
{
"begin_idx": "137",
"end_idx": "195",
"entity_id": "C535601",
"entity_type": "Disease",
"text_name": "Dosage-sensitive sex reversal-Adrenal hypoplasia congenita"
},
{
"begin_idx": "24",
"end_idx": "61",
"entity_id": "C536757",
"entity_type": "Disease",
"text_name": "X-linked adrenal hypoplasia congenita"
},
{
"begin_idx": "326",
"end_idx": "363",
"entity_id": "C536757",
"entity_type": "Disease",
"text_name": "X-linked adrenal hypoplasia congenita"
},
{
"begin_idx": "365",
"end_idx": "368",
"entity_id": "C536757",
"entity_type": "Disease",
"text_name": "AHC"
},
{
"begin_idx": "451",
"end_idx": "454",
"entity_id": "C536757",
"entity_type": "Disease",
"text_name": "AHC"
},
{
"begin_idx": "601",
"end_idx": "625",
"entity_id": "C536961",
"entity_type": "Disease",
"text_name": "gonadotrophin deficiency"
},
{
"begin_idx": "1598",
"end_idx": "1622",
"entity_id": "C536961",
"entity_type": "Disease",
"text_name": "gonadotrophin deficiency"
},
{
"begin_idx": "1520",
"end_idx": "1538",
"entity_id": "C538429",
"entity_type": "Disease",
"text_name": "adrenal hypoplasia"
},
{
"begin_idx": "66",
"end_idx": "96",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "hypogonadotrophic hypogonadism"
},
{
"begin_idx": "374",
"end_idx": "404",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "hypogonadotrophic hypogonadism"
},
{
"begin_idx": "406",
"end_idx": "409",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "HHG"
},
{
"begin_idx": "459",
"end_idx": "462",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "HHG"
},
{
"begin_idx": "1543",
"end_idx": "1573",
"entity_id": "D007006",
"entity_type": "Disease",
"text_name": "hypogonadotrophic hypogonadism"
},
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "126",
"end_idx": "130",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "467",
"end_idx": "471",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "693",
"end_idx": "697",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "795",
"end_idx": "799",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "1465",
"end_idx": "1469",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "1765",
"end_idx": "1769",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
},
{
"begin_idx": "1765",
"end_idx": "1769",
"entity_id": "190",
"entity_type": "Gene",
"text_name": "DAX1"
}
] | [
{
"begin_idx": "24",
"end_idx": "61",
"entity_id": "C536757",
"entity_type": "Disease",
"text_name": "X-linked adrenal hypoplasia congenita"
},
{
"begin_idx": "1520",
"end_idx": "1538",
"entity_id": "C538429",
"entity_type": "Disease",
"text_name": "adrenal hypoplasia"
}
] | [
"DAX1",
"DAX1"
] | [
"X-linked adrenal hypoplasia congenita",
"adrenal hypoplasia"
] |
10343282 | Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. | Six types of human 17beta-hydroxysteroid dehydrogenases catalyzing the conversion of estrogens and androgens at position C17 have been identified so far. The peroxisomal 17beta-hydroxysteroid dehydrogenase type 4 (17beta-HSD 4, gene name HSD17B4) catalyzes the oxidation of estradiol with high preference over the reduction of estrone. The highest levels of 17beta-HSD 4 mRNA transcription and specific activity are found in liver and kidney followed by ovary and testes. A 3 kb mRNA codes for an 80 kDa (737 amino acids) protein featuring domains which are not present in the other 17beta-HSDs. The N-terminal domain of 17beta-HSD 4 reveals only 25% amino acid similarity with the other types of 17beta-HSDs. The 80 kDa protein is N-terminally cleaved to a 32 kDa enzymatically active fragment. Both the 80 kDa and the N-terminal 32 kDa (amino acids 1-323) protein are able to perform the dehydrogenase reaction not only with steroids at the C17 position but also with D-3-hydroxyacyl-coenzyme A (CoA). The enzyme is not active with L-stereoisomers. The central part of the 80 kDa protein (amino acids 324-596) catalyzes the 2-enoyl-acyl-CoA hydratase reaction with high efficiency. The C-terminal part of the 80 kDa protein (amino acids 597-737) facilitates the transfer of 7-dehydrocholesterol and phosphatidylcholine between membranes in vitro. The HSD17B4 gene is stimulated by progesterone, and ligands of PPARalpha (peroxisomal proliferator activated receptor alpha) such as clofibrate, and is down-regulated by phorbol esters. Mutations in the HSD17B4 lead to a fatal form of Zellweger syndrome. | [
{
"begin_idx": "624",
"end_idx": "640",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovary and testes"
},
{
"begin_idx": "150",
"end_idx": "168",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "1754",
"end_idx": "1772",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "340",
"end_idx": "396",
"entity_id": "26869",
"entity_type": "Gene",
"text_name": "17beta-hydroxysteroid dehydrogenase type 4 (17beta-HSD 4"
},
{
"begin_idx": "23",
"end_idx": "30",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "HSD17B4"
},
{
"begin_idx": "45",
"end_idx": "82",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "17beta-hydroxysteroid dehydrogenase 4"
},
{
"begin_idx": "408",
"end_idx": "415",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "HSD17B4"
},
{
"begin_idx": "528",
"end_idx": "540",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "17beta-HSD 4"
},
{
"begin_idx": "791",
"end_idx": "803",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "17beta-HSD 4"
},
{
"begin_idx": "1523",
"end_idx": "1530",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "HSD17B4"
},
{
"begin_idx": "1722",
"end_idx": "1729",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "HSD17B4"
},
{
"begin_idx": "1582",
"end_idx": "1591",
"entity_id": "5465",
"entity_type": "Gene",
"text_name": "PPARalpha"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "45",
"end_idx": "82",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "17beta-hydroxysteroid dehydrogenase 4"
},
{
"begin_idx": "1722",
"end_idx": "1729",
"entity_id": "3295",
"entity_type": "Gene",
"text_name": "HSD17B4"
}
] | [
{
"begin_idx": "150",
"end_idx": "168",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "624",
"end_idx": "640",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovary and testes"
}
] | [
"17beta-hydroxysteroid dehydrogenase 4",
"HSD17B4"
] | [
"Zellweger syndrome",
"ovary and testes"
] |
10344739 | Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. | The vitamin D3 receptor gene (VDR) contains a TaqI RFLP that is associated with increased VDR mRNA stability, increased serum levels of 1alpha,25-dihydroxyvitamin D3 (1,25-D3), and decreased risk for prostate cancer. Determination of the TaqI genotype, in a group of young women with breast cancer (n = 111; age, <37 years) and a control population (n = 130), revealed no overall association to risk for breast cancer. However, patients without TaqI site (TT genotype) showed a significantly increased risk for lymph node metastasis (relative risk, 1.8, 95% confidence interval, 1.3-2.6). Furthermore, a tendency toward an increased survival was found among estrogen receptor-positive, tamoxifen-treated patients who were homozygous for the TaqI site (P = 0.075). We conclude that polymorphism in the VDR gene may influence tumor progression and tamoxifen treatment response in early-onset breast carcinomas. | [
{
"begin_idx": "15",
"end_idx": "28",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "104",
"end_idx": "117",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "Breast Cancer"
},
{
"begin_idx": "409",
"end_idx": "422",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "529",
"end_idx": "542",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1015",
"end_idx": "1032",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast carcinomas"
},
{
"begin_idx": "647",
"end_idx": "657",
"entity_id": "D009362",
"entity_type": "Disease",
"text_name": "metastasis"
},
{
"begin_idx": "949",
"end_idx": "954",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "325",
"end_idx": "340",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "48",
"end_idx": "66",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "155",
"end_idx": "158",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "215",
"end_idx": "218",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "926",
"end_idx": "929",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "48",
"end_idx": "66",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "215",
"end_idx": "218",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
}
] | [
{
"begin_idx": "1015",
"end_idx": "1032",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast carcinomas"
},
{
"begin_idx": "647",
"end_idx": "657",
"entity_id": "D009362",
"entity_type": "Disease",
"text_name": "metastasis"
}
] | [
"vitamin D receptor",
"VDR"
] | [
"breast carcinomas",
"metastasis"
] |
10351920 | The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. | The renin angiotensin system plays an important role in the development of pulmonary artery remodeling and right ventricular hypertrophy in hypoxia-induced pulmonary hypertension as may occur in patients with COPD. Several polymorphisms of genes encoding for components of the renin angiotensin system such as the M235T polymorphism in the angiotensinogen gene, the 287-base-pair insertion (I)/deletion (D) polymorphism at intron 16 of the ACE gene, and the A1166C polymorphism in the angiotensin II type 1 receptor gene have been associated with an increased risk of cardiovascular diseases. With respect to the pulmonary circulation, only limited data exist on possible associations between polymorphisms of these genes and pulmonary hypertension and/or right ventricular hypertrophy. The objective of the present study was to investigate a possible relationship between polymorphisms of the renin angiotensin system and electrocardiographic evidence of right ventricular hypertrophy in patients with COPD. We therefore determined the angiotensinogen (M235T), angiotensin converting enzyme (I/D), and angiotensin II type 1 receptor (A1166C) genotypes in 87 patients with severe COPD and correlated these data with electrocardiographic parameters of right ventricular hypertrophy. Thirty-one patients (36%) of 87 patients with COPD showed electrocardiographic evidence of right ventricular hypertrophy. In the male, but not in the female, subgroup, the angiotensin-converting enzyme DD genotype was negatively associated with electrocardiographic evidence of right ventricular hypertrophy (male: chi2 = 3.8, p = 0.05; female: chi2 = 0.05, p = 0.82). We found no associations between the investigated polymorphisms in the angiotensinogen and angiotensin II type 1 receptor genes and electrocardiographic evidence of right ventricular hypertrophy. | [
{
"begin_idx": "4",
"end_idx": "6",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1663",
"end_idx": "1665",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "319",
"end_idx": "326",
"entity_id": "D000860",
"entity_type": "Disease",
"text_name": "hypoxia"
},
{
"begin_idx": "747",
"end_idx": "770",
"entity_id": "D002318",
"entity_type": "Disease",
"text_name": "cardiovascular diseases"
},
{
"begin_idx": "335",
"end_idx": "357",
"entity_id": "D006976",
"entity_type": "Disease",
"text_name": "pulmonary hypertension"
},
{
"begin_idx": "905",
"end_idx": "927",
"entity_id": "D006976",
"entity_type": "Disease",
"text_name": "pulmonary hypertension"
},
{
"begin_idx": "88",
"end_idx": "117",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "286",
"end_idx": "315",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "935",
"end_idx": "964",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "1135",
"end_idx": "1164",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "1430",
"end_idx": "1459",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "1552",
"end_idx": "1581",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "1739",
"end_idx": "1768",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "1995",
"end_idx": "2024",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
},
{
"begin_idx": "140",
"end_idx": "177",
"entity_id": "D029424",
"entity_type": "Disease",
"text_name": "chronic obstructive pulmonary disease"
},
{
"begin_idx": "388",
"end_idx": "392",
"entity_id": "D029424",
"entity_type": "Disease",
"text_name": "COPD"
},
{
"begin_idx": "1182",
"end_idx": "1186",
"entity_id": "D029424",
"entity_type": "Disease",
"text_name": "COPD"
},
{
"begin_idx": "1359",
"end_idx": "1363",
"entity_id": "D029424",
"entity_type": "Disease",
"text_name": "COPD"
},
{
"begin_idx": "1507",
"end_idx": "1511",
"entity_id": "D029424",
"entity_type": "Disease",
"text_name": "COPD"
},
{
"begin_idx": "254",
"end_idx": "281",
"entity_id": "D066253",
"entity_type": "Disease",
"text_name": "pulmonary artery remodeling"
},
{
"begin_idx": "23",
"end_idx": "52",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "619",
"end_idx": "622",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "1241",
"end_idx": "1270",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "519",
"end_idx": "534",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
},
{
"begin_idx": "1216",
"end_idx": "1231",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
},
{
"begin_idx": "1901",
"end_idx": "1916",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
},
{
"begin_idx": "664",
"end_idx": "694",
"entity_id": "185",
"entity_type": "Gene",
"text_name": "angiotensin II type 1 receptor"
},
{
"begin_idx": "1282",
"end_idx": "1312",
"entity_id": "185",
"entity_type": "Gene",
"text_name": "angiotensin II type 1 receptor"
},
{
"begin_idx": "1921",
"end_idx": "1951",
"entity_id": "185",
"entity_type": "Gene",
"text_name": "angiotensin II type 1 receptor"
},
{
"begin_idx": "183",
"end_idx": "188",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
},
{
"begin_idx": "456",
"end_idx": "461",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
},
{
"begin_idx": "1073",
"end_idx": "1078",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "23",
"end_idx": "52",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "1073",
"end_idx": "1078",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
}
] | [
{
"begin_idx": "140",
"end_idx": "177",
"entity_id": "D029424",
"entity_type": "Disease",
"text_name": "chronic obstructive pulmonary disease"
},
{
"begin_idx": "1135",
"end_idx": "1164",
"entity_id": "D017380",
"entity_type": "Disease",
"text_name": "right ventricular hypertrophy"
}
] | [
"angiotensin converting enzyme",
"renin"
] | [
"chronic obstructive pulmonary disease",
"right ventricular hypertrophy"
] |
10353779 | Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTEN. | Cowden syndrome (CS) and Bannayan-Zonana syndrome (BZS) are two hamartoma syndromes with distinct phenotypic features. Although partial clinical overlap exists between CS and BZS, they are considered to be separate entities. PTEN has been identified as the susceptibility gene for both disorders, suggesting allelism. We have identified a germline mutation, R335X, in PTEN in a family consisting of two female members with the phenotypic findings of CS and two male members with the phenotypic findings of BZS. To our knowledge, this is the first report that shows the presence of separate subjects with CS and with BZS in a single family associated with a single germline PTEN mutation. | [
{
"begin_idx": "196",
"end_idx": "215",
"entity_id": "D006222",
"entity_type": "Disease",
"text_name": "hamartoma syndromes"
},
{
"begin_idx": "23",
"end_idx": "38",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Cowden syndrome"
},
{
"begin_idx": "43",
"end_idx": "67",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Bannayan-Zonana syndrome"
},
{
"begin_idx": "132",
"end_idx": "147",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Cowden syndrome"
},
{
"begin_idx": "149",
"end_idx": "151",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CS"
},
{
"begin_idx": "157",
"end_idx": "181",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Bannayan-Zonana syndrome"
},
{
"begin_idx": "183",
"end_idx": "186",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "BZS"
},
{
"begin_idx": "300",
"end_idx": "302",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CS"
},
{
"begin_idx": "307",
"end_idx": "310",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "BZS"
},
{
"begin_idx": "582",
"end_idx": "584",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CS"
},
{
"begin_idx": "638",
"end_idx": "641",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "BZS"
},
{
"begin_idx": "736",
"end_idx": "738",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "CS"
},
{
"begin_idx": "748",
"end_idx": "751",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "BZS"
},
{
"begin_idx": "126",
"end_idx": "130",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "357",
"end_idx": "361",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "500",
"end_idx": "504",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "805",
"end_idx": "809",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "126",
"end_idx": "130",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
},
{
"begin_idx": "357",
"end_idx": "361",
"entity_id": "5728",
"entity_type": "Gene",
"text_name": "PTEN"
}
] | [
{
"begin_idx": "43",
"end_idx": "67",
"entity_id": "D006223",
"entity_type": "Disease",
"text_name": "Bannayan-Zonana syndrome"
},
{
"begin_idx": "196",
"end_idx": "215",
"entity_id": "D006222",
"entity_type": "Disease",
"text_name": "hamartoma syndromes"
}
] | [
"PTEN",
"PTEN"
] | [
"Bannayan-Zonana syndrome",
"hamartoma syndromes"
] |
10357835 | Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. | The apoAI-CIII-AIV gene cluster, located on chromosome 11, contributes to the phenotype of familial combined hyperlipidemia (FCH), but this contribution is genetically complex. Combinations of haplotypes, based on three restriction enzyme polymorphisms: XmnI and MspI sites, 5' of the start site of the apoA-I gene and SstI polymorphism in the 3' untranslated region of exon 4 of the apoC-III gene, were analyzed to characterize their effect on the expression of severe hyperlipidemia. An epistatic interaction was demonstrated: the S2 allele on one haplotype was synergistic in its hyperlipidemic effect to the X2M2 allele on the other haplotype (Dallinga-Thie, G. M. et al. J. Clin. Invest. 1997. 99: 953-961). In the present study two additional polymorphic sites in the insulin response element (IRE) of the apoC-III gene promoter, T-455C: FokI restriction site, C-482T: MspI restriction site, were studied in 34 FCH pedigrees including 34 probands, 220 hyperlipidemic relatives, 300 normolipidemic relatives, and 236 spouses. In contrast to the earlier data for the other polymorphisms in this gene cluster (XmnI, MspI/AI, and SstI), there were no differences in frequency distributions of the T-455C and the C-482T variants between probands, hyperlipidemic and normolipidemic relatives and spouses. No significant associations between plasma lipid traits and DNA variants in the IRE were observed. Analysis of combinations of haplotypes based on the five polymorphisms in the gene cluster provided further evidence for a dominant role of the SstI polymorphism as a major susceptibility locus in FCH. The inclusion of the IRE markers did not improve genetic informativeness, nor our understanding of the observed synergistic relationship associated with the high risk combination of haplotypes in FCH families. | [
{
"begin_idx": "622",
"end_idx": "636",
"entity_id": "D006949",
"entity_type": "Disease",
"text_name": "hyperlipidemia"
},
{
"begin_idx": "118",
"end_idx": "150",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "familial combined hyperlipidemia"
},
{
"begin_idx": "243",
"end_idx": "275",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "familial combined hyperlipidemia"
},
{
"begin_idx": "277",
"end_idx": "280",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "FCH"
},
{
"begin_idx": "1069",
"end_idx": "1072",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "FCH"
},
{
"begin_idx": "1753",
"end_idx": "1756",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "FCH"
},
{
"begin_idx": "1954",
"end_idx": "1957",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "FCH"
},
{
"begin_idx": "455",
"end_idx": "461",
"entity_id": "335",
"entity_type": "Gene",
"text_name": "apoA-I"
},
{
"begin_idx": "90",
"end_idx": "98",
"entity_id": "345",
"entity_type": "Gene",
"text_name": "apoC-III"
},
{
"begin_idx": "536",
"end_idx": "544",
"entity_id": "345",
"entity_type": "Gene",
"text_name": "apoC-III"
},
{
"begin_idx": "964",
"end_idx": "972",
"entity_id": "345",
"entity_type": "Gene",
"text_name": "apoC-III"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "90",
"end_idx": "98",
"entity_id": "345",
"entity_type": "Gene",
"text_name": "apoC-III"
},
{
"begin_idx": "536",
"end_idx": "544",
"entity_id": "345",
"entity_type": "Gene",
"text_name": "apoC-III"
}
] | [
{
"begin_idx": "118",
"end_idx": "150",
"entity_id": "D006950",
"entity_type": "Disease",
"text_name": "familial combined hyperlipidemia"
},
{
"begin_idx": "622",
"end_idx": "636",
"entity_id": "D006949",
"entity_type": "Disease",
"text_name": "hyperlipidemia"
}
] | [
"apoC-III",
"apoC-III"
] | [
"familial combined hyperlipidemia",
"hyperlipidemia"
] |
10359483 | Association of a regulatory polymorphism in the promoter region of the monoamine oxidase A gene with antisocial alcoholism. | We analyzed a novel functional 30-bp repeat polymorphism in the promoter region of the X-chromosomal monoamine oxidase A gene (MAOA) to test whether length variation of the repeat polymorphism contributes to variation in the individual vulnerability to antisocial behavior and liability to alcohol dependence. The repeat number (3-5) of the MAOA polymorphism was assessed in 488 male subjects of German descent, a sample comprising 185 psychiatrically screened control subjects and 303 alcohol-dependent subjects including 59 alcoholics with antisocial personality disorder. The frequency of the low-activity 3-repeat allele was significantly increased in 59 antisocial alcoholics compared to 185 control subjects (51 vs. 35%; P = 0.031) and to 244 alcoholics without antisocial personality disorder (51 vs. 32%; P = 0.008), respectively. We found no significant difference in the frequency of the 3-repeat allele between 244 alcoholics without an antisocial personality disorder and the control subjects. Our findings suggest that the low-activity 3-repeat allele of the MAOA promoter polymorphism confers increased susceptibility to antisocial behavior rather than alcohol dependence per se in alcohol-dependent males. | [
{
"begin_idx": "112",
"end_idx": "122",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "414",
"end_idx": "432",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "1291",
"end_idx": "1309",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "666",
"end_idx": "697",
"entity_id": "D000987",
"entity_type": "Disease",
"text_name": "antisocial personality disorder"
},
{
"begin_idx": "892",
"end_idx": "923",
"entity_id": "D000987",
"entity_type": "Disease",
"text_name": "antisocial personality disorder"
},
{
"begin_idx": "1072",
"end_idx": "1103",
"entity_id": "D000987",
"entity_type": "Disease",
"text_name": "antisocial personality disorder"
},
{
"begin_idx": "377",
"end_idx": "396",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behavior"
},
{
"begin_idx": "1259",
"end_idx": "1278",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behavior"
},
{
"begin_idx": "71",
"end_idx": "90",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "monoamine oxidase A"
},
{
"begin_idx": "225",
"end_idx": "244",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "monoamine oxidase A"
},
{
"begin_idx": "251",
"end_idx": "255",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
},
{
"begin_idx": "465",
"end_idx": "469",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
},
{
"begin_idx": "1196",
"end_idx": "1200",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "71",
"end_idx": "90",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "monoamine oxidase A"
},
{
"begin_idx": "1196",
"end_idx": "1200",
"entity_id": "4128",
"entity_type": "Gene",
"text_name": "MAOA"
}
] | [
{
"begin_idx": "414",
"end_idx": "432",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "377",
"end_idx": "396",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behavior"
}
] | [
"monoamine oxidase A",
"MAOA"
] | [
"alcohol dependence",
"antisocial behavior"
] |
10362030 | The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. | Angiotensin-converting enzyme (ACE) genotypes may reflect prognosis in sarcoidosis. They were determined in 59 Finnish sarcoidosis patients and 70 healthy control subjects. The prognosis of the sarcoidosis patients was determined after follow-up for 1, 2, 3, 5 and >5 yrs and classified as good (normal chest radiograph and lung function, no signs of extrapulmonary disease activity within 2 yrs from diagnosis), intermediate (neither good nor poor) or poor (persisting unstable pulmonary infiltrates, vital capacity and diffusing capacity of the lung for carbon monoxide <50% predicted and/or extrapulmonary disease activity after >5 yrs follow-up). The DD, ID and II genotypes were found in 31 and 27%, in 54 and 49%, and in 15 and 24% of patients and control subjects respectively. The odds ratio (DD+ID to II) was 1.45 (95% confidence interval 0.60-3.49). The D alelle was found more often in patients (58%) and in control subjects (51%) than the I allele but the difference was not statistically significant. Statistically significantly more patients with the DD genotype had a poor prognosis compared with patients with II homozygotes and ID heterozygotes. Among 11 patients with L fgren's syndrome (bilateral hilar lymphadenopathy and erythema nodosum), four had the DD genotype. Three of these patients had a prognosis despite presenting a clinical picture usually associated with a good prognosis. The angiotensin-converting enzyme genotype may be a prognostic marker in sarcoidosis and larger studies are warranted to define its clinical utility. | [
{
"begin_idx": "34",
"end_idx": "36",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "764",
"end_idx": "766",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "910",
"end_idx": "912",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1174",
"end_idx": "1176",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1384",
"end_idx": "1386",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "768",
"end_idx": "770",
"entity_id": "C537985",
"entity_type": "Disease",
"text_name": "ID"
},
{
"begin_idx": "913",
"end_idx": "915",
"entity_id": "C537985",
"entity_type": "Disease",
"text_name": "ID"
},
{
"begin_idx": "1254",
"end_idx": "1256",
"entity_id": "C537985",
"entity_type": "Disease",
"text_name": "ID"
},
{
"begin_idx": "1352",
"end_idx": "1368",
"entity_id": "D004893",
"entity_type": "Disease",
"text_name": "erythema nodosum"
},
{
"begin_idx": "1316",
"end_idx": "1347",
"entity_id": "D008206",
"entity_type": "Disease",
"text_name": "bilateral hilar lymphadenopathy"
},
{
"begin_idx": "87",
"end_idx": "98",
"entity_id": "D012507",
"entity_type": "Disease",
"text_name": "sarcoidosis"
},
{
"begin_idx": "180",
"end_idx": "191",
"entity_id": "D012507",
"entity_type": "Disease",
"text_name": "sarcoidosis"
},
{
"begin_idx": "228",
"end_idx": "239",
"entity_id": "D012507",
"entity_type": "Disease",
"text_name": "sarcoidosis"
},
{
"begin_idx": "303",
"end_idx": "314",
"entity_id": "D012507",
"entity_type": "Disease",
"text_name": "sarcoidosis"
},
{
"begin_idx": "1590",
"end_idx": "1601",
"entity_id": "D012507",
"entity_type": "Disease",
"text_name": "sarcoidosis"
},
{
"begin_idx": "1295",
"end_idx": "1314",
"entity_id": "D014899",
"entity_type": "Disease",
"text_name": "L fgren's syndrome"
},
{
"begin_idx": "140",
"end_idx": "143",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "140",
"end_idx": "143",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "140",
"end_idx": "143",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
}
] | [
{
"begin_idx": "87",
"end_idx": "98",
"entity_id": "D012507",
"entity_type": "Disease",
"text_name": "sarcoidosis"
},
{
"begin_idx": "768",
"end_idx": "770",
"entity_id": "C537985",
"entity_type": "Disease",
"text_name": "ID"
}
] | [
"ACE",
"ACE"
] | [
"sarcoidosis",
"ID"
] |
10364516 | X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. | Dyskeratosis congenita is a rare inherited bone marrow-failure syndrome characterized by abnormal skin pigmentation, nail dystrophy, and mucosal leukoplakia. More than 80% of patients develop bone-marrow failure, and this is the major cause of premature death. The X-linked form of the disease (MIM 305000) has been shown to be caused by mutations in the DKC1 gene. The gene encodes a 514-amino-acid protein, dyskerin, that is homologous to Saccharomyces cerevisiae Cbf5p and rat Nap57 proteins. By analogy to the homologues in other species, dyskerin is predicted to be a nucleolar protein with a role in both the biogenesis of ribosomes and, in particular, the pseudouridylation of rRNA precursors. We have determined the genomic structure of the DKC1 gene; it consists of 15 exons spanning a region of 15 kb. This has enabled us to screen for mutations in the genomic DNA, by using SSCP analysis. Mutations were detected in 21 of 37 additional families with dyskeratosis congenita that were analyzed. These mutations consisted of 11 different single-nucleotide substitutions, which resulted in 10 missense mutations and 1 putative splicing mutation within an intron. The missense change A353V was observed in 10 different families and was shown to be a recurring de novo event. Two polymorphisms were also detected, one of which resulted in the insertion of an additional lysine in the carboxy-terminal polylysine domain. It is apparent that X-linked dyskeratosis congenita is predominantly caused by missense mutations; the precise effect on the function of dyskerin remains to be determined. | [
{
"begin_idx": "144",
"end_idx": "167",
"entity_id": "C536572",
"entity_type": "Disease",
"text_name": "marrow-failure syndrome"
},
{
"begin_idx": "340",
"end_idx": "355",
"entity_id": "D003643",
"entity_type": "Disease",
"text_name": "premature death"
},
{
"begin_idx": "213",
"end_idx": "252",
"entity_id": "D009260",
"entity_type": "Disease",
"text_name": "nail dystrophy, and mucosal leukoplakia"
},
{
"begin_idx": "194",
"end_idx": "211",
"entity_id": "D010859",
"entity_type": "Disease",
"text_name": "skin pigmentation"
},
{
"begin_idx": "0",
"end_idx": "31",
"entity_id": "D019871",
"entity_type": "Disease",
"text_name": "X-linked dyskeratosis congenita"
},
{
"begin_idx": "96",
"end_idx": "118",
"entity_id": "D019871",
"entity_type": "Disease",
"text_name": "Dyskeratosis congenita"
},
{
"begin_idx": "1057",
"end_idx": "1079",
"entity_id": "D019871",
"entity_type": "Disease",
"text_name": "dyskeratosis congenita"
},
{
"begin_idx": "1541",
"end_idx": "1572",
"entity_id": "D019871",
"entity_type": "Disease",
"text_name": "X-linked dyskeratosis congenita"
},
{
"begin_idx": "361",
"end_idx": "389",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked form of the disease"
},
{
"begin_idx": "85",
"end_idx": "89",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "DKC1"
},
{
"begin_idx": "451",
"end_idx": "455",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "DKC1"
},
{
"begin_idx": "562",
"end_idx": "567",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "Cbf5p"
},
{
"begin_idx": "576",
"end_idx": "581",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "Nap57"
},
{
"begin_idx": "845",
"end_idx": "849",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "DKC1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "562",
"end_idx": "567",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "Cbf5p"
},
{
"begin_idx": "562",
"end_idx": "567",
"entity_id": "1736",
"entity_type": "Gene",
"text_name": "Cbf5p"
}
] | [
{
"begin_idx": "0",
"end_idx": "31",
"entity_id": "D019871",
"entity_type": "Disease",
"text_name": "X-linked dyskeratosis congenita"
},
{
"begin_idx": "213",
"end_idx": "252",
"entity_id": "D009260",
"entity_type": "Disease",
"text_name": "nail dystrophy, and mucosal leukoplakia"
}
] | [
"Cbf5p",
"Cbf5p"
] | [
"X-linked dyskeratosis congenita",
"nail dystrophy, and mucosal leukoplakia"
] |
10364917 | CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. | BACKGROUND: The aetiology of systemic lupus erythematosus (SLE) is still unknown. In several cases, however, chemicals or drugs were identified as aetiological agents and associations with certain phenotypes of drug metabolising enzymes have been reported. The purpose of this study was to discover if there is an association between CYP2C19 polymorphism and susceptibility to SLE. METHODS: Racemic mephenytoin (100 mg orally) was given to healthy volunteers (n = 161) and SLE patients (n = 37) and then S-mephenytoin and R-mephenytoin were determined in eight hour urine samples. A 10 ml blood sample was obtained from healthy volunteers (n = 80) and SLE patients (n = 69) for genotypic assay. Each blood sample was tested for the detection of CYP2C19*1 and CYP2C19*2 (formerly wt and m1 respectively) by oligonucleotide ligation assay. RESULTS: The ratio of S/R-mephenytoin ranged from < 0.1 to 1.293 in healthy subjects and from < 0.1 to 1.067 in SLE patients. PM phenotype was observed in 2 of 37 patients with idiopathic SLE (5.4%) and 6 of 161 healthy subjects (3.7%). There were no significant differences in the frequency of PM phenotypes between the groups (Fisher's exact test, p = 0.64) or in the frequency distribution profiles of ratios of S-mephenytoin to R-mephenytoin. No significant differences in distribution of overall genotypes and in allele frequencies were observed between the two groups. No significant relation was found between clinical features and the overall genotype. CONCLUSION: The results of this study indicate that CYP2C19 genotype does not represent a genetic predisposition in idiopathic SLE patients. | [
{
"begin_idx": "64",
"end_idx": "103",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "idiopathic systemic lupus erythematosus"
},
{
"begin_idx": "134",
"end_idx": "162",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "164",
"end_idx": "167",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "482",
"end_idx": "485",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "578",
"end_idx": "581",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "757",
"end_idx": "760",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1055",
"end_idx": "1058",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1131",
"end_idx": "1134",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1731",
"end_idx": "1734",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "0",
"end_idx": "7",
"entity_id": "1557",
"entity_type": "Gene",
"text_name": "CYP2C19"
},
{
"begin_idx": "439",
"end_idx": "446",
"entity_id": "1557",
"entity_type": "Gene",
"text_name": "CYP2C19"
},
{
"begin_idx": "850",
"end_idx": "857",
"entity_id": "1557",
"entity_type": "Gene",
"text_name": "CYP2C19"
},
{
"begin_idx": "864",
"end_idx": "871",
"entity_id": "1557",
"entity_type": "Gene",
"text_name": "CYP2C19"
},
{
"begin_idx": "1656",
"end_idx": "1663",
"entity_id": "1557",
"entity_type": "Gene",
"text_name": "CYP2C19"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "0",
"end_idx": "7",
"entity_id": "1557",
"entity_type": "Gene",
"text_name": "CYP2C19"
}
] | [
{
"begin_idx": "64",
"end_idx": "103",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "idiopathic systemic lupus erythematosus"
}
] | [
"CYP2C19"
] | [
"idiopathic systemic lupus erythematosus"
] |
10365914 | Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. | Insulin-like growth factor-1 (IGF-1) and its receptor are believed to play an important role in mitogenesis and neoplastic transformation. The purpose of this study was to further examine the role of IGF-1 during tumor promotion in mouse skin. HK1.IGF1 transgenic mice, which overexpress IGF-1 in epidermis via the human keratin 1 promoter, were previously shown to be hypersensitive to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA). We examined these mice for their sensitivity to diverse classes of tumor-promoting agents. HK1.IGF-1 transgenic mice initiated with 7,12-dimethylbenz[a]anthracene were more sensitive to treatment with a wide variety of tumor promoters, including chrysarobin, okadaic acid, and benzoyl peroxide, which resulted in more rapid development of tumors and a dramatic increase in the number of tumors per mouse compared with corresponding non-transgenic mice treated with the same compounds. Histological analyses of skin from HK1.IGF-1 mice treated with various tumor promoters revealed that these mice were also more sensitive to the induction of epidermal hyperplasia and cell proliferation. Analysis of the IGF-1 receptor (IGF-1r) and epidermal growth factor (EGFr) in the epidermis of TPA-treated HK1.IGF-1 transgenic and non-transgenic mice revealed that both receptors were activated (hyperphosphorylated on tyrosine residues), and the level of activation was higher in transgenic mice. The mechanism for the increased sensitivity of HK1.IGF-1 mice to tumor promoters may involve cooperation between the IGF-1r and EGFr signaling pathways. Our data suggest that IGF-1r signaling may play an important role in the process of tumor promotion by diverse classes of tumor promoters. | [
{
"begin_idx": "1255",
"end_idx": "1276",
"entity_id": "D006965",
"entity_type": "Disease",
"text_name": "epidermal hyperplasia"
},
{
"begin_idx": "371",
"end_idx": "376",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "680",
"end_idx": "685",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "832",
"end_idx": "837",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "952",
"end_idx": "958",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
},
{
"begin_idx": "1000",
"end_idx": "1006",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
},
{
"begin_idx": "1169",
"end_idx": "1174",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1665",
"end_idx": "1670",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1837",
"end_idx": "1842",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1875",
"end_idx": "1880",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "41",
"end_idx": "51",
"entity_id": "D012878",
"entity_type": "Disease",
"text_name": "skin tumor"
},
{
"begin_idx": "545",
"end_idx": "555",
"entity_id": "D012878",
"entity_type": "Disease",
"text_name": "skin tumor"
},
{
"begin_idx": "402",
"end_idx": "405",
"entity_id": "3098",
"entity_type": "Gene",
"text_name": "HK1"
},
{
"begin_idx": "704",
"end_idx": "707",
"entity_id": "3098",
"entity_type": "Gene",
"text_name": "HK1"
},
{
"begin_idx": "1133",
"end_idx": "1136",
"entity_id": "3098",
"entity_type": "Gene",
"text_name": "HK1"
},
{
"begin_idx": "1408",
"end_idx": "1411",
"entity_id": "3098",
"entity_type": "Gene",
"text_name": "HK1"
},
{
"begin_idx": "1647",
"end_idx": "1650",
"entity_id": "3098",
"entity_type": "Gene",
"text_name": "HK1"
},
{
"begin_idx": "83",
"end_idx": "111",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "insulin-like growth factor-1"
},
{
"begin_idx": "158",
"end_idx": "186",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "Insulin-like growth factor-1"
},
{
"begin_idx": "188",
"end_idx": "193",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "358",
"end_idx": "363",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "406",
"end_idx": "410",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF1"
},
{
"begin_idx": "446",
"end_idx": "451",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "708",
"end_idx": "713",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "1137",
"end_idx": "1142",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "1412",
"end_idx": "1417",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "1651",
"end_idx": "1656",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-1"
},
{
"begin_idx": "1317",
"end_idx": "1331",
"entity_id": "3480",
"entity_type": "Gene",
"text_name": "IGF-1 receptor"
},
{
"begin_idx": "1333",
"end_idx": "1339",
"entity_id": "3480",
"entity_type": "Gene",
"text_name": "IGF-1r"
},
{
"begin_idx": "1717",
"end_idx": "1723",
"entity_id": "3480",
"entity_type": "Gene",
"text_name": "IGF-1r"
},
{
"begin_idx": "1775",
"end_idx": "1781",
"entity_id": "3480",
"entity_type": "Gene",
"text_name": "IGF-1r"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "1317",
"end_idx": "1331",
"entity_id": "3480",
"entity_type": "Gene",
"text_name": "IGF-1 receptor"
},
{
"begin_idx": "83",
"end_idx": "111",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "insulin-like growth factor-1"
}
] | [
{
"begin_idx": "41",
"end_idx": "51",
"entity_id": "D012878",
"entity_type": "Disease",
"text_name": "skin tumor"
},
{
"begin_idx": "1169",
"end_idx": "1174",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
}
] | [
"IGF-1 receptor",
"insulin-like growth factor-1"
] | [
"skin tumor",
"tumor"
] |
10366111 | Polymorphism of beta2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. | OBJECTIVE: To determine the frequency of mutations in the phospholipid binding domain of beta2-glycoprotein I (beta2GPI) in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS), and to analyze the clinical correlations of such mutations with thromboembolic complications. METHODS: Exons 7 and 8 of beta2GPI, which encode for its fifth domain, were amplified by polymerase chain reaction, and the presence of mutations was determined by restriction digestion and single-strand conformation polymorphism analysis. A clinical correlation with these mutations and the presence of antiphospholipid antibodies (aPL), lupus anticoagulant (LAC), anti-beta2GPI antibody, and the development of thromboembolic complications was performed using chi-square and Fisher's exact tests. RESULTS: From a total of 143 patients studied, we found that 5.6% were heterozygous for the mutation at exon 7 (codon 306), and 7.7% were heterozygous for the mutation at exon 8 (codon 316). No homozygous subjects were found for either mutation. No significant correlation between these mutations and the presence of aPL, LAC, or anti-beta2GPI antibodies was found. In patients with SLE (n = 95), 4 of 6 patients with exon 8 mutation had thrombosis, compared with 22 of 82 patients without the mutation (P = 0.043). CONCLUSION: The prevalence of mutations in the fifth domain of beta2GPI in these patients with SLE and/or APS were similar to those previously reported for the general population. Heterozygosity for either mutation does not influence the incidence of aPL, but in patients with SLE, the mutation at exon 8 may predispose to thrombosis as an independent factor. | [
{
"begin_idx": "782",
"end_idx": "801",
"entity_id": "C531622",
"entity_type": "Disease",
"text_name": "lupus anticoagulant"
},
{
"begin_idx": "803",
"end_idx": "806",
"entity_id": "C531622",
"entity_type": "Disease",
"text_name": "LAC"
},
{
"begin_idx": "1264",
"end_idx": "1267",
"entity_id": "C531622",
"entity_type": "Disease",
"text_name": "LAC"
},
{
"begin_idx": "76",
"end_idx": "104",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "274",
"end_idx": "341",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome"
},
{
"begin_idx": "1325",
"end_idx": "1328",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1553",
"end_idx": "1556",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1735",
"end_idx": "1738",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "413",
"end_idx": "427",
"entity_id": "D013923",
"entity_type": "Disease",
"text_name": "thromboembolic"
},
{
"begin_idx": "856",
"end_idx": "870",
"entity_id": "D013923",
"entity_type": "Disease",
"text_name": "thromboembolic"
},
{
"begin_idx": "1380",
"end_idx": "1390",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "1781",
"end_idx": "1791",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "109",
"end_idx": "134",
"entity_id": "D016736",
"entity_type": "Disease",
"text_name": "antiphospholipid syndrome"
},
{
"begin_idx": "343",
"end_idx": "346",
"entity_id": "D016736",
"entity_type": "Disease",
"text_name": "APS"
},
{
"begin_idx": "1564",
"end_idx": "1567",
"entity_id": "D016736",
"entity_type": "Disease",
"text_name": "APS"
},
{
"begin_idx": "16",
"end_idx": "36",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2-glycoprotein I"
},
{
"begin_idx": "225",
"end_idx": "245",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2-glycoprotein I"
},
{
"begin_idx": "247",
"end_idx": "255",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2GPI"
},
{
"begin_idx": "469",
"end_idx": "477",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2GPI"
},
{
"begin_idx": "814",
"end_idx": "822",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2GPI"
},
{
"begin_idx": "1277",
"end_idx": "1285",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2GPI"
},
{
"begin_idx": "1521",
"end_idx": "1529",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2GPI"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "16",
"end_idx": "36",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2-glycoprotein I"
},
{
"begin_idx": "1521",
"end_idx": "1529",
"entity_id": "350",
"entity_type": "Gene",
"text_name": "beta2GPI"
}
] | [
{
"begin_idx": "274",
"end_idx": "341",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome"
},
{
"begin_idx": "1564",
"end_idx": "1567",
"entity_id": "D016736",
"entity_type": "Disease",
"text_name": "APS"
}
] | [
"beta2-glycoprotein I",
"beta2GPI"
] | [
"systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome",
"APS"
] |
10366128 | Association of interleukin-4 receptor and interleukin-4 promoter gene polymorphisms with systemic lupus erythematosus. | [
{
"begin_idx": "89",
"end_idx": "117",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "42",
"end_idx": "55",
"entity_id": "3565",
"entity_type": "Gene",
"text_name": "interleukin-4"
},
{
"begin_idx": "15",
"end_idx": "37",
"entity_id": "3566",
"entity_type": "Gene",
"text_name": "interleukin-4 receptor"
}
] | [
"Yes",
"Yes"
] | [
true,
true
] | [
{
"begin_idx": "15",
"end_idx": "37",
"entity_id": "3566",
"entity_type": "Gene",
"text_name": "interleukin-4 receptor"
},
{
"begin_idx": "42",
"end_idx": "55",
"entity_id": "3565",
"entity_type": "Gene",
"text_name": "interleukin-4"
}
] | [
{
"begin_idx": "89",
"end_idx": "117",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "89",
"end_idx": "117",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
}
] | [
"interleukin-4 receptor",
"interleukin-4"
] | [
"systemic lupus erythematosus",
"systemic lupus erythematosus"
] |
|
10369261 | Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. | Hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM 260920) is an autosomal recessive disorder characterized by recurrent episodes of fever associated with lymphadenopathy, arthralgia, gastrointestinal dismay and skin rash. Diagnostic hallmark of HIDS is a constitutively elevated level of serum immunoglobulin D (IgD), although patients have been reported with normal IgD levels. To determine the underlying defect in HIDS, we analysed urine of several patients and discovered increased concentrations of mevalonic acid during severe episodes of fever, but not between crises. Subsequent analysis of cells from four unrelated HIDS patients revealed reduced activities of mevalonate kinase (MK; encoded by the gene MVK), a key enzyme of isoprenoid biosynthesis. Sequence analysis of MVK cDNA from the patients identified three different mutations, one of which was common to all patients. Expression of the mutant cDNAs in Escherichia coli showed that all three mutations affect the activity of the encoded proteins. Moreover, immunoblot analysis demonstrated a deficiency of MK protein in patient fibroblasts, indicating a protein-destabilizing effect of the mutations. | [
{
"begin_idx": "335",
"end_idx": "344",
"entity_id": "D005076",
"entity_type": "Disease",
"text_name": "skin rash"
},
{
"begin_idx": "83",
"end_idx": "106",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "periodic fever syndrome"
},
{
"begin_idx": "139",
"end_idx": "162",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "periodic fever syndrome"
},
{
"begin_idx": "256",
"end_idx": "261",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "fever"
},
{
"begin_idx": "669",
"end_idx": "674",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "fever"
},
{
"begin_idx": "307",
"end_idx": "330",
"entity_id": "D005767",
"entity_type": "Disease",
"text_name": "gastrointestinal dismay"
},
{
"begin_idx": "278",
"end_idx": "293",
"entity_id": "D008206",
"entity_type": "Disease",
"text_name": "lymphadenopathy"
},
{
"begin_idx": "295",
"end_idx": "305",
"entity_id": "D018771",
"entity_type": "Disease",
"text_name": "arthralgia"
},
{
"begin_idx": "188",
"end_idx": "216",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "164",
"end_idx": "168",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "369",
"end_idx": "373",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "541",
"end_idx": "545",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "749",
"end_idx": "753",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "1184",
"end_idx": "1200",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "deficiency of MK"
},
{
"begin_idx": "13",
"end_idx": "16",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
},
{
"begin_idx": "27",
"end_idx": "44",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "794",
"end_idx": "811",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "813",
"end_idx": "815",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MK"
},
{
"begin_idx": "837",
"end_idx": "840",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
},
{
"begin_idx": "905",
"end_idx": "908",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
},
{
"begin_idx": "1198",
"end_idx": "1200",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MK"
}
] | [
"Yes",
"Yes",
"Yes",
"No",
"No",
"No"
] | [
false,
false,
true,
true,
false,
true
] | [
{
"begin_idx": "27",
"end_idx": "44",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "27",
"end_idx": "44",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "27",
"end_idx": "44",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "837",
"end_idx": "840",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
},
{
"begin_idx": "905",
"end_idx": "908",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
},
{
"begin_idx": "27",
"end_idx": "44",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
}
] | [
{
"begin_idx": "335",
"end_idx": "344",
"entity_id": "D005076",
"entity_type": "Disease",
"text_name": "skin rash"
},
{
"begin_idx": "295",
"end_idx": "305",
"entity_id": "D018771",
"entity_type": "Disease",
"text_name": "arthralgia"
},
{
"begin_idx": "83",
"end_idx": "106",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "periodic fever syndrome"
},
{
"begin_idx": "164",
"end_idx": "168",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "188",
"end_idx": "216",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "541",
"end_idx": "545",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
}
] | [
"mevalonate kinase",
"mevalonate kinase",
"mevalonate kinase",
"MVK",
"MVK",
"mevalonate kinase"
] | [
"skin rash",
"arthralgia",
"periodic fever syndrome",
"HIDS",
"autosomal recessive disorder",
"HIDS"
] |
10369262 | Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. | Hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM 260920) is a rare, apparently monogenic, autosomal recessive disorder characterized by recurrent episodes of fever accompanied with lymphadenopathy, abdominal distress, joint involvement and skin lesions. All patients have high serum IgD values (>100 U/ml) and HIDS 'attacks' are associated with an intense acute phase reaction whose exact pathophysiology remains obscure. Two other hereditary febrile disorders have been described. Familial Mediterranean fever (MIM 249100) is an autosomal recessive disorder affecting mostly populations from the Mediterranean basin and is caused by mutations in the gene MEFV (refs 5,6). Familial Hibernian fever (MIM 142680), also known as autosomal dominant familial recurrent fever, is caused by missense mutations in the gene encoding type I tumour necrosis factor receptor. Here we perform a genome-wide search to map the HIDS gene. Haplotype analysis placed the gene at 12q24 between D12S330 and D12S79. We identified the gene MVK, encoding mevalonate kinase (MK, ATP:mevalonate 5-phosphotransferase; EC 2.7.1.36), as a candidate gene. We characterized 3 missense mutations, a 92-bp loss stemming from a deletion or from exon skipping, and the absence of expression of one allele. Functional analysis demonstrated diminished MK activity in fibroblasts from HIDS patients. Our data establish MVK as the gene responsible for HIDS. | [
{
"begin_idx": "821",
"end_idx": "845",
"entity_id": "C536657",
"entity_type": "Disease",
"text_name": "Familial Hibernian fever"
},
{
"begin_idx": "55",
"end_idx": "92",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "hyper-IgD and periodic fever syndrome"
},
{
"begin_idx": "162",
"end_idx": "185",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "periodic fever syndrome"
},
{
"begin_idx": "306",
"end_idx": "311",
"entity_id": "D005334",
"entity_type": "Disease",
"text_name": "fever"
},
{
"begin_idx": "366",
"end_idx": "383",
"entity_id": "D007592",
"entity_type": "Disease",
"text_name": "joint involvement"
},
{
"begin_idx": "329",
"end_idx": "344",
"entity_id": "D008206",
"entity_type": "Disease",
"text_name": "lymphadenopathy"
},
{
"begin_idx": "979",
"end_idx": "985",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumour"
},
{
"begin_idx": "630",
"end_idx": "658",
"entity_id": "D010505",
"entity_type": "Disease",
"text_name": "Familial Mediterranean fever"
},
{
"begin_idx": "388",
"end_idx": "400",
"entity_id": "D012871",
"entity_type": "Disease",
"text_name": "skin lesions"
},
{
"begin_idx": "238",
"end_idx": "266",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "580",
"end_idx": "608",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary febrile disorders"
},
{
"begin_idx": "678",
"end_idx": "706",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "187",
"end_idx": "191",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "458",
"end_idx": "462",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "1060",
"end_idx": "1064",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "1496",
"end_idx": "1500",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "1562",
"end_idx": "1566",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "874",
"end_idx": "917",
"entity_id": "D056660",
"entity_type": "Disease",
"text_name": "autosomal dominant familial recurrent fever"
},
{
"begin_idx": "804",
"end_idx": "808",
"entity_id": "4210",
"entity_type": "Gene",
"text_name": "MEFV"
},
{
"begin_idx": "31",
"end_idx": "48",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "1166",
"end_idx": "1169",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
},
{
"begin_idx": "1180",
"end_idx": "1197",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "1199",
"end_idx": "1201",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MK"
},
{
"begin_idx": "1464",
"end_idx": "1466",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MK"
},
{
"begin_idx": "1530",
"end_idx": "1533",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MVK"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "31",
"end_idx": "48",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "1199",
"end_idx": "1201",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MK"
}
] | [
{
"begin_idx": "187",
"end_idx": "191",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "HIDS"
},
{
"begin_idx": "821",
"end_idx": "845",
"entity_id": "C536657",
"entity_type": "Disease",
"text_name": "Familial Hibernian fever"
}
] | [
"mevalonate kinase",
"MK"
] | [
"HIDS",
"Familial Hibernian fever"
] |
10369264 | Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. | The metabolic pathways that produce 11-cis retinal are important for vision because this retinoid is the chromophore residing in rhodopsin and the cone opsins. The all-trans retinal that is generated after cone and rod photopigments absorb photons of light is recycled back to 11-cis retinal by the retinal pigment epithelium and M ller cells of the retina. Several of the enzymes involved have recently been purified and molecularly cloned; here we focus on 11-cis retinol dehydrogenase (encoded by the gene RDH5; chromosome 12q13-14; ref. 4), the first cloned enzyme in this pathway. This microsomal enzyme is abundant in the retinal pigment epithelium, where it has been proposed to catalyse the conversion of 11-cis retinol to 11-cis retinal. We evaluated patients with hereditary retinal diseases featuring subretinal spots (retinitis punctata albescens and fundus albipunctatus) and patients with typical dominant or recessive retinitis pigmentosa for mutations in RDH5. Mutations were found only in two unrelated patients, both with fundus albipunctatus; they segregated with disease in the respective families. Recombinant mutant 11-cis retinol dehydrogenases had reduced activity compared with recombinant enzyme with wild-type sequence. Our results suggest that mutant alleles in RDH5 are a cause of fundus albipunctatus, a rare form of stationary night blindness characterized by a delay in the regeneration of cone and rod photopigments. | [
{
"begin_idx": "79",
"end_idx": "114",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "adaptation and fundus albipunctatus"
},
{
"begin_idx": "947",
"end_idx": "975",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "retinitis punctata albescens"
},
{
"begin_idx": "980",
"end_idx": "1000",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "fundus albipunctatus"
},
{
"begin_idx": "1157",
"end_idx": "1177",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "fundus albipunctatus"
},
{
"begin_idx": "1427",
"end_idx": "1447",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "fundus albipunctatus"
},
{
"begin_idx": "1050",
"end_idx": "1070",
"entity_id": "D012174",
"entity_type": "Disease",
"text_name": "retinitis pigmentosa"
},
{
"begin_idx": "891",
"end_idx": "918",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary retinal diseases"
},
{
"begin_idx": "626",
"end_idx": "630",
"entity_id": "5959",
"entity_type": "Gene",
"text_name": "RDH5"
},
{
"begin_idx": "1088",
"end_idx": "1092",
"entity_id": "5959",
"entity_type": "Gene",
"text_name": "RDH5"
},
{
"begin_idx": "1407",
"end_idx": "1411",
"entity_id": "5959",
"entity_type": "Gene",
"text_name": "RDH5"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "626",
"end_idx": "630",
"entity_id": "5959",
"entity_type": "Gene",
"text_name": "RDH5"
},
{
"begin_idx": "626",
"end_idx": "630",
"entity_id": "5959",
"entity_type": "Gene",
"text_name": "RDH5"
}
] | [
{
"begin_idx": "79",
"end_idx": "114",
"entity_id": "C562733",
"entity_type": "Disease",
"text_name": "adaptation and fundus albipunctatus"
},
{
"begin_idx": "891",
"end_idx": "918",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary retinal diseases"
}
] | [
"RDH5",
"RDH5"
] | [
"adaptation and fundus albipunctatus",
"hereditary retinal diseases"
] |
10369266 | Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. | Holoprosencephaly (HPE) is a common, severe malformation of the brain that involves separation of the central nervous system into left and right halves. Mild HPE can consist of signs such as a single central incisor, hypotelorism, microcephaly, or other craniofacial findings that can be present with or without associated brain malformations. The aetiology of HPE is extremely heterogeneous, with the proposed participation of a minimum of 12 HPE-associated genetic loci as well as the causal involvement of specific teratogens acting at the earliest stages of neurulation. The HPE2 locus was recently characterized as a 1-Mb interval on human chromosome 2p21 that contained a gene associated with HPE. A minimal critical region was defined by a set of six overlapping deletions and three clustered translocations in HPE patients. We describe here the isolation and characterization of the human homeobox-containing SIX3 gene from the HPE2 minimal critical region (MCR). We show that at least 2 of the HPE-associated translocation breakpoints in 2p21 are less than 200 kb from the 5' end of SIX3. Mutational analysis has identified four different mutations in the homeodomain of SIX3 that are predicted to interfere with transcriptional activation and are associated with HPE. We propose that SIX3 is the HPE2 gene, essential for the development of the anterior neural plate and eye in humans. | [
{
"begin_idx": "294",
"end_idx": "306",
"entity_id": "C563509",
"entity_type": "Disease",
"text_name": "hypotelorism"
},
{
"begin_idx": "121",
"end_idx": "146",
"entity_id": "D001927",
"entity_type": "Disease",
"text_name": "malformation of the brain"
},
{
"begin_idx": "400",
"end_idx": "419",
"entity_id": "D001927",
"entity_type": "Disease",
"text_name": "brain malformations"
},
{
"begin_idx": "161",
"end_idx": "201",
"entity_id": "D002493",
"entity_type": "Disease",
"text_name": "separation of the central nervous system"
},
{
"begin_idx": "308",
"end_idx": "320",
"entity_id": "D008831",
"entity_type": "Disease",
"text_name": "microcephaly"
},
{
"begin_idx": "58",
"end_idx": "75",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "holoprosencephaly"
},
{
"begin_idx": "77",
"end_idx": "94",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "Holoprosencephaly"
},
{
"begin_idx": "96",
"end_idx": "99",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "235",
"end_idx": "238",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "438",
"end_idx": "441",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "521",
"end_idx": "524",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "776",
"end_idx": "779",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "895",
"end_idx": "898",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "1080",
"end_idx": "1083",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "1350",
"end_idx": "1353",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "HPE"
},
{
"begin_idx": "42",
"end_idx": "46",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
},
{
"begin_idx": "656",
"end_idx": "660",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "HPE2"
},
{
"begin_idx": "994",
"end_idx": "998",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
},
{
"begin_idx": "1013",
"end_idx": "1017",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "HPE2"
},
{
"begin_idx": "1169",
"end_idx": "1173",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
},
{
"begin_idx": "1257",
"end_idx": "1261",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
},
{
"begin_idx": "1371",
"end_idx": "1375",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
},
{
"begin_idx": "1383",
"end_idx": "1387",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "HPE2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "42",
"end_idx": "46",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
},
{
"begin_idx": "42",
"end_idx": "46",
"entity_id": "6496",
"entity_type": "Gene",
"text_name": "SIX3"
}
] | [
{
"begin_idx": "58",
"end_idx": "75",
"entity_id": "D016142",
"entity_type": "Disease",
"text_name": "holoprosencephaly"
},
{
"begin_idx": "121",
"end_idx": "146",
"entity_id": "D001927",
"entity_type": "Disease",
"text_name": "malformation of the brain"
}
] | [
"SIX3",
"SIX3"
] | [
"holoprosencephaly",
"malformation of the brain"
] |
10369308 | A novel mutation in the gene for the adult skeletal muscle sodium channel alpha-subunit (SCN4A) that causes paramyotonia congenita of von Eulenburg. | BACKGROUND: Paramyotonia congenita (PMC) of von Eulenburg is an autosomal dominant muscular disease characterized by exercise- and cold-induced myotonia and weakness. To date, 18 missense mutations in the adult skeletal muscle sodium channel alpha-subunit (SCN4A) gene have been identified to cause a spectrum of muscular diseases, including PMC of von Eulenburg, PMC without cold paralysis, potassium-aggravating myotonia, and hyperkalemic periodic paralysis. However, no obvious correlations can be made between the location or nature of amino acid substitutions in SCN4A and its clinical phenotypes. OBJECTIVE: To describe clinical and genetic features of a family with PMC of von Eulenburg. RESULTS: A Japanese family with cold-induced myotonia and weakness was diagnosed as having PMC of von Eulenburg. This phenotype was identified to be caused by a novel mutation that substituted a glutamic acid residue for a highly conserved glycine residue in the fourth transmembrane segment (S4) of domain IV. This predicted a decrease in positive charge specific for the S4. CONCLUSION: In addition to the G1456E identified in this study, 4 mutations that cause a decrease in positive charge in the S4/D4 are associated with the phenotype of PMC of von Eulenburg. This provides an important genotype-phenotype correlation in sodium channelopathies. | [
{
"begin_idx": "462",
"end_idx": "479",
"entity_id": "D009135",
"entity_type": "Disease",
"text_name": "muscular diseases"
},
{
"begin_idx": "293",
"end_idx": "301",
"entity_id": "D009222",
"entity_type": "Disease",
"text_name": "myotonia"
},
{
"begin_idx": "563",
"end_idx": "571",
"entity_id": "D009222",
"entity_type": "Disease",
"text_name": "myotonia"
},
{
"begin_idx": "889",
"end_idx": "897",
"entity_id": "D009222",
"entity_type": "Disease",
"text_name": "myotonia"
},
{
"begin_idx": "530",
"end_idx": "539",
"entity_id": "D010243",
"entity_type": "Disease",
"text_name": "paralysis"
},
{
"begin_idx": "599",
"end_idx": "608",
"entity_id": "D010243",
"entity_type": "Disease",
"text_name": "paralysis"
},
{
"begin_idx": "306",
"end_idx": "314",
"entity_id": "D018908",
"entity_type": "Disease",
"text_name": "weakness"
},
{
"begin_idx": "902",
"end_idx": "910",
"entity_id": "D018908",
"entity_type": "Disease",
"text_name": "weakness"
},
{
"begin_idx": "577",
"end_idx": "589",
"entity_id": "D020513",
"entity_type": "Disease",
"text_name": "hyperkalemic"
},
{
"begin_idx": "161",
"end_idx": "183",
"entity_id": "D020967",
"entity_type": "Disease",
"text_name": "Paramyotonia congenita"
},
{
"begin_idx": "185",
"end_idx": "188",
"entity_id": "D020967",
"entity_type": "Disease",
"text_name": "PMC"
},
{
"begin_idx": "513",
"end_idx": "516",
"entity_id": "D020967",
"entity_type": "Disease",
"text_name": "PMC"
},
{
"begin_idx": "213",
"end_idx": "248",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant muscular disease"
},
{
"begin_idx": "89",
"end_idx": "94",
"entity_id": "6329",
"entity_type": "Gene",
"text_name": "SCN4A"
},
{
"begin_idx": "406",
"end_idx": "411",
"entity_id": "6329",
"entity_type": "Gene",
"text_name": "SCN4A"
},
{
"begin_idx": "717",
"end_idx": "722",
"entity_id": "6329",
"entity_type": "Gene",
"text_name": "SCN4A"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "89",
"end_idx": "94",
"entity_id": "6329",
"entity_type": "Gene",
"text_name": "SCN4A"
},
{
"begin_idx": "89",
"end_idx": "94",
"entity_id": "6329",
"entity_type": "Gene",
"text_name": "SCN4A"
}
] | [
{
"begin_idx": "161",
"end_idx": "183",
"entity_id": "D020967",
"entity_type": "Disease",
"text_name": "Paramyotonia congenita"
},
{
"begin_idx": "577",
"end_idx": "589",
"entity_id": "D020513",
"entity_type": "Disease",
"text_name": "hyperkalemic"
}
] | [
"SCN4A",
"SCN4A"
] | [
"Paramyotonia congenita",
"hyperkalemic"
] |
10371375 | Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. | Previous studies evaluating the angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism have revealed that expression of the DD genotype is associated with an increase in myocardial infarction, cardiomyopathy, and left ventricular (LV) mass in nondiabetic patients. In the present study, a cross-sectional analysis was performed to evaluate the potential relationship between the ACE I/D genotypes and the LV mass index in 289 non-insulin-dependent diabetes mellitus (NIDDM) subjects without known coronary artery disease. Two dimensional directed M-mode echocardiograms along with selected patient characteristics were obtained from the study population. The distribution of the I/D polymorphism was as follows: 63 were II (22%), 137 were ID (47%), and 89 were DD (31%). Univariately, the DD genotype was associated with an increase in LV mass in men but not in women. When subjected to a multiple regression model that included age, systolic blood pressure, duration of diabetes, duration of hypertension, presence of the black race, and the presence of the DD genotype, the DD genotype was independently associated with an increase in the LV mass index with a parameter estimate of 10.5 g/m2 (95% CI = 3.9, 17.0; P < .002) in the male subjects. Thus, in this NIDDM study population, male patients with the DD genotype are independently associated with an increased LV mass. | [
{
"begin_idx": "306",
"end_idx": "308",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "943",
"end_idx": "945",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "971",
"end_idx": "973",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1241",
"end_idx": "1243",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1258",
"end_idx": "1260",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "1490",
"end_idx": "1492",
"entity_id": "C536170",
"entity_type": "Disease",
"text_name": "DD"
},
{
"begin_idx": "921",
"end_idx": "923",
"entity_id": "C537985",
"entity_type": "Disease",
"text_name": "ID"
},
{
"begin_idx": "679",
"end_idx": "702",
"entity_id": "D003324",
"entity_type": "Disease",
"text_name": "coronary artery disease"
},
{
"begin_idx": "132",
"end_idx": "156",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "type 2 diabetes mellitus"
},
{
"begin_idx": "1153",
"end_idx": "1161",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "608",
"end_idx": "647",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "non-insulin-dependent diabetes mellitus"
},
{
"begin_idx": "649",
"end_idx": "654",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1443",
"end_idx": "1448",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "NIDDM"
},
{
"begin_idx": "1175",
"end_idx": "1187",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "375",
"end_idx": "389",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "cardiomyopathy"
},
{
"begin_idx": "352",
"end_idx": "373",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "29",
"end_idx": "58",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "190",
"end_idx": "219",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "221",
"end_idx": "224",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "561",
"end_idx": "564",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "29",
"end_idx": "58",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
},
{
"begin_idx": "29",
"end_idx": "58",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "angiotensin converting enzyme"
}
] | [
{
"begin_idx": "608",
"end_idx": "647",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "non-insulin-dependent diabetes mellitus"
},
{
"begin_idx": "679",
"end_idx": "702",
"entity_id": "D003324",
"entity_type": "Disease",
"text_name": "coronary artery disease"
}
] | [
"angiotensin converting enzyme",
"angiotensin converting enzyme"
] | [
"non-insulin-dependent diabetes mellitus",
"coronary artery disease"
] |
10371548 | Diagnostic Notch3 sequence analysis in CADASIL: three new mutations in Dutch patients. Dutch CADASIL Research Group. | To confirm the clinical diagnosis in individual Dutch patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), we performed direct sequence analysis of the abnormal gene, Notch3, in patients from 11 families without prior linkage analysis to chromosome 19. Eleven missense mutations involving the loss or gain of a cysteine residue were found, of which 3 are new. Exon 4 is a mutation hotspot (9 of 11 families). Notch3 sequence analysis of CADASIL patients in a diagnostic laboratory is a feasible procedure to confirm the clinical diagnosis in individual patients. | [
{
"begin_idx": "39",
"end_idx": "46",
"entity_id": "D046589",
"entity_type": "Disease",
"text_name": "CADASIL"
},
{
"begin_idx": "93",
"end_idx": "100",
"entity_id": "D046589",
"entity_type": "Disease",
"text_name": "CADASIL"
},
{
"begin_idx": "185",
"end_idx": "275",
"entity_id": "D046589",
"entity_type": "Disease",
"text_name": "cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy"
},
{
"begin_idx": "277",
"end_idx": "284",
"entity_id": "D046589",
"entity_type": "Disease",
"text_name": "CADASIL"
},
{
"begin_idx": "617",
"end_idx": "624",
"entity_id": "D046589",
"entity_type": "Disease",
"text_name": "CADASIL"
},
{
"begin_idx": "11",
"end_idx": "17",
"entity_id": "4854",
"entity_type": "Gene",
"text_name": "Notch3"
},
{
"begin_idx": "347",
"end_idx": "353",
"entity_id": "4854",
"entity_type": "Gene",
"text_name": "Notch3"
},
{
"begin_idx": "589",
"end_idx": "595",
"entity_id": "4854",
"entity_type": "Gene",
"text_name": "Notch3"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "11",
"end_idx": "17",
"entity_id": "4854",
"entity_type": "Gene",
"text_name": "Notch3"
}
] | [
{
"begin_idx": "185",
"end_idx": "275",
"entity_id": "D046589",
"entity_type": "Disease",
"text_name": "cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy"
}
] | [
"Notch3"
] | [
"cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy"
] |
10372542 | CD28/CTLA4 gene region on chromosome 2q33 confers genetic susceptibility to celiac disease. A linkage and family-based association study. | Celiac disease (CD) is a common small intestinal injury caused by sensitivity to gliadin in genetically-predisposed individuals. The only susceptibility locus established is the HLA-DQ. We tested whether the chromosomal region of the CD28/CTLA4 genes on 2q33 is linked to CD. These genes encode receptors regulating the T-lymphocyte activation. Recently, this gene region was reported to be linked to the susceptibility to many autoimmune diseases, including insulin-dependent diabetes (IDDM12locus). It is thus an obvious candidate locus also for CD, since the intestinal injury is mediated by the immune system. Genetic linkage between seven marker loci in this gene region and CD was studied in 69 Finnish families. In the multipoint linkage analysis, the highest non-pararametric linkage score (NPL) was 1.75 (P=0.04) for D2S116, suggesting weak linkage for this candidate locus. To evaluate this finding, an additional 31 families were typed for all markers. In the combined set of 100 families the NPL score for marker D2S116 was 2.55 (P=0.006) and for other markers 1.90-2.47 (P=0.029-0.007), supporting genuine linkage at this region. Significantly, locus D2S116 also showed a clear allelic association in these 100 families (P=0.0001). The transmission/disequilibrium test (TDT) for locus D2S116 gave preliminary evidence for preferential maternal non-transmission of allele *136 to patients (TDTmax=8.3; P<0.05). No paternal deviation was found suggesting that the effect of the locus might be mediated by a sex-dependent factor protective against CD. Our results indicate that the CD28/CTLA4 gene region can contain a novel susceptibility locus for CD and support the hypothesis that CD has an immune system-mediated component. Like the HLA, the CD28/CTLA4 genes appear to be associated with genetic susceptibility to various autoimmune diseases. | [
{
"begin_idx": "566",
"end_idx": "585",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmune diseases"
},
{
"begin_idx": "1975",
"end_idx": "1994",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmune diseases"
},
{
"begin_idx": "76",
"end_idx": "90",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "celiac disease"
},
{
"begin_idx": "138",
"end_idx": "152",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "Celiac disease"
},
{
"begin_idx": "154",
"end_idx": "156",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "410",
"end_idx": "412",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "686",
"end_idx": "688",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "818",
"end_idx": "820",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1696",
"end_idx": "1698",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1798",
"end_idx": "1800",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1833",
"end_idx": "1835",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "597",
"end_idx": "623",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "insulin-dependent diabetes"
},
{
"begin_idx": "176",
"end_idx": "193",
"entity_id": "D007410",
"entity_type": "Disease",
"text_name": "intestinal injury"
},
{
"begin_idx": "700",
"end_idx": "717",
"entity_id": "D007410",
"entity_type": "Disease",
"text_name": "intestinal injury"
},
{
"begin_idx": "5",
"end_idx": "10",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA4"
},
{
"begin_idx": "377",
"end_idx": "382",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA4"
},
{
"begin_idx": "1735",
"end_idx": "1740",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA4"
},
{
"begin_idx": "1900",
"end_idx": "1905",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA4"
},
{
"begin_idx": "0",
"end_idx": "4",
"entity_id": "940",
"entity_type": "Gene",
"text_name": "CD28"
},
{
"begin_idx": "372",
"end_idx": "376",
"entity_id": "940",
"entity_type": "Gene",
"text_name": "CD28"
},
{
"begin_idx": "1730",
"end_idx": "1734",
"entity_id": "940",
"entity_type": "Gene",
"text_name": "CD28"
},
{
"begin_idx": "1895",
"end_idx": "1899",
"entity_id": "940",
"entity_type": "Gene",
"text_name": "CD28"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "5",
"end_idx": "10",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA4"
},
{
"begin_idx": "0",
"end_idx": "4",
"entity_id": "940",
"entity_type": "Gene",
"text_name": "CD28"
}
] | [
{
"begin_idx": "76",
"end_idx": "90",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "celiac disease"
},
{
"begin_idx": "1798",
"end_idx": "1800",
"entity_id": "D002446",
"entity_type": "Disease",
"text_name": "CD"
}
] | [
"CTLA4",
"CD28"
] | [
"celiac disease",
"CD"
] |
10376119 | Functional PAX-6 gene-linked polymorphic region: potential association with paranoid schizophrenia. | BACKGROUND: Early differentiation of the nervous system and adult CNS neuroplasticity is modulated by PAX-6. We have shown previously that a highly polymorphic, functional AC/AG repeat in the 5' regulatory region of the gene showed significantly increased promoter activity, if containing > or = 29 repeats, and that the heterozygous genotype (< or = 28/> or = 29) revealed increased mRNA PAX-6 levels in human brain tissue compared to the homozygous short variant. METHODS: In a case-control study of 655 unrelated individuals, allele frequencies and genotype distributions of the functional PAX-6 promoter polymorphism were investigated comprising patients with DSM-IV schizophrenia, patients with affective disorders, and population controls. RESULTS: No allelic or genotypic association of the PAX-6 promoter polymorphism to affective disorder or to schizophrenia as one disease entity was observed. After subtyping schizophrenia into paranoid and nonparanoid forms, potential evidence was found for a genotypic association of the high-activity variant with the paranoid subtype of schizophrenia (p = .02). The estimated odds ratio was 1.7 (95% CI .98 to 2.95) for those heterozygous and 1.4 (95% CI .82 to 2.42) for those heterozygous or homozygous for the high-activity variant compared to the homozygous low-activity variant. CONCLUSIONS: Our finding indicates that early developmental genes may be involved in the etiopathogenesis of schizophrenia subtypes via variable transcriptional regulation in the developing and adult human brain. | [
{
"begin_idx": "85",
"end_idx": "98",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "771",
"end_idx": "784",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "954",
"end_idx": "967",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "1020",
"end_idx": "1033",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "1186",
"end_idx": "1199",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "1542",
"end_idx": "1555",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "800",
"end_idx": "819",
"entity_id": "D019964",
"entity_type": "Disease",
"text_name": "affective disorders"
},
{
"begin_idx": "11",
"end_idx": "16",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
},
{
"begin_idx": "202",
"end_idx": "207",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
},
{
"begin_idx": "489",
"end_idx": "494",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
},
{
"begin_idx": "693",
"end_idx": "698",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
},
{
"begin_idx": "898",
"end_idx": "903",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "11",
"end_idx": "16",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
},
{
"begin_idx": "489",
"end_idx": "494",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX-6"
}
] | [
{
"begin_idx": "85",
"end_idx": "98",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "800",
"end_idx": "819",
"entity_id": "D019964",
"entity_type": "Disease",
"text_name": "affective disorders"
}
] | [
"PAX-6",
"PAX-6"
] | [
"schizophrenia",
"affective disorders"
] |
10381328 | Metachromatic leukodystrophy: subtype genotype/phenotype correlations and identification of novel missense mutations (P148L and P191T) causing the juvenile-onset disease. | Metachromatic leukodystrophy (MLD) is a lysosomal storage disease resulting from the deficient activity of arylsulfatase A (ASA) and the accumulation of sulfatides. The disease is characterized by several subtypes, designated by age at onset: the late-infantile-, juvenile-, and adult-onset variants. Mutation analysis of genomic DNA from a proband with each variant was performed to identify and characterize their causative ASA mutations. Two sisters with the infantile-onset disease were homoallelic for the missense mutation D335V, a juvenile-onset proband was heteroallelic for two novel missense mutations, P148L and P191T, and an adult-onset patient was heteroallelic for the H397Y and P426L mutations. The novel mutations were not identified in 108 normal alleles indicating that these base substitutions were not common polymorphisms. To further characterize the mutant gene products, the mutant enzymes were partially purified from cultured fibroblasts and their molecular weights and charges were compared by immunoblotting following SDS-PAGE or isoelectric focusing (IEF). Normal fibroblast ASA had a single, broad band at 54 kDa. The enzyme from the late-infantile-onset patient had distinct bands of 36 and 78 kDa, but lacked the normal 54-kDa species. The juvenile- and adult-onset patients each had a faint band of 54 kDa and several other bands ranging from 29 to 64 kDa. IEF revealed several bands for the partially purified normal enzyme with a relatively narrow pH range around 4.0, whereas numerous bands with a wider range of isoelectric points were observed with the enzymes from the juvenile- and adult-onset fibroblasts. In contrast, the enzyme from the late-infantile-onset proband had four bands with more acidic isoelectric points, none corresponding to those of the normal enzyme. These results document changes in both size and charge of the mutant enzymes from patients with different mutations and MLD subtypes. | [
{
"begin_idx": "633",
"end_idx": "656",
"entity_id": "D004194",
"entity_type": "Disease",
"text_name": "infantile-onset disease"
},
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "Metachromatic leukodystrophy"
},
{
"begin_idx": "171",
"end_idx": "199",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "Metachromatic leukodystrophy"
},
{
"begin_idx": "201",
"end_idx": "204",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "MLD"
},
{
"begin_idx": "2101",
"end_idx": "2104",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "MLD"
},
{
"begin_idx": "211",
"end_idx": "236",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal storage disease"
},
{
"begin_idx": "278",
"end_idx": "293",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "arylsulfatase A"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "278",
"end_idx": "293",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "arylsulfatase A"
},
{
"begin_idx": "278",
"end_idx": "293",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "arylsulfatase A"
}
] | [
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "Metachromatic leukodystrophy"
},
{
"begin_idx": "211",
"end_idx": "236",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal storage disease"
}
] | [
"arylsulfatase A",
"arylsulfatase A"
] | [
"Metachromatic leukodystrophy",
"lysosomal storage disease"
] |
10381515 | Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. | Heparin-induced thrombocytopenia with thrombosis (HITT) is associated with antibodies specific for complexes consisting of heparin and platelet factor 4 (PF4). Studies in individual patients with HITT have demonstrated immunoglobulin (Ig) class switching from IgM to the IgG or IgA isotypes. This transition is thought to require helper T cells, but no studies of the cellular or molecular basis of this process have yet been reported. To characterize T-cell involvement in HITT, peripheral blood mononuclear cells (PBMC) from two patients with classical HITT obtained shortly after the acute episode were restimulated with heparin:PF4 complexes, PF4 alone, heparin alone, and medium alone in the presence of autologous antigen-presenting cells (APC). Responding T cells were then examined using the technique of "spectratyping," in which sequences encoding CDR3 domains of individual V beta (BV) families are amplified and separated by gel electrophoresis. After 14 days in culture with antigen (heparin:PF4 complexes), but not after culture with PF4, heparin, or medium alone, patient cells, but not cells from normal subjects, preferentially expressed T-cell receptor (TCR)-containing beta chains of the BV 5.1 family. Nucleotide sequencing of BV 5.1 TCR CDR3 showed that each patient had a personal repertoire, but also shared a tetrapeptide motif (PGTG). These findings provide evidence that the humoral immune response associated with HITT is driven by helper T cells that presumably recognize peptides derived from PF4. Identification of a common beta-chain CDR3 motif in responding T cells from each of two patients suggests that a limited number of helper TCRs may be used to mount an antibody response to heparin:PF4 complexes. TCR spectratyping appears to offer a new way to examine the molecular basis of pathologic immune responses and may be useful in further studies of HITT and other immune-mediated hematologic disorders. | [
{
"begin_idx": "858",
"end_idx": "882",
"entity_id": "D002292",
"entity_type": "Disease",
"text_name": "antigen-presenting cells"
},
{
"begin_idx": "884",
"end_idx": "887",
"entity_id": "D002292",
"entity_type": "Disease",
"text_name": "APC"
},
{
"begin_idx": "2054",
"end_idx": "2075",
"entity_id": "D006402",
"entity_type": "Disease",
"text_name": "hematologic disorders"
},
{
"begin_idx": "109",
"end_idx": "125",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "thrombocytopenia"
},
{
"begin_idx": "138",
"end_idx": "186",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "Heparin-induced thrombocytopenia with thrombosis"
},
{
"begin_idx": "188",
"end_idx": "192",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "334",
"end_idx": "338",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "612",
"end_idx": "616",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "693",
"end_idx": "697",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "1579",
"end_idx": "1583",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "2023",
"end_idx": "2027",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "126",
"end_idx": "136",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "1703",
"end_idx": "1707",
"entity_id": "4879",
"entity_type": "Gene",
"text_name": "CDR3"
},
{
"begin_idx": "25",
"end_idx": "42",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "platelet factor 4"
},
{
"begin_idx": "273",
"end_idx": "290",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "platelet factor 4"
},
{
"begin_idx": "292",
"end_idx": "295",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "770",
"end_idx": "773",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "785",
"end_idx": "788",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "1143",
"end_idx": "1146",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "1186",
"end_idx": "1189",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "1660",
"end_idx": "1663",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "1861",
"end_idx": "1864",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "PF4"
},
{
"begin_idx": "996",
"end_idx": "1000",
"entity_id": "8163",
"entity_type": "Gene",
"text_name": "CDR3"
},
{
"begin_idx": "1385",
"end_idx": "1400",
"entity_id": "8163",
"entity_type": "Gene",
"text_name": "BV 5.1 TCR CDR3"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "25",
"end_idx": "42",
"entity_id": "5196",
"entity_type": "Gene",
"text_name": "platelet factor 4"
},
{
"begin_idx": "1703",
"end_idx": "1707",
"entity_id": "4879",
"entity_type": "Gene",
"text_name": "CDR3"
}
] | [
{
"begin_idx": "138",
"end_idx": "186",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "Heparin-induced thrombocytopenia with thrombosis"
},
{
"begin_idx": "2054",
"end_idx": "2075",
"entity_id": "D006402",
"entity_type": "Disease",
"text_name": "hematologic disorders"
}
] | [
"platelet factor 4",
"CDR3"
] | [
"Heparin-induced thrombocytopenia with thrombosis",
"hematologic disorders"
] |
10381903 | A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. | BACKGROUND _ AIMS: In pancreatitis, a key role has been attributed to the inappropriate conversion of trypsinogen to trypsin. Recently, two mutations of the cationic trypsinogen gene were found in families with hereditary pancreatitis. This study was conducted to determine the spectrum and frequency of cationic trypsinogen mutations in unrelated patients with idiopathic or hereditary chronic pancreatitis (CP). METHODS: DNA samples from 44 unrelated children and adolescents with CP (30 patients with idiopathic CP and 14 with hereditary CP) and from 56 family members were investigated. The cationic trypsinogen gene was screened for mutations by single-strand conformation polymorphism analysis and DNA sequencing. RESULTS: A mutation in the cationic trypsinogen gene was detected in 5 patients: in 2 patients with a family history of CP and in 3 patients with idiopathic CP. In 1 patient the formerly described R122H mutation was detected. In 4 patients a hitherto unknown mutation was found at the signal peptide cleavage site leading to an alanine to valine exchange in codon 16. The mutations were inherited in all cases. In 95 unrelated control individuals the A16V mutation was not found. CONCLUSIONS: Heterozygosity for the A16V mutation is strongly associated with CP. These results indicate that a significant percentage of patients with idiopathic CP may have a genetic basis for their disorder; therefore, genetic testing should be included in the diagnostic evaluation of these patients. | [
{
"begin_idx": "334",
"end_idx": "357",
"entity_id": "C537262",
"entity_type": "Disease",
"text_name": "hereditary pancreatitis"
},
{
"begin_idx": "485",
"end_idx": "530",
"entity_id": "C537262",
"entity_type": "Disease",
"text_name": "idiopathic or hereditary chronic pancreatitis"
},
{
"begin_idx": "627",
"end_idx": "666",
"entity_id": "C537262",
"entity_type": "Disease",
"text_name": "idiopathic CP and 14 with hereditary CP"
},
{
"begin_idx": "145",
"end_idx": "157",
"entity_id": "D010190",
"entity_type": "Disease",
"text_name": "pancreatitis"
},
{
"begin_idx": "101",
"end_idx": "121",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "chronic pancreatitis"
},
{
"begin_idx": "532",
"end_idx": "534",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "CP"
},
{
"begin_idx": "606",
"end_idx": "608",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "CP"
},
{
"begin_idx": "963",
"end_idx": "965",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "CP"
},
{
"begin_idx": "1000",
"end_idx": "1002",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "CP"
},
{
"begin_idx": "1401",
"end_idx": "1403",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "CP"
},
{
"begin_idx": "1486",
"end_idx": "1488",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "CP"
},
{
"begin_idx": "47",
"end_idx": "67",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
},
{
"begin_idx": "280",
"end_idx": "300",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
},
{
"begin_idx": "427",
"end_idx": "447",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
},
{
"begin_idx": "718",
"end_idx": "738",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
},
{
"begin_idx": "870",
"end_idx": "890",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "47",
"end_idx": "67",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
},
{
"begin_idx": "718",
"end_idx": "738",
"entity_id": "5644",
"entity_type": "Gene",
"text_name": "cationic trypsinogen"
}
] | [
{
"begin_idx": "101",
"end_idx": "121",
"entity_id": "D050500",
"entity_type": "Disease",
"text_name": "chronic pancreatitis"
},
{
"begin_idx": "145",
"end_idx": "157",
"entity_id": "D010190",
"entity_type": "Disease",
"text_name": "pancreatitis"
}
] | [
"cationic trypsinogen",
"cationic trypsinogen"
] | [
"chronic pancreatitis",
"pancreatitis"
] |
10383749 | Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. | The inherited mechanobullous disease, dystrophic epidermolysis bullosa, is caused by type VII collagen gene (COL7A1) mutations. We studied six unrelated patients with a distinct clinical subtype of this disease, epidermolysis bullosa pruriginosa, characterized by pruritus, excoriated prurigo nodules, and skin fragility. Mutation analysis using polymerase chain reaction amplification of genomic DNA, heteroduplex analysis and direct nucleotide sequencing demonstrated pathogenetic COL7A1 mutations in each case. Four patients had a glycine substitution mutation on one COL7A1 allele (G1791E, G2242R, G2369S, and G2713R), a fifth was a compound heterozygote for a splice site mutation (5532 + 1G-to-A) and a single base pair deletion (7786delG), and a sixth patient was heterozygous for an out-of-frame deletion mutation (6863del16). This study shows that the molecular pathology in patients with the distinctive clinical features of epidermolysis bullosa pruriginosa is heterogeneous and suggests that other factors, in addition to the inherent COL7A1 mutation(s), may be responsible for an epidermolysis bullosa pruriginosa phenotype. | [
{
"begin_idx": "417",
"end_idx": "431",
"entity_id": "C536183",
"entity_type": "Disease",
"text_name": "skin fragility"
},
{
"begin_idx": "76",
"end_idx": "109",
"entity_id": "C563192",
"entity_type": "Disease",
"text_name": "epidermolysis bullosa pruriginosa"
},
{
"begin_idx": "323",
"end_idx": "356",
"entity_id": "C563192",
"entity_type": "Disease",
"text_name": "epidermolysis bullosa pruriginosa"
},
{
"begin_idx": "1046",
"end_idx": "1079",
"entity_id": "C563192",
"entity_type": "Disease",
"text_name": "epidermolysis bullosa pruriginosa"
},
{
"begin_idx": "1204",
"end_idx": "1237",
"entity_id": "C563192",
"entity_type": "Disease",
"text_name": "epidermolysis bullosa pruriginosa"
},
{
"begin_idx": "375",
"end_idx": "383",
"entity_id": "D011537",
"entity_type": "Disease",
"text_name": "pruritus"
},
{
"begin_idx": "149",
"end_idx": "181",
"entity_id": "D016108",
"entity_type": "Disease",
"text_name": "dystrophic epidermolysis bullosa"
},
{
"begin_idx": "115",
"end_idx": "147",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited mechanobullous disease"
},
{
"begin_idx": "48",
"end_idx": "54",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "220",
"end_idx": "226",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "594",
"end_idx": "600",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "682",
"end_idx": "688",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "1158",
"end_idx": "1164",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "48",
"end_idx": "54",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
},
{
"begin_idx": "682",
"end_idx": "688",
"entity_id": "1294",
"entity_type": "Gene",
"text_name": "COL7A1"
}
] | [
{
"begin_idx": "76",
"end_idx": "109",
"entity_id": "C563192",
"entity_type": "Disease",
"text_name": "epidermolysis bullosa pruriginosa"
},
{
"begin_idx": "417",
"end_idx": "431",
"entity_id": "C536183",
"entity_type": "Disease",
"text_name": "skin fragility"
}
] | [
"COL7A1",
"COL7A1"
] | [
"epidermolysis bullosa pruriginosa",
"skin fragility"
] |
10389978 | Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. | The major risk factors for hepatocellular carcinomas (HCC) in high incidence areas include infection with hepatitis B and C viruses (HBV, HCV) and exposure to aflatoxin. Genetic alterations in 24 liver resection specimens from Shanghai and Qidong were studied. Hepatitis B virus was integrated in all patient samples, and a null phenotype for the GSTM1 enzyme was present in 63% of patients. Alteration of p53 was present in 95% (23/24) of cases: mutations of the p53 gene in 12 HCC, p53 overexpression in 13 and loss of heterozygosity (LOH) of chromosome 17p in 17. All seven HCCs with a p53 mutation from Qidong and three of five from Shanghai had the aflatoxin-associated point mutation with a G to T transversion at codon 249, position 3. No HCC had microsatellite instability. LOH of chromosome 4q, 1p, 16q and 13q was present in 50%, 46%, 42% and 38%, respectively, and 4q was preferentially lost in HCCs containing a p53 mutation: LOH of 4q was present in 75% (9/12) of HCC with, but only 25% (3/12) of HCC without, a p53 gene mutation (P = 0.01). These data indicate a possible interaction between p53 gene mutation and 4q loss in the pathogenesis of HCC. | [
{
"begin_idx": "207",
"end_idx": "233",
"entity_id": "D006509",
"entity_type": "Disease",
"text_name": "infection with hepatitis B"
},
{
"begin_idx": "377",
"end_idx": "394",
"entity_id": "D006509",
"entity_type": "Disease",
"text_name": "Hepatitis B virus"
},
{
"begin_idx": "23",
"end_idx": "48",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "hepatocellular carcinomas"
},
{
"begin_idx": "143",
"end_idx": "168",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "hepatocellular carcinomas"
},
{
"begin_idx": "170",
"end_idx": "173",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "HCC"
},
{
"begin_idx": "595",
"end_idx": "598",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "HCC"
},
{
"begin_idx": "862",
"end_idx": "865",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "HCC"
},
{
"begin_idx": "1093",
"end_idx": "1096",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "HCC"
},
{
"begin_idx": "1126",
"end_idx": "1129",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "HCC"
},
{
"begin_idx": "1275",
"end_idx": "1278",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "HCC"
},
{
"begin_idx": "463",
"end_idx": "468",
"entity_id": "2944",
"entity_type": "Gene",
"text_name": "GSTM1"
},
{
"begin_idx": "96",
"end_idx": "99",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "522",
"end_idx": "525",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "580",
"end_idx": "583",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "600",
"end_idx": "603",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "705",
"end_idx": "708",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1040",
"end_idx": "1043",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1141",
"end_idx": "1144",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1222",
"end_idx": "1225",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "96",
"end_idx": "99",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "705",
"end_idx": "708",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
}
] | [
{
"begin_idx": "23",
"end_idx": "48",
"entity_id": "D006528",
"entity_type": "Disease",
"text_name": "hepatocellular carcinomas"
},
{
"begin_idx": "377",
"end_idx": "394",
"entity_id": "D006509",
"entity_type": "Disease",
"text_name": "Hepatitis B virus"
}
] | [
"p53",
"p53"
] | [
"hepatocellular carcinomas",
"Hepatitis B virus"
] |
10391221 | Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. | Thiamine-responsive megaloblastic anaemia (TRMA), also known as Rogers syndrome, is an early onset, autosomal recessive disorder defined by the occurrence of megaloblastic anaemia, diabetes mellitus and sensorineural deafness, responding in varying degrees to thiamine treatment (MIM 249270). We have previously narrowed the TRMA locus from a 16-cM to a 4-cM interval on chromosomal region 1q23.3 (refs 3,4) and this region has been further refined to a 1.4-cM interval. Previous studies have suggested that deficiency in a high-affinity thiamine transporter may cause this disorder. Here we identify the TRMA gene by positional cloning. We assembled a P1-derived artificial chromosome (PAC) contig spanning the TRMA candidate region. This clarified the order of genetic markers across the TRMA locus, provided 9 new polymorphic markers and narrowed the locus to an approximately 400-kb region. Mutations in a new gene, SLC19A2, encoding a putative transmembrane protein homologous to the reduced folate carrier proteins, were found in all affected individuals in six TRMA families, suggesting that a defective thiamine transporter protein (THTR-1) may underlie the TRMA syndrome. | [
{
"begin_idx": "181",
"end_idx": "196",
"entity_id": "C536510",
"entity_type": "Disease",
"text_name": "Rogers syndrome"
},
{
"begin_idx": "27",
"end_idx": "68",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "thiamine-responsive megaloblastic anaemia"
},
{
"begin_idx": "117",
"end_idx": "158",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "Thiamine-responsive megaloblastic anaemia"
},
{
"begin_idx": "160",
"end_idx": "164",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
},
{
"begin_idx": "275",
"end_idx": "296",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "megaloblastic anaemia"
},
{
"begin_idx": "442",
"end_idx": "446",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
},
{
"begin_idx": "722",
"end_idx": "726",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
},
{
"begin_idx": "829",
"end_idx": "833",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
},
{
"begin_idx": "907",
"end_idx": "911",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
},
{
"begin_idx": "1185",
"end_idx": "1189",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
},
{
"begin_idx": "1283",
"end_idx": "1296",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA syndrome"
},
{
"begin_idx": "107",
"end_idx": "115",
"entity_id": "D003638",
"entity_type": "Disease",
"text_name": "deafness"
},
{
"begin_idx": "85",
"end_idx": "102",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes mellitus"
},
{
"begin_idx": "298",
"end_idx": "315",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes mellitus"
},
{
"begin_idx": "320",
"end_idx": "342",
"entity_id": "D006319",
"entity_type": "Disease",
"text_name": "sensorineural deafness"
},
{
"begin_idx": "217",
"end_idx": "245",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "13",
"end_idx": "20",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "SLC19A2"
},
{
"begin_idx": "160",
"end_idx": "164",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "TRMA"
},
{
"begin_idx": "442",
"end_idx": "446",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "TRMA"
},
{
"begin_idx": "722",
"end_idx": "726",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "TRMA"
},
{
"begin_idx": "829",
"end_idx": "833",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "TRMA"
},
{
"begin_idx": "907",
"end_idx": "911",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "TRMA"
},
{
"begin_idx": "1037",
"end_idx": "1044",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "SLC19A2"
},
{
"begin_idx": "1185",
"end_idx": "1189",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "TRMA"
},
{
"begin_idx": "1258",
"end_idx": "1264",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "THTR-1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "13",
"end_idx": "20",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "SLC19A2"
},
{
"begin_idx": "13",
"end_idx": "20",
"entity_id": "10560",
"entity_type": "Gene",
"text_name": "SLC19A2"
}
] | [
{
"begin_idx": "181",
"end_idx": "196",
"entity_id": "C536510",
"entity_type": "Disease",
"text_name": "Rogers syndrome"
},
{
"begin_idx": "160",
"end_idx": "164",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "TRMA"
}
] | [
"SLC19A2",
"SLC19A2"
] | [
"Rogers syndrome",
"TRMA"
] |
10394937 | Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease. | We have sequenced the entire (89 exons) open reading frame of the LRP gene in 12 cases of Alzheimer's disease (AD) from Northern France. We have found no novel changes but confirm the occurrence of a polymorphism in exon 6 of the gene (A216V). This polymorphism is rare (2.8% of controls) and is in linkage equilibrium with previously reported polymorphisms. The V216 allele is negatively associated with the disease in a large case-controlled series. These data suggest that the LRP receptor may be involved in the pathobiology of AD, but the association that we report here cannot explain the previously reported genetic data implicating the LRP gene in AD. If the LRP gene is a major site of genetic variability leading to AD, there must be other biologically relevant variability in promoter or other regulatory elements of this large gene. | [
{
"begin_idx": "82",
"end_idx": "101",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "193",
"end_idx": "212",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "214",
"end_idx": "216",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "635",
"end_idx": "637",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "759",
"end_idx": "761",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "829",
"end_idx": "831",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "46",
"end_idx": "49",
"entity_id": "4035",
"entity_type": "Gene",
"text_name": "LRP"
},
{
"begin_idx": "169",
"end_idx": "172",
"entity_id": "4035",
"entity_type": "Gene",
"text_name": "LRP"
},
{
"begin_idx": "583",
"end_idx": "586",
"entity_id": "4035",
"entity_type": "Gene",
"text_name": "LRP"
},
{
"begin_idx": "747",
"end_idx": "750",
"entity_id": "4035",
"entity_type": "Gene",
"text_name": "LRP"
},
{
"begin_idx": "770",
"end_idx": "773",
"entity_id": "4035",
"entity_type": "Gene",
"text_name": "LRP"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "46",
"end_idx": "49",
"entity_id": "4035",
"entity_type": "Gene",
"text_name": "LRP"
}
] | [
{
"begin_idx": "82",
"end_idx": "101",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
}
] | [
"LRP"
] | [
"Alzheimer's disease"
] |
10395102 | Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. | Multiple genetic as well as environmental factors are considered to be involved in the development of systemic lupus erythematosus (SLE). A number of previous studies have suggested a possible role for tumor necrosis factor (TNF) in the pathogenesis of SLE. In addition, one of the candidate loci suggested by the genome-wide linkage analysis corresponds to the chromosomal position encompassing the TNF receptor 2 gene (TNFR2). The purpose of this study was to analyze the polymorphism of TNFR2 and its possible association with the susceptibility to SLE, using the case-control association analysis. Polymorphism screening of the exons containing previously reported nonsynonymous base substitutions was carried out by the polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) method, using genomic DNA from 81 Japanese patients with SLE and 207 healthy individuals. Two alleles were present in exon 6, coding for methionine (196M) and arginine (196R) at position 196. 30 of 81 patients (37.0%) with SLE were positive for the 196R allele, which was significantly more frequent compared with 39 of 207 healthy individuals (18.8%) (chi2=10.6, df=l, P=0.001, odds ratio=2.53, 95% CI: 1.45-4.43). Genotype analysis revealed that the presence of one 196R allele was sufficient for rendering susceptibility. The association of 196R allele with SLE was independent from that of HLA-DRB1*1501. In conclusion, the TNFR2 196R allele was found to be significantly associated with the susceptibility to SLE in the Japanese population. Further population and functional studies will be of particular importance to establish TNFR2 as one of the susceptibility genes to SLE. | [
{
"begin_idx": "92",
"end_idx": "120",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "224",
"end_idx": "252",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "254",
"end_idx": "257",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "375",
"end_idx": "378",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "674",
"end_idx": "677",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "983",
"end_idx": "986",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1149",
"end_idx": "1152",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1487",
"end_idx": "1490",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1640",
"end_idx": "1643",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1804",
"end_idx": "1807",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1520",
"end_idx": "1528",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "324",
"end_idx": "345",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor"
},
{
"begin_idx": "347",
"end_idx": "350",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF"
},
{
"begin_idx": "522",
"end_idx": "525",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF"
},
{
"begin_idx": "15",
"end_idx": "47",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "tumor necrosis factor receptor 2"
},
{
"begin_idx": "49",
"end_idx": "54",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "TNFR2"
},
{
"begin_idx": "543",
"end_idx": "548",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "TNFR2"
},
{
"begin_idx": "612",
"end_idx": "617",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "TNFR2"
},
{
"begin_idx": "1554",
"end_idx": "1559",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "TNFR2"
},
{
"begin_idx": "1760",
"end_idx": "1765",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "TNFR2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "15",
"end_idx": "47",
"entity_id": "7133",
"entity_type": "Gene",
"text_name": "tumor necrosis factor receptor 2"
},
{
"begin_idx": "1520",
"end_idx": "1528",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
}
] | [
{
"begin_idx": "92",
"end_idx": "120",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "375",
"end_idx": "378",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
}
] | [
"tumor necrosis factor receptor 2",
"HLA-DRB1"
] | [
"systemic lupus erythematosus",
"SLE"
] |
10395222 | Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. | Catechol-O-methyltransferase (COMT) is an enzyme which has a crucial role in the metabolism of dopamine. It has been suggested that a common functional genetic polymorphism in the COMT gene, which results in 3 to 4-fold difference in COMT enzyme activity, may contribute to the etiology of mental disorders such as bipolar disorder and alcoholism. Since ethanol-induced euphoria is associated with the rapid release of dopamine in limbic areas, it is conceivable that subjects who inherit the allele encoding the low activity COMT variant would have a relatively low dopamine inactivation rate, and therefore would be more vulnerable to the development of ethanol dependence. The aim of this study was to test this hypothesis among type 1 (late-onset) alcoholics. The COMT polymorphism was determined in two independent male late onset (type 1) alcoholic populations in Turku (n = 67) and Kuopio (n = 56). The high (H) and low (L) activity COMT genotype and allele frequencies were compared with previously published data from 3140 Finnish blood donors (general population) and 267 race- and gender-matched controls. The frequency of low activity allele (L) was markedly higher among the patients both in Turku (P = 0.023) and in Kuopio (P = 0.005) when compared with the general population. When all patients were compared with the general population (blood donors), the difference was even more significant (P = 0.0004). When genotypes of all alcoholics (n = 123) were compared with genotypes of matched controls, the odds ratio (OR) for alcoholism for those subjects having the LL genotype vs those with HH genotype was 2.51, 95% CI 1.22-5.19, P = 0.006. Also, L allele frequency was significantly higher among alcoholics when compared with controls (P = 0.009). The estimate for population etiological (attributable) fraction for the LL genotype in alcoholism was 13.3% (95% CI 2.3-25.7%). The results indicate that the COMT polymorphism contributes significantly to the development of late-onset alcoholism. | [
{
"begin_idx": "102",
"end_idx": "112",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "450",
"end_idx": "460",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1654",
"end_idx": "1664",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1967",
"end_idx": "1977",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "2115",
"end_idx": "2125",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "404",
"end_idx": "420",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "mental disorders"
},
{
"begin_idx": "429",
"end_idx": "445",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "bipolar disorder"
},
{
"begin_idx": "1721",
"end_idx": "1723",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "HH"
},
{
"begin_idx": "50",
"end_idx": "78",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "80",
"end_idx": "84",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "114",
"end_idx": "142",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "Catechol-O-methyltransferase"
},
{
"begin_idx": "144",
"end_idx": "148",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "294",
"end_idx": "298",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "348",
"end_idx": "352",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "640",
"end_idx": "644",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "882",
"end_idx": "886",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "1054",
"end_idx": "1058",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "2038",
"end_idx": "2042",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "50",
"end_idx": "78",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "882",
"end_idx": "886",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
}
] | [
{
"begin_idx": "102",
"end_idx": "112",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1721",
"end_idx": "1723",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "HH"
}
] | [
"catechol-O-methyltransferase",
"COMT"
] | [
"alcoholism",
"HH"
] |
10395868 | Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. | There are indications that the cytokine interleukin (IL)-10 has a regulatory role in Epstein-Barr virus (EBV)-induced infections. Because the human IL-10 gene demonstrates polymorphism resulting in interindividual differences in cytokine production, the frequencies of the alleles defined by the base exchange polymorphism at the position -1082 (allele 1=G, allele 2=A) were analyzed in EBV-seronegative adults, seropositive adults, and in patients hospitalized because of a severe EBV infection. The frequencies of allele 1 were 0.80, 0.46, and 0.29, respectively. Because this allele is associated with a high IL-10-producing capability, these data suggest that high IL-10 levels protect against EBV infection and, conversely, that low IL-10-producing capability makes individuals more susceptible to a severe EBV infection. | [
{
"begin_idx": "225",
"end_idx": "235",
"entity_id": "D007239",
"entity_type": "Disease",
"text_name": "infections"
},
{
"begin_idx": "77",
"end_idx": "105",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "Epstein-Barr virus infection"
},
{
"begin_idx": "192",
"end_idx": "210",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "Epstein-Barr virus"
},
{
"begin_idx": "212",
"end_idx": "215",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "EBV"
},
{
"begin_idx": "494",
"end_idx": "497",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "EBV"
},
{
"begin_idx": "589",
"end_idx": "602",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "EBV infection"
},
{
"begin_idx": "805",
"end_idx": "818",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "EBV infection"
},
{
"begin_idx": "919",
"end_idx": "932",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "EBV infection"
},
{
"begin_idx": "255",
"end_idx": "260",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "719",
"end_idx": "724",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "776",
"end_idx": "781",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "845",
"end_idx": "850",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "255",
"end_idx": "260",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "719",
"end_idx": "724",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
}
] | [
{
"begin_idx": "77",
"end_idx": "105",
"entity_id": "D020031",
"entity_type": "Disease",
"text_name": "Epstein-Barr virus infection"
},
{
"begin_idx": "225",
"end_idx": "235",
"entity_id": "D007239",
"entity_type": "Disease",
"text_name": "infections"
}
] | [
"IL-10",
"IL-10"
] | [
"Epstein-Barr virus infection",
"infections"
] |
10397258 | hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. | The chromatin-remodeling hSNF5/INI1 gene has recently been shown to act as a tumor suppressor gene in rhabdoid tumors (RTs). In an attempt to further characterize the main chromosomal mechanisms involved in hSNF5/INI1 inactivation in RTs, we report here the molecular cytogenetic data obtained in 12 cell lines harboring hSNF5/INI1 mutations and/or deletions in relation to the molecular genetic analysis using polymorphic markers extended to both extremities of chromosome 22q. On the whole, mitotic recombination occurring in the proximal part of chromosome 22q, as demonstrated in five cases, and nondisjunction/duplication, highly suspected in two cases (processes leading respectively to partial or complete isodisomy), appear to be major mechanisms associated with hSNF5/INI1 inactivation. Such isodisomy accompanies each of the RTs exhibiting two cytogenetically normal chromosomes 22. This results in homozygosity for the mutation at the hSNF5/INI1 locus. An alternate mechanism accounting for hSNF5/INI1 inactivation observed in these tumors is homozygous deletion in the rhabdoid consensus region. This was observed in each of the four tumors carrying a chromosome 22q abnormality and, in particular, in the three tumors with chromosomal translocations. Only one case of our series illustrates the mutation/deletion classical model proposed for the double-hit inactivation of a tumor suppressor gene. | [
{
"begin_idx": "195",
"end_idx": "200",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1162",
"end_idx": "1168",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
},
{
"begin_idx": "1264",
"end_idx": "1270",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
},
{
"begin_idx": "1342",
"end_idx": "1348",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
},
{
"begin_idx": "1506",
"end_idx": "1511",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "101",
"end_idx": "116",
"entity_id": "D018335",
"entity_type": "Disease",
"text_name": "rhabdoid tumors"
},
{
"begin_idx": "220",
"end_idx": "235",
"entity_id": "D018335",
"entity_type": "Disease",
"text_name": "rhabdoid tumors"
},
{
"begin_idx": "237",
"end_idx": "240",
"entity_id": "D018335",
"entity_type": "Disease",
"text_name": "RTs"
},
{
"begin_idx": "352",
"end_idx": "355",
"entity_id": "D018335",
"entity_type": "Disease",
"text_name": "RTs"
},
{
"begin_idx": "953",
"end_idx": "956",
"entity_id": "D018335",
"entity_type": "Disease",
"text_name": "RTs"
},
{
"begin_idx": "0",
"end_idx": "5",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "6",
"end_idx": "10",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
},
{
"begin_idx": "143",
"end_idx": "148",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "149",
"end_idx": "153",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
},
{
"begin_idx": "325",
"end_idx": "330",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "331",
"end_idx": "335",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
},
{
"begin_idx": "439",
"end_idx": "444",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "445",
"end_idx": "449",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
},
{
"begin_idx": "889",
"end_idx": "894",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "895",
"end_idx": "899",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
},
{
"begin_idx": "1064",
"end_idx": "1069",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "1070",
"end_idx": "1074",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
},
{
"begin_idx": "1120",
"end_idx": "1125",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "1126",
"end_idx": "1130",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "INI1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "5",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
},
{
"begin_idx": "325",
"end_idx": "330",
"entity_id": "6598",
"entity_type": "Gene",
"text_name": "hSNF5"
}
] | [
{
"begin_idx": "101",
"end_idx": "116",
"entity_id": "D018335",
"entity_type": "Disease",
"text_name": "rhabdoid tumors"
},
{
"begin_idx": "1264",
"end_idx": "1270",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
}
] | [
"hSNF5",
"hSNF5"
] | [
"rhabdoid tumors",
"tumors"
] |
10398237 | Carpenter-Waziri syndrome results from a mutation in XNP. | [
{
"begin_idx": "0",
"end_idx": "25",
"entity_id": "C537457",
"entity_type": "Disease",
"text_name": "Carpenter-Waziri syndrome"
},
{
"begin_idx": "53",
"end_idx": "56",
"entity_id": "546",
"entity_type": "Gene",
"text_name": "XNP"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "53",
"end_idx": "56",
"entity_id": "546",
"entity_type": "Gene",
"text_name": "XNP"
}
] | [
{
"begin_idx": "0",
"end_idx": "25",
"entity_id": "C537457",
"entity_type": "Disease",
"text_name": "Carpenter-Waziri syndrome"
}
] | [
"XNP"
] | [
"Carpenter-Waziri syndrome"
] |
|
10399104 | Is the common 844ins68 polymorphism in the cystathionine beta-synthase gene associated with atherosclerosis? | [
{
"begin_idx": "92",
"end_idx": "107",
"entity_id": "D050197",
"entity_type": "Disease",
"text_name": "atherosclerosis"
},
{
"begin_idx": "43",
"end_idx": "70",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "cystathionine beta-synthase"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "43",
"end_idx": "70",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "cystathionine beta-synthase"
}
] | [
{
"begin_idx": "92",
"end_idx": "107",
"entity_id": "D050197",
"entity_type": "Disease",
"text_name": "atherosclerosis"
}
] | [
"cystathionine beta-synthase"
] | [
"atherosclerosis"
] |
|
10399947 | Germline brca2 sequence variants in patients with ocular melanoma. | On the basis, chiefly, of anecdotal reports of cases of ocular melanoma (OM) occurring in families with inherited susceptibility to breast cancer due to brca2 germline mutations, we examined the frequency of brca2 alterations in a series of 62 ocular melanoma cases. These cases were preferentially selected on the basis of reported family history of breast or ovarian cancer, or OM, although the series also included a randomly selected set of cases without family history of cancer. A total of 7 germline alterations were found, of which 3 were likely to be associated with disease. While all 3 deleterious mutations were found in patients who also had a personal history of breast cancer, only 1 of the 3 families had a family history of breast/ovarian cancer or OM. Although germline brca2 mutations may account for a small proportion of all OM cases, there may be additional loci that contribute to familial aggregation of OM and to the familial association between OM and breast cancer. | [
{
"begin_idx": "199",
"end_idx": "212",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "744",
"end_idx": "757",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1045",
"end_idx": "1058",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "50",
"end_idx": "65",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "ocular melanoma"
},
{
"begin_idx": "123",
"end_idx": "138",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "ocular melanoma"
},
{
"begin_idx": "140",
"end_idx": "142",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
},
{
"begin_idx": "311",
"end_idx": "326",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "ocular melanoma"
},
{
"begin_idx": "447",
"end_idx": "449",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
},
{
"begin_idx": "833",
"end_idx": "835",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
},
{
"begin_idx": "913",
"end_idx": "915",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
},
{
"begin_idx": "995",
"end_idx": "997",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
},
{
"begin_idx": "1038",
"end_idx": "1040",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
},
{
"begin_idx": "544",
"end_idx": "550",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "418",
"end_idx": "442",
"entity_id": "D061325",
"entity_type": "Disease",
"text_name": "breast or ovarian cancer"
},
{
"begin_idx": "808",
"end_idx": "829",
"entity_id": "D061325",
"entity_type": "Disease",
"text_name": "breast/ovarian cancer"
},
{
"begin_idx": "9",
"end_idx": "14",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "brca2"
},
{
"begin_idx": "220",
"end_idx": "225",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "brca2"
},
{
"begin_idx": "275",
"end_idx": "280",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "brca2"
},
{
"begin_idx": "855",
"end_idx": "860",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "brca2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "9",
"end_idx": "14",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "brca2"
},
{
"begin_idx": "275",
"end_idx": "280",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "brca2"
}
] | [
{
"begin_idx": "199",
"end_idx": "212",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "833",
"end_idx": "835",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "OM"
}
] | [
"brca2",
"brca2"
] | [
"breast cancer",
"OM"
] |
10400139 | Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. | Studies have shown the important roles of several regulatory and proinflammatory cytokines in insulin-dependent diabetes mellitus (IDDM). CC-chemokine receptors CCR2 and CCR5 bind chemokines that are involved in the trafficking of leukocytes in both basal and inflammatory states. A common 32-bp deletion mutation in the CCR5 gene (CCR5delta32) and a G-to-A nucleotide substitution in the CCR2 at position 190 (CCR2-64I) have recently been described. In the present study, we have determined the frequency of the CCR5delta32 and CCR2-64I alleles in children with IDDM [n = 115; age 1-14 (9.3+/-4.3) y] and in nondiabetic subjects [n = 280; age 1-14 (8.5+/-4.5) y]. The CCR5delta32 allele frequencies were 0.117 in children with IDDM and 0.111 in nondiabetic subjects, indicating that the deletion allele has no association with IDDM. The CCR2-64I allele frequency in children with IDDM was 0.226, which differed significantly from the allele frequency in controls (0.114, p = 0.001). The role of this mutation in IDDM cannot be explained yet, but, because CCR2 mediates the chemotaxis of CD4+ and CD8+ T cells to areas of inflammation and because these cells play important roles in insulitis, a mutation in the CCR2 gene may contribute to the susceptibility to the disease. Alternatively, the 64I allele could be a marker of a linked mutation through linkage disequilibrium. According to these results, the CCR2 gene may be a new candidate for the susceptibility locus of IDDM. However, because no IDDM locus has been identified near 3p21 until now, further investigations are needed to confirm this statement. | [
{
"begin_idx": "64",
"end_idx": "99",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "insulin-dependent diabetes mellitus"
},
{
"begin_idx": "195",
"end_idx": "230",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "insulin-dependent diabetes mellitus"
},
{
"begin_idx": "232",
"end_idx": "236",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "664",
"end_idx": "668",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "829",
"end_idx": "833",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "929",
"end_idx": "933",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "982",
"end_idx": "986",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1114",
"end_idx": "1118",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1574",
"end_idx": "1578",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1600",
"end_idx": "1604",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1223",
"end_idx": "1235",
"entity_id": "D007249",
"entity_type": "Disease",
"text_name": "inflammation"
},
{
"begin_idx": "28",
"end_idx": "32",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "271",
"end_idx": "275",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "422",
"end_idx": "426",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "19",
"end_idx": "23",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "262",
"end_idx": "266",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "490",
"end_idx": "494",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "512",
"end_idx": "516",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "630",
"end_idx": "634",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "939",
"end_idx": "943",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "1157",
"end_idx": "1161",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "1313",
"end_idx": "1317",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
},
{
"begin_idx": "1509",
"end_idx": "1513",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "28",
"end_idx": "32",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "262",
"end_idx": "266",
"entity_id": "729230",
"entity_type": "Gene",
"text_name": "CCR2"
}
] | [
{
"begin_idx": "64",
"end_idx": "99",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "insulin-dependent diabetes mellitus"
},
{
"begin_idx": "664",
"end_idx": "668",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
}
] | [
"CCR5",
"CCR2"
] | [
"insulin-dependent diabetes mellitus",
"IDDM"
] |
10400907 | Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. | Angiotensin II and hypertension increase vascular oxidant stress. We examined how these might affect expression of the extracellular superoxide dismutase (ecSOD), a major form of vascular SOD. In mice, angiotensin II infusion (1.1 mg/kg for 7 days) increased systolic blood pressure from 107+/-3 to 152+/-9 mm Hg and caused a 3-fold increase in ecSOD, but there was no change in the cytosolic Cu/Zn SOD protein, as determined by Western blot analysis. This was associated with a similar increase in ecSOD mRNA as assessed by RNase protection assay and was prevented by losartan. Induction of ecSOD by angiotensin II was not due to hypertension alone, because hypertension caused by norepinephrine (5.6 mg. kg-1. d-1) had no effect on ecSOD. Similarly, exposure of mouse aortas to angiotensin II (100 nmol/L) in organoid culture increased ecSOD by approximately 2-fold. In the organoid culture, angiotensin II-induced upregulation of ecSOD was prevented by losartan (10 micromol/L) and PD985059 (30 micromol/L), a specific inhibitor of p42/44 MAP kinase kinase. Angiotensin II activates the NADH/NADPH oxidase; however, diphenyleneiodonium chloride (10 micromol/L), an inhibitor of this oxidase, did not prevent p42/44 MAP kinase phosphorylation or ecSOD induction by angiotensin II. Finally, in human aortic smooth muscle cells, angiotensin II moderately increased transcriptional rate (as assessed by nuclear run-on analysis) but markedly increased ecSOD mRNA stability. Thus, angiotensin II increases ecSOD expression independent of hypertension, and this increase involves both an increase in ecSOD transcription and stabilization of ecSOD mRNA. This effect of angiotensin II on ecSOD expression may modulate the oxidative state of the vessel wall in pathological processes in which the renin-angiotensin system is activated. | [
{
"begin_idx": "82",
"end_idx": "94",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "115",
"end_idx": "127",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "727",
"end_idx": "739",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "755",
"end_idx": "767",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "1631",
"end_idx": "1643",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "63",
"end_idx": "77",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "96",
"end_idx": "110",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "Angiotensin II"
},
{
"begin_idx": "298",
"end_idx": "312",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "697",
"end_idx": "711",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "876",
"end_idx": "890",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "990",
"end_idx": "1004",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1157",
"end_idx": "1171",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "Angiotensin II"
},
{
"begin_idx": "1363",
"end_idx": "1377",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1425",
"end_idx": "1439",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1574",
"end_idx": "1588",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1760",
"end_idx": "1774",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1131",
"end_idx": "1134",
"entity_id": "23552",
"entity_type": "Gene",
"text_name": "p42"
},
{
"begin_idx": "1307",
"end_idx": "1310",
"entity_id": "23552",
"entity_type": "Gene",
"text_name": "p42"
},
{
"begin_idx": "251",
"end_idx": "256",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "441",
"end_idx": "446",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "595",
"end_idx": "600",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "688",
"end_idx": "693",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "830",
"end_idx": "835",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "934",
"end_idx": "939",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1029",
"end_idx": "1034",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1344",
"end_idx": "1349",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1546",
"end_idx": "1551",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1599",
"end_idx": "1604",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1692",
"end_idx": "1697",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1733",
"end_idx": "1738",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
},
{
"begin_idx": "1778",
"end_idx": "1783",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "63",
"end_idx": "77",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "688",
"end_idx": "693",
"entity_id": "6649",
"entity_type": "Gene",
"text_name": "ecSOD"
}
] | [
{
"begin_idx": "82",
"end_idx": "94",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "82",
"end_idx": "94",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
}
] | [
"angiotensin II",
"ecSOD"
] | [
"hypertension",
"hypertension"
] |
10400992 | Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. | Mutations in superoxide dismutase 1 (SOD1) polypeptides cause a form of familial amyotrophic lateral sclerosis (FALS). In different kindreds, harboring different mutations, the duration of illness tends to be similar for a given mutation. For example, patients inheriting a substitution of valine for alanine at position four (A4V) average a 1.5 year life expectancy after the onset of symptoms, whereas patients harboring a substitution of arginine for histidine at position 46 (H46R) average an 18 year life expectancy after disease onset. Here, we examine a number of biochemical and biophysical properties of nine different FALS variants of SOD1 polypeptides, including enzymatic activity (which relates indirectly to the affinity of the enzyme for copper), polypeptide half-life, resistance to proteolytic degradation and solubility, in an effort to determine whether a specific property of these enzymes correlates with clinical progression. We find that although all the mutants tested appear to be soluble, the different mutants show a remarkable degree of variation with respect to activity, polypeptide half-life and resistance to proteolysis. However, these variables do not stratify in a manner that correlates with clinical progression. We conclude that the basis for the different life expectancies of patients in different kindreds of sod1-linked FALS may result from an as yet unidentified property of these mutant enzymes. | [
{
"begin_idx": "132",
"end_idx": "170",
"entity_id": "C531617",
"entity_type": "Disease",
"text_name": "familial amyotrophic lateral sclerosis"
},
{
"begin_idx": "253",
"end_idx": "291",
"entity_id": "C531617",
"entity_type": "Disease",
"text_name": "familial amyotrophic lateral sclerosis"
},
{
"begin_idx": "293",
"end_idx": "297",
"entity_id": "C531617",
"entity_type": "Disease",
"text_name": "FALS"
},
{
"begin_idx": "809",
"end_idx": "813",
"entity_id": "C531617",
"entity_type": "Disease",
"text_name": "FALS"
},
{
"begin_idx": "1543",
"end_idx": "1547",
"entity_id": "C531617",
"entity_type": "Disease",
"text_name": "FALS"
},
{
"begin_idx": "62",
"end_idx": "84",
"entity_id": "6647",
"entity_type": "Gene",
"text_name": "superoxide dismutase 1"
},
{
"begin_idx": "194",
"end_idx": "216",
"entity_id": "6647",
"entity_type": "Gene",
"text_name": "superoxide dismutase 1"
},
{
"begin_idx": "218",
"end_idx": "222",
"entity_id": "6647",
"entity_type": "Gene",
"text_name": "SOD1"
},
{
"begin_idx": "826",
"end_idx": "830",
"entity_id": "6647",
"entity_type": "Gene",
"text_name": "SOD1"
},
{
"begin_idx": "1531",
"end_idx": "1535",
"entity_id": "6647",
"entity_type": "Gene",
"text_name": "sod1"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "62",
"end_idx": "84",
"entity_id": "6647",
"entity_type": "Gene",
"text_name": "superoxide dismutase 1"
}
] | [
{
"begin_idx": "132",
"end_idx": "170",
"entity_id": "C531617",
"entity_type": "Disease",
"text_name": "familial amyotrophic lateral sclerosis"
}
] | [
"superoxide dismutase 1"
] | [
"familial amyotrophic lateral sclerosis"
] |
10401001 | Identification and characterization of three novel missense mutations in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of isoprene biosynthesis. | Mevalonic aciduria is a rare autosomal recessive metabolic disorder, characterized by psychomotor retardation, failure to thrive, hepatosplenomegaly, anemia and recurrent febrile crises. The disorder is caused by a deficient activity of mevalonate kinase due to mutations in the encoding gene. Thus far, only two disease-causing mutations have been identified. We now report four different missense mutations including three novel ones, which were identified by sequence analysis of mevalonate kinase cDNA from three mevalonic aciduria patients. All mutations affect conserved amino acids. Heterologous expression of the corresponding mutant mevalonate kinases as fusion proteins with glutathione S -transferase in Escherichia coli showed a profound effect of each of the mutations on enzyme activity. In addition, immunoblot analysis of fibroblast lysates from patients using specific antibodies against mevalonate kinase identified virtually no protein. These results demonstrate that the mutations affect not only the activity but also the stability of the mutant proteins. | [
{
"begin_idx": "291",
"end_idx": "309",
"entity_id": "C535727",
"entity_type": "Disease",
"text_name": "hepatosplenomegaly"
},
{
"begin_idx": "311",
"end_idx": "317",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "247",
"end_idx": "270",
"entity_id": "D011596",
"entity_type": "Disease",
"text_name": "psychomotor retardation"
},
{
"begin_idx": "190",
"end_idx": "228",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive metabolic disorder"
},
{
"begin_idx": "104",
"end_idx": "122",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "mevalonic aciduria"
},
{
"begin_idx": "161",
"end_idx": "179",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "Mevalonic aciduria"
},
{
"begin_idx": "678",
"end_idx": "696",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "mevalonic aciduria"
},
{
"begin_idx": "73",
"end_idx": "90",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "398",
"end_idx": "415",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "644",
"end_idx": "661",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "1066",
"end_idx": "1083",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "73",
"end_idx": "90",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
},
{
"begin_idx": "644",
"end_idx": "661",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "mevalonate kinase"
}
] | [
{
"begin_idx": "104",
"end_idx": "122",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "mevalonic aciduria"
},
{
"begin_idx": "311",
"end_idx": "317",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
}
] | [
"mevalonate kinase",
"mevalonate kinase"
] | [
"mevalonic aciduria",
"anemia"
] |
10401004 | Defective copper-induced trafficking and localization of the Menkes protein in patients with mild and copper-treated classical Menkes disease. | Menkes disease is an X-linked disorder of copper metabolism. An overall copper deficiency reduces the activity of copper-dependent enzymes accounting for the clinical presentation of affected individuals. The Menkes gene product (MNK) is a P-type ATPase and is considered to be the main copper efflux protein in most cells. The protein is located primarily at the trans -Golgi network (TGN), but relocalizes to the plasma membrane in elevated copper conditions to expel the excess copper from the cell. Here we report the first missense mutation which causes mild Menkes disease, a mutation in a successfully copper-treated classical Menkes patient and the effect of each mutation on the localization of MNK within the cell. Using western blot analysis, MNK was detectable in cells from both patients, but appeared to be mislocalized in the treated case. In the mild Menkes patient, the protein appeared to be located in the TGN but failed to redistribute towards the cell periphery in response to copper. This is the first description of a mutation in a Menkes patient which affects the trafficking of MNK, and the loss of this process is consistent with the clinical phenotype. | [
{
"begin_idx": "207",
"end_idx": "232",
"entity_id": "C535468",
"entity_type": "Disease",
"text_name": "overall copper deficiency"
},
{
"begin_idx": "586",
"end_idx": "603",
"entity_id": "C535468",
"entity_type": "Disease",
"text_name": "copper conditions"
},
{
"begin_idx": "61",
"end_idx": "67",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "127",
"end_idx": "141",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "143",
"end_idx": "157",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "164",
"end_idx": "202",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "X-linked disorder of copper metabolism"
},
{
"begin_idx": "352",
"end_idx": "358",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "373",
"end_idx": "376",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "707",
"end_idx": "721",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes disease"
},
{
"begin_idx": "777",
"end_idx": "783",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "847",
"end_idx": "850",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "897",
"end_idx": "900",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "1010",
"end_idx": "1016",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "1198",
"end_idx": "1204",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "Menkes"
},
{
"begin_idx": "1246",
"end_idx": "1249",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "MNK"
},
{
"begin_idx": "507",
"end_idx": "527",
"entity_id": "D012183",
"entity_type": "Disease",
"text_name": "trans -Golgi network"
},
{
"begin_idx": "529",
"end_idx": "532",
"entity_id": "D012183",
"entity_type": "Disease",
"text_name": "TGN"
},
{
"begin_idx": "1068",
"end_idx": "1071",
"entity_id": "D012183",
"entity_type": "Disease",
"text_name": "TGN"
},
{
"begin_idx": "373",
"end_idx": "376",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "847",
"end_idx": "850",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "897",
"end_idx": "900",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "1246",
"end_idx": "1249",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "373",
"end_idx": "376",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
},
{
"begin_idx": "373",
"end_idx": "376",
"entity_id": "538",
"entity_type": "Gene",
"text_name": "MNK"
}
] | [
{
"begin_idx": "164",
"end_idx": "202",
"entity_id": "D007706",
"entity_type": "Disease",
"text_name": "X-linked disorder of copper metabolism"
},
{
"begin_idx": "507",
"end_idx": "527",
"entity_id": "D012183",
"entity_type": "Disease",
"text_name": "trans -Golgi network"
}
] | [
"MNK",
"MNK"
] | [
"X-linked disorder of copper metabolism",
"trans -Golgi network"
] |
10402502 | Trend for an association between schizophrenia and D3S1310, a marker in proximity to the dopamine D3 receptor gene. | There is considerable controversy regarding a putative association between schizophrenia and a biallelic BalI polymorphism in the first exon of the dopamine D3 receptor gene (DRD3), although meta-analyses of published data suggest an association. If such an association exists, it may be detectable at markers physically close to DRD3. Accordingly, we conducted a case-control association study using D3S1310, a short tandem repeat polymorphism located approximately 700 kb telomeric to DRD3 on chromosome 3q13.3. The subjects were Swedish patients with schizophrenia (DSM III-R criteria, n = 110) and screened adult controls (n = 83). A trend for a negative association with the 141 bp allele was detected (chi2 = 7.6, d.f. = 1, P = 0.006; odds ratio 0.46, 95% confidence intervals 0.26, 0.81). However, following corrections for multiple comparisons using subgroups (n = 15) the difference was not significant. Also, due to the risk for population stratification in case-control association studies the results must be treated as tentative. If replicated the results may lend further support for the proposition of an association between schizophrenia and DRD3 or a gene in close proximity to DRD3 on chromosome 3q. | [
{
"begin_idx": "33",
"end_idx": "46",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "191",
"end_idx": "204",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "670",
"end_idx": "683",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "1256",
"end_idx": "1269",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "291",
"end_idx": "295",
"entity_id": "1814",
"entity_type": "Gene",
"text_name": "DRD3"
},
{
"begin_idx": "446",
"end_idx": "450",
"entity_id": "1814",
"entity_type": "Gene",
"text_name": "DRD3"
},
{
"begin_idx": "603",
"end_idx": "607",
"entity_id": "1814",
"entity_type": "Gene",
"text_name": "DRD3"
},
{
"begin_idx": "1274",
"end_idx": "1278",
"entity_id": "1814",
"entity_type": "Gene",
"text_name": "DRD3"
},
{
"begin_idx": "1311",
"end_idx": "1315",
"entity_id": "1814",
"entity_type": "Gene",
"text_name": "DRD3"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "291",
"end_idx": "295",
"entity_id": "1814",
"entity_type": "Gene",
"text_name": "DRD3"
}
] | [
{
"begin_idx": "33",
"end_idx": "46",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
}
] | [
"DRD3"
] | [
"schizophrenia"
] |
10402509 | -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. | Dopamine has long been hypothesised to be involved in the pathogenesis of schizophrenia. The dopamine D2 receptor is a major site of action of neuroleptic agents used in the treatment of schizophrenia. Arinami et al. [1997; Human Mol Genet 6:577-582] have recently sequenced the dopamine receptor 2 (DRD2) gene in Japanese individuals and identified a novel polymorphism: a single cytosine deletion at position -141 disrupting a BstN1 restriction site with a frequency of 0.22 in their control group. They then found a strong association with this polymorphism and schizophrenia (p < 0.001) with an odds ratio of 0.60 in a Japanese population. We have attempted to verify their results by repeating the RFLP analysis on a sample of Scottish schizophrenics and controls. We then combined our data with those from another British sample recruited using similar procedures. The total combined sample size was 439 schizophrenics and 437 controls. We obtained a significant association--p = 0.02 with an odds ratio of 1.41. Schizophrenia is associated with the C insertion in the Japanese, but that association is reversed in Caucasians. Linkage disequilibrium with a causative polymorphism nearby is the most likely explanation for this reverse association. | [
{
"begin_idx": "79",
"end_idx": "92",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "192",
"end_idx": "205",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "305",
"end_idx": "318",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "683",
"end_idx": "696",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "859",
"end_idx": "873",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "1028",
"end_idx": "1042",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
},
{
"begin_idx": "1137",
"end_idx": "1150",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "Schizophrenia"
},
{
"begin_idx": "211",
"end_idx": "231",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "dopamine D2 receptor"
},
{
"begin_idx": "418",
"end_idx": "422",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "DRD2"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "211",
"end_idx": "231",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "dopamine D2 receptor"
}
] | [
{
"begin_idx": "859",
"end_idx": "873",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenics"
}
] | [
"dopamine D2 receptor"
] | [
"schizophrenics"
] |
10403259 | HLA-DRB1 alleles associated with susceptibility or resistance to rheumatoid arthritis, articular deformities, and disability in Mexican Americans. | OBJECTIVE: To study the genetics (HLA-DRB1 allele associations) of rheumatoid arthritis (RA) susceptibility and severity among Mexican Americans, an important, but understudied, US population. METHODS: HLA-DRB1 alleles were compared between 141 Mexican American patients with RA and 54 unrelated Mexican Americans without RA, and the association of these alleles with articular deformities and disability was examined. HLA-DRB1 alleles were typed using polymerase chain reaction-sequence-specific primer amplification and were classified according to the 1996 World Health Organization nomenclature. RESULTS: Of the 141 patients, 105 (74%) had at least 1 copy of the shared epitope (SE) sequence, compared with 29 (54%) of the 54 controls (P = 0.007). A significant gene-dose effect was observed, with 31 patients (22%) being homozygous for the SE compared with 1 (2%) of the controls (P = 0.004). In terms of disease severity, only 3% of RA patients who were "null" for the SE were outliers in the rate of development of articular deformities, compared with 10% of heterozygotes and 27% of homozygotes (P = 0.002). Patients who were DRB1*08 positive had significantly fewer deformities per year of disease and a slower rate of development of disability than did patients with other DRB1 alleles. CONCLUSION: HLA-DRB1 alleles containing the SE are associated with susceptibility to RA in Mexican Americans, and may also be associated with a more rapid development of articular deformities and disability. HLA-DRB1*08 appears to have a protective influence on RA susceptibility and disease severity in Mexican Americans. | [
{
"begin_idx": "65",
"end_idx": "85",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "214",
"end_idx": "234",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "236",
"end_idx": "238",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "423",
"end_idx": "425",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "469",
"end_idx": "471",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "1086",
"end_idx": "1088",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "1529",
"end_idx": "1531",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "1706",
"end_idx": "1708",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "RA"
},
{
"begin_idx": "87",
"end_idx": "108",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "articular deformities"
},
{
"begin_idx": "515",
"end_idx": "536",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "articular deformities"
},
{
"begin_idx": "1169",
"end_idx": "1190",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "articular deformities"
},
{
"begin_idx": "1322",
"end_idx": "1353",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "deformities per year of disease"
},
{
"begin_idx": "1614",
"end_idx": "1635",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "articular deformities"
},
{
"begin_idx": "814",
"end_idx": "828",
"entity_id": "D012753",
"entity_type": "Disease",
"text_name": "shared epitope"
},
{
"begin_idx": "830",
"end_idx": "832",
"entity_id": "D012753",
"entity_type": "Disease",
"text_name": "SE"
},
{
"begin_idx": "992",
"end_idx": "994",
"entity_id": "D012753",
"entity_type": "Disease",
"text_name": "SE"
},
{
"begin_idx": "1122",
"end_idx": "1124",
"entity_id": "D012753",
"entity_type": "Disease",
"text_name": "SE"
},
{
"begin_idx": "1488",
"end_idx": "1490",
"entity_id": "D012753",
"entity_type": "Disease",
"text_name": "SE"
},
{
"begin_idx": "0",
"end_idx": "8",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "181",
"end_idx": "189",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "349",
"end_idx": "357",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "566",
"end_idx": "574",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "1281",
"end_idx": "1285",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "1430",
"end_idx": "1434",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "1456",
"end_idx": "1464",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "1652",
"end_idx": "1660",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "8",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "1281",
"end_idx": "1285",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
}
] | [
{
"begin_idx": "65",
"end_idx": "85",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "rheumatoid arthritis"
},
{
"begin_idx": "87",
"end_idx": "108",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "articular deformities"
}
] | [
"HLA-DRB1",
"DRB1"
] | [
"rheumatoid arthritis",
"articular deformities"
] |
10403400 | The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. | Genetic factors seem to play a significant role in susceptibility to systemic lupus erythematosus (SLE). We previously described the amino acid polymorphism (Val14Met) within the IFN-gamma receptor 1 (IFN-gammaRI), and that the frequency of the Metl4 allele in SLE patients was significantly higher than that of the healthy control population [Tanaka et al. (1999) Immunogenetics 49, 266-271]. We also found an amino acid polymorphism (Gln64Arg) within IFN-gamma receptor 2 (IFN-gammaR2). Since the IFN-gamma receptor is a complex consisting of IFN-gammaR1 and IFN-gammaR2, we searched for the particular combination of two kinds of amino acid polymorphisms found within the IFN-gamma receptor which plays a prominent role in susceptibility to SLE. The greatest risk of the development of SLE was detected in the individuals who had the combination of IFNGR1 Met14/Val14 genotype and IFNGR2 Gln64/Gln64 genotype. | [
{
"begin_idx": "111",
"end_idx": "139",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "210",
"end_idx": "238",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "240",
"end_idx": "243",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "402",
"end_idx": "405",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "885",
"end_idx": "888",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "930",
"end_idx": "933",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "640",
"end_idx": "649",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
},
{
"begin_idx": "816",
"end_idx": "825",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
},
{
"begin_idx": "40",
"end_idx": "82",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "interferon-gamma receptor 1 and receptor 2"
},
{
"begin_idx": "320",
"end_idx": "340",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFN-gamma receptor 1"
},
{
"begin_idx": "686",
"end_idx": "697",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFN-gammaR1"
},
{
"begin_idx": "993",
"end_idx": "999",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFNGR1"
},
{
"begin_idx": "594",
"end_idx": "614",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFN-gamma receptor 2"
},
{
"begin_idx": "616",
"end_idx": "627",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFN-gammaR2"
},
{
"begin_idx": "702",
"end_idx": "713",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFN-gammaR2"
},
{
"begin_idx": "1025",
"end_idx": "1031",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNGR2"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
true,
true,
true
] | [
{
"begin_idx": "40",
"end_idx": "82",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "interferon-gamma receptor 1 and receptor 2"
},
{
"begin_idx": "594",
"end_idx": "614",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFN-gamma receptor 2"
},
{
"begin_idx": "816",
"end_idx": "825",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
},
{
"begin_idx": "816",
"end_idx": "825",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
}
] | [
{
"begin_idx": "111",
"end_idx": "139",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "111",
"end_idx": "139",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "111",
"end_idx": "139",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "210",
"end_idx": "238",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
}
] | [
"interferon-gamma receptor 1 and receptor 2",
"IFN-gamma receptor 2",
"IFN-gamma",
"IFN-gamma"
] | [
"systemic lupus erythematosus",
"systemic lupus erythematosus",
"systemic lupus erythematosus",
"systemic lupus erythematosus"
] |
10404084 | Association between CYP17 gene polymorphism and risk of breast cancer in young women. | Long-term exposure to oestrogens is a well-recognised risk factor for breast cancer, whereas little is known about the influence of polymorphisms of genes involved in oestrogen biosynthesis and metabolism. A candidate, containing a single bp polymorphism, T-->C, (designated, A2 allele), might be the CYP17 gene, which codes for an enzyme involved in oestrogen synthesis. This polymorphism creates an additional Sp1-type promoter site (CCACC box), which has been shown to be associated with increased serum oestrogen levels. We performed a case-control study, to evaluate association of the CYP17 gene polymorphism with risk of breast cancer in young women (younger than 37 years). We found a statistically significant increased risk in carriers of at least 1 A2 allele [odds ratio (OR), 2.0; 95% confidence interval (CI), 1.1-3.5, p = 0.027], and a trend toward a gene-dose effect illustrated by a slightly higher risk for A2-homozygous subjects (OR, 2.8) than for heterozygous women (OR, 1. 9). Furthermore, when we investigated the CYP17 genotype in relation to tumour characteristics, breast cancer patients with 1 or 2 A2 alleles tended to have lower oestrogen receptor levels (risk ratio, 0.70; CI, 0.41-1.2, p = 0.44). Our findings suggest that CYP17 gene polymorphism influences breast carcinogenesis in young women. Int. J. Cancer (Pred. Oncol.) 84:350-353, 1999. | [
{
"begin_idx": "56",
"end_idx": "69",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "156",
"end_idx": "169",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "714",
"end_idx": "727",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1175",
"end_idx": "1188",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1151",
"end_idx": "1157",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumour"
},
{
"begin_idx": "1419",
"end_idx": "1425",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Cancer"
},
{
"begin_idx": "20",
"end_idx": "25",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
},
{
"begin_idx": "387",
"end_idx": "392",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
},
{
"begin_idx": "677",
"end_idx": "682",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
},
{
"begin_idx": "1121",
"end_idx": "1126",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
},
{
"begin_idx": "1338",
"end_idx": "1343",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "20",
"end_idx": "25",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
},
{
"begin_idx": "20",
"end_idx": "25",
"entity_id": "1586",
"entity_type": "Gene",
"text_name": "CYP17"
}
] | [
{
"begin_idx": "56",
"end_idx": "69",
"entity_id": "D001943",
"entity_type": "Disease",
"text_name": "breast cancer"
},
{
"begin_idx": "1419",
"end_idx": "1425",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Cancer"
}
] | [
"CYP17",
"CYP17"
] | [
"breast cancer",
"Cancer"
] |
10404093 | Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. | Overexpression of cyclooxygenase-2 (COX-2) has been reported in gastric cancers. However, the relationship between expression of COX-2 and clinico-pathological or genotypic features has not been elucidated. To address the issue, expression of COX-2 protein was analyzed in 100 gastric cancers as well as 7 gastric cancer cell lines by using immunoblot analysis. Overexpression of COX-2 in cancer tissues compared with matched non-cancerous tissues was found in 70% of cases and was significantly associated with lymphatic involvement, lymph node metastasis and advanced tumor stage. Interestingly, overexpression of COX-2 was less frequent in gastric cancers with microsatellite instability (MSI) than in those without MSI (8/20 vs. 62/80, p < 0.01). Expression of COX-2 protein was detected in some gastric cancer cell lines without MSI at various levels, but not in those with MSI. Our results suggest that overexpression of COX-2 may play an important role in tumor progression of gastric cancer and also support the notion that gastric cancers with and without MSI represent distinctive pathways of carcinogenesis. We also observed a reduction of MSI phenotype after aspirin or sulindac treatment in a hMLH1-defective gastric cancer cell line SNU-1, which lacks COX-2 expression. Int. J. Cancer (Pred. Oncol.) 84:400-403, 1999. | [
{
"begin_idx": "658",
"end_idx": "668",
"entity_id": "D009362",
"entity_type": "Disease",
"text_name": "metastasis"
},
{
"begin_idx": "501",
"end_idx": "507",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "682",
"end_idx": "687",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1075",
"end_idx": "1080",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "1404",
"end_idx": "1410",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "Cancer"
},
{
"begin_idx": "63",
"end_idx": "78",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancers"
},
{
"begin_idx": "176",
"end_idx": "191",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancers"
},
{
"begin_idx": "389",
"end_idx": "404",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancers"
},
{
"begin_idx": "418",
"end_idx": "432",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "755",
"end_idx": "770",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancers"
},
{
"begin_idx": "912",
"end_idx": "926",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1096",
"end_idx": "1110",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "1144",
"end_idx": "1159",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancers"
},
{
"begin_idx": "1334",
"end_idx": "1348",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancer"
},
{
"begin_idx": "84",
"end_idx": "110",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "microsatellite instability"
},
{
"begin_idx": "776",
"end_idx": "802",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "microsatellite instability"
},
{
"begin_idx": "804",
"end_idx": "807",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
},
{
"begin_idx": "831",
"end_idx": "834",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
},
{
"begin_idx": "946",
"end_idx": "949",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
},
{
"begin_idx": "991",
"end_idx": "994",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
},
{
"begin_idx": "1177",
"end_idx": "1180",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
},
{
"begin_idx": "1263",
"end_idx": "1266",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
},
{
"begin_idx": "1215",
"end_idx": "1229",
"entity_id": "D063646",
"entity_type": "Disease",
"text_name": "carcinogenesis"
},
{
"begin_idx": "1318",
"end_idx": "1323",
"entity_id": "4292",
"entity_type": "Gene",
"text_name": "hMLH1"
},
{
"begin_idx": "18",
"end_idx": "34",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "cyclooxygenase-2"
},
{
"begin_idx": "130",
"end_idx": "146",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "cyclooxygenase-2"
},
{
"begin_idx": "148",
"end_idx": "153",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "241",
"end_idx": "246",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "355",
"end_idx": "360",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "492",
"end_idx": "497",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "728",
"end_idx": "733",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "877",
"end_idx": "882",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "1039",
"end_idx": "1044",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
},
{
"begin_idx": "1378",
"end_idx": "1383",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "18",
"end_idx": "34",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "cyclooxygenase-2"
},
{
"begin_idx": "355",
"end_idx": "360",
"entity_id": "5743",
"entity_type": "Gene",
"text_name": "COX-2"
}
] | [
{
"begin_idx": "63",
"end_idx": "78",
"entity_id": "D013274",
"entity_type": "Disease",
"text_name": "gastric cancers"
},
{
"begin_idx": "946",
"end_idx": "949",
"entity_id": "D053842",
"entity_type": "Disease",
"text_name": "MSI"
}
] | [
"cyclooxygenase-2",
"COX-2"
] | [
"gastric cancers",
"MSI"
] |
10405934 | Frequency of the Fc gamma RIIIA-158F allele in African American patients with systemic lupus erythematosus. | OBJECTIVE: Defects in genes involved in immune complex clearance constitute one of the most common gene defects identified in patients with systemic lupus erythematosus (SLE). Defects in early complement components, complement receptors, and Fc receptors have all been implicated in the susceptibility to SLE. Recently, the role of functionally relevant Fc receptor polymorphisms in the etiology of SLE has been investigated. Specifically, a polymorphism of FC gamma RIII, termed Fc gamma RIIIA-158F, has been found to be associated with SLE in 2 largely Caucasian populations and appeared to constitute a risk factor for nephritis. We investigated the association of the Fc gamma RIIIA-158F and Fc gamma RIIIA-131R polymorphisms with SLE in an African American study population. METHODS: Nested polymerase chain reaction (PCR) and allele-specific PCR was used to genotype patients with SLE and controls. RESULTS: There was no difference in Fc gamma RIIIA-158F or Fc gamma RIIA-131R gene frequencies in the SLE populations compared to controls. There was no significant association between Fc gamma RIIIA-158F or Fc gamma RIIA-131R and any specific clinical or laboratory variable. CONCLUSION: In our African American study population, there did not appear to be any association of Fc gamma RIIA-158F or Fc gamma RIIA-131R with SLE. | [
{
"begin_idx": "78",
"end_idx": "106",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "248",
"end_idx": "276",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "278",
"end_idx": "281",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "413",
"end_idx": "416",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "507",
"end_idx": "510",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "646",
"end_idx": "649",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "843",
"end_idx": "846",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "995",
"end_idx": "998",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1115",
"end_idx": "1118",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "1436",
"end_idx": "1439",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "730",
"end_idx": "739",
"entity_id": "D009393",
"entity_type": "Disease",
"text_name": "nephritis"
},
{
"begin_idx": "566",
"end_idx": "579",
"entity_id": "2214",
"entity_type": "Gene",
"text_name": "FC gamma RIII"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "566",
"end_idx": "579",
"entity_id": "2214",
"entity_type": "Gene",
"text_name": "FC gamma RIII"
},
{
"begin_idx": "566",
"end_idx": "579",
"entity_id": "2214",
"entity_type": "Gene",
"text_name": "FC gamma RIII"
}
] | [
{
"begin_idx": "78",
"end_idx": "106",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "730",
"end_idx": "739",
"entity_id": "D009393",
"entity_type": "Disease",
"text_name": "nephritis"
}
] | [
"FC gamma RIII",
"FC gamma RIII"
] | [
"systemic lupus erythematosus",
"nephritis"
] |
10406990 | Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. | OBJECTIVES: Allelic variants of the APOE gene are known to influence the course of many neurological diseases and there is increasing evidence that apolipoprotein E (APOE) is a pivotal component in reinnervation and dendritic remodelling after neuronal injury. Previous studies did not show significant differences in the APOE allele frequencies in multiple sclerosis compared with controls but did not examine for correlation with disease severity. This study explores the relation of APOE genotypes with the disease severity. METHODS: Ninety five patients with multiple sclerosis were studied. Age of onset, type, and activity of the disease were recorded prospectively and genotyping was performed according to standard protocols. RESULTS: APOE allele frequencies of the group as a whole, the relapsing group, or the primary progressive group were not significantly different from those reported from matched historical controls. The epsilon4 allele was found to be more common in patients with a more aggressive type of multiple sclerosis (odds ratio=2.95, p=0.03). CONCLUSIONS: Although APOE does not seem to be implicated in the early pathogenesis of the disease, patients possessing the epsilon4 allele might have a reduced capacity for neuronal remodelling after relapses. | [
{
"begin_idx": "65",
"end_idx": "83",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "434",
"end_idx": "452",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "648",
"end_idx": "666",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "1109",
"end_idx": "1127",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "301",
"end_idx": "344",
"entity_id": "D009410",
"entity_type": "Disease",
"text_name": "dendritic remodelling after neuronal injury"
},
{
"begin_idx": "1329",
"end_idx": "1349",
"entity_id": "D009410",
"entity_type": "Disease",
"text_name": "neuronal remodelling"
},
{
"begin_idx": "173",
"end_idx": "194",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neurological diseases"
},
{
"begin_idx": "19",
"end_idx": "23",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "121",
"end_idx": "125",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "233",
"end_idx": "249",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "251",
"end_idx": "255",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "407",
"end_idx": "411",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "571",
"end_idx": "575",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "828",
"end_idx": "832",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1177",
"end_idx": "1181",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "233",
"end_idx": "249",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "1177",
"end_idx": "1181",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
{
"begin_idx": "65",
"end_idx": "83",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "173",
"end_idx": "194",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neurological diseases"
}
] | [
"apolipoprotein E",
"APOE"
] | [
"multiple sclerosis",
"neurological diseases"
] |
10408777 | Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers families. | The Peutz-Jeghers syndrome (PJS) is a rare hereditary disorder in which gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation, and a predisposition for developing cancer are transmitted in an autosomal dominant fashion. The recently identified LKB1/STK11 gene located at chromosome 19p13.3 is mutated in a number of PJS pedigrees. We performed mutation analysis in 19, predominantly Dutch, PJS families. In 12 of these families, we identified LKB1/STK11 mutations, none of which has been described before. These 12 novel LKB1/STK11 mutations consist of one nonsense mutation, three frameshift deletions, three frameshift insertions, two acceptor splice site mutations, and three missense mutations. In addition, we detected four polymorphisms in LKB1/STK11. In the remaining seven PJS families, we found no apparent abnormalities of the LKB1/STK1I gene, which could reflect the existence of locus heterogeneity in PJS. None of the mutations occurred in more than one family, and a number were demonstrated to have arisen de novo. The diverse array of mutations found, the apparent high mutation rate, as well as the existence of a possible second PJS locus, renders diagnostic or predictive genetic testing in individual patients difficult, although future identification of additional mutations or even gene(s) will help in increasing the yield of direct mutation analysis. | [
{
"begin_idx": "250",
"end_idx": "256",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "48",
"end_idx": "61",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "Peutz-Jeghers"
},
{
"begin_idx": "76",
"end_idx": "98",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "Peutz-Jeghers syndrome"
},
{
"begin_idx": "100",
"end_idx": "103",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "PJS"
},
{
"begin_idx": "161",
"end_idx": "184",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "hamartomatous polyposis"
},
{
"begin_idx": "403",
"end_idx": "406",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "PJS"
},
{
"begin_idx": "477",
"end_idx": "480",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "PJS"
},
{
"begin_idx": "868",
"end_idx": "871",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "PJS"
},
{
"begin_idx": "1001",
"end_idx": "1004",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "PJS"
},
{
"begin_idx": "1234",
"end_idx": "1237",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "PJS"
},
{
"begin_idx": "186",
"end_idx": "212",
"entity_id": "D010859",
"entity_type": "Disease",
"text_name": "mucocutaneous pigmentation"
},
{
"begin_idx": "115",
"end_idx": "134",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary disorder"
},
{
"begin_idx": "23",
"end_idx": "27",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "LKB1"
},
{
"begin_idx": "28",
"end_idx": "33",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
},
{
"begin_idx": "331",
"end_idx": "335",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "LKB1"
},
{
"begin_idx": "336",
"end_idx": "341",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
},
{
"begin_idx": "530",
"end_idx": "534",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "LKB1"
},
{
"begin_idx": "535",
"end_idx": "540",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
},
{
"begin_idx": "608",
"end_idx": "612",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "LKB1"
},
{
"begin_idx": "613",
"end_idx": "618",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
},
{
"begin_idx": "833",
"end_idx": "837",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "LKB1"
},
{
"begin_idx": "838",
"end_idx": "843",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
},
{
"begin_idx": "924",
"end_idx": "928",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "LKB1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "28",
"end_idx": "33",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
},
{
"begin_idx": "838",
"end_idx": "843",
"entity_id": "6794",
"entity_type": "Gene",
"text_name": "STK11"
}
] | [
{
"begin_idx": "161",
"end_idx": "184",
"entity_id": "D010580",
"entity_type": "Disease",
"text_name": "hamartomatous polyposis"
},
{
"begin_idx": "250",
"end_idx": "256",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
}
] | [
"STK11",
"STK11"
] | [
"hamartomatous polyposis",
"cancer"
] |
10408778 | Steroid 21-hydroxylase deficiency: mutational spectrum in Denmark, three novel mutations, and in vitro expression analysis. | We have investigated 68 unrelated 21-hydroxylase deficient Danish patients, representing 136 alleles, and determined the mutational spectrum of the CYP21 gene. The most frequent mutations detected were deletion of CYP21 and the splice mutation in intron 2 (I2-splice). Segregation analysis showed evidence of a de novo mutation in each of two patients. Three novel mutations were detected: G64E in exon 1, Q262X in exon 7, and A362V in exon 8. G64E and A362V were introduced in the CYP21 cDNA by in vitro site-directed mutagenesis, and the two corresponding proteins were transiently expressed in COS-7 cells. The activity of 21-hydroxylase was determined using the two hormone substrates 17-hydroxyprogesterone and progesterone. The analysis showed no enzyme activity for any of the substrates, a result that correlates well with the severity of the patients' disease. | [
{
"begin_idx": "0",
"end_idx": "33",
"entity_id": "C535979",
"entity_type": "Disease",
"text_name": "Steroid 21-hydroxylase deficiency"
},
{
"begin_idx": "272",
"end_idx": "277",
"entity_id": "1589",
"entity_type": "Gene",
"text_name": "CYP21"
},
{
"begin_idx": "338",
"end_idx": "343",
"entity_id": "1589",
"entity_type": "Gene",
"text_name": "CYP21"
},
{
"begin_idx": "606",
"end_idx": "611",
"entity_id": "1589",
"entity_type": "Gene",
"text_name": "CYP21"
}
] | [
"Yes"
] | [
false
] | [
{
"begin_idx": "272",
"end_idx": "277",
"entity_id": "1589",
"entity_type": "Gene",
"text_name": "CYP21"
}
] | [
{
"begin_idx": "0",
"end_idx": "33",
"entity_id": "C535979",
"entity_type": "Disease",
"text_name": "Steroid 21-hydroxylase deficiency"
}
] | [
"CYP21"
] | [
"Steroid 21-hydroxylase deficiency"
] |
10408783 | A series of mutations in the dihydropteridine reductase gene resulting in either abnormal RNA splicing or DHPR protein defects. Mutations in brief no. 244. Online. | Five novel mutations are described which result in the rare hyperphenylalaninemia DHPR-deficiency. Three of these are located at different intron/exon boundaries within the DHPR gene, and disrupt the maturation of the DHPR transcript such that little full-length mRNA can be detected by RT-PCR. Each mutation alters a conserved nucleotide within the splice site consensus sequence, and results in the skipping of an exon and, in one case, the activation of an inappropriate splicing signal. Two further mutations are missense mutations resulting in a non-conservative amino acid change within the DHPR protein (L14P and G17V) and are associated with a severe phenotype. | [
{
"begin_idx": "219",
"end_idx": "261",
"entity_id": "D010661",
"entity_type": "Disease",
"text_name": "rare hyperphenylalaninemia DHPR-deficiency"
},
{
"begin_idx": "106",
"end_idx": "110",
"entity_id": "5860",
"entity_type": "Gene",
"text_name": "DHPR"
},
{
"begin_idx": "337",
"end_idx": "341",
"entity_id": "5860",
"entity_type": "Gene",
"text_name": "DHPR"
},
{
"begin_idx": "382",
"end_idx": "386",
"entity_id": "5860",
"entity_type": "Gene",
"text_name": "DHPR"
},
{
"begin_idx": "761",
"end_idx": "765",
"entity_id": "5860",
"entity_type": "Gene",
"text_name": "DHPR"
}
] | [
"Yes"
] | [
false
] | [
{
"begin_idx": "106",
"end_idx": "110",
"entity_id": "5860",
"entity_type": "Gene",
"text_name": "DHPR"
}
] | [
{
"begin_idx": "219",
"end_idx": "261",
"entity_id": "D010661",
"entity_type": "Disease",
"text_name": "rare hyperphenylalaninemia DHPR-deficiency"
}
] | [
"DHPR"
] | [
"rare hyperphenylalaninemia DHPR-deficiency"
] |
10408784 | Mutational-screening in the factor VIII gene resulting in the identification of three novel mutations, one of which is a donor splice mutation. Mutations in brief no. 245. Online. | Hemophilia A is an X-linked bleeding disease caused by mutations in the coagulation factor VIII gene. The identification and characterization of pathogenic mutations allows the recognition of new mechanisms of functional disturbances of factor VIII. To screen for mutations exons 1-26 of the factor VIII gene have been amplified genomically and analyzed by SSCP followed by direct sequencing of respective exons showing abnormal electrophoretic mobility on SSCP analysis. In the present study we report the detection of four mutations in the factor VIII gene, of which three are novel. The mutational analysis of a patient with severe hemophilia A has revealed that the ac transversion at position 3 of the donor-splice-site of intron 23 results in the skipping of exon 23. A novel nonsense mutation Q1778X in exon 16 of factor VIII gene has been identified in a second hemophilia A case. Furthermore two missense mutations have been ascertained: a novel, S183R, causing a mild phenotype of hemophilia A and R282H, previously described in association with severe hemophilia A. | [
{
"begin_idx": "180",
"end_idx": "192",
"entity_id": "D006467",
"entity_type": "Disease",
"text_name": "Hemophilia A"
},
{
"begin_idx": "815",
"end_idx": "827",
"entity_id": "D006467",
"entity_type": "Disease",
"text_name": "hemophilia A"
},
{
"begin_idx": "1050",
"end_idx": "1062",
"entity_id": "D006467",
"entity_type": "Disease",
"text_name": "hemophilia A"
},
{
"begin_idx": "1171",
"end_idx": "1183",
"entity_id": "D006467",
"entity_type": "Disease",
"text_name": "hemophilia A"
},
{
"begin_idx": "1243",
"end_idx": "1255",
"entity_id": "D006467",
"entity_type": "Disease",
"text_name": "hemophilia A"
},
{
"begin_idx": "199",
"end_idx": "224",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked bleeding disease"
},
{
"begin_idx": "252",
"end_idx": "275",
"entity_id": "2157",
"entity_type": "Gene",
"text_name": "coagulation factor VIII"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "252",
"end_idx": "275",
"entity_id": "2157",
"entity_type": "Gene",
"text_name": "coagulation factor VIII"
},
{
"begin_idx": "252",
"end_idx": "275",
"entity_id": "2157",
"entity_type": "Gene",
"text_name": "coagulation factor VIII"
}
] | [
{
"begin_idx": "180",
"end_idx": "192",
"entity_id": "D006467",
"entity_type": "Disease",
"text_name": "Hemophilia A"
},
{
"begin_idx": "199",
"end_idx": "224",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked bleeding disease"
}
] | [
"coagulation factor VIII",
"coagulation factor VIII"
] | [
"Hemophilia A",
"X-linked bleeding disease"
] |
10408807 | Reduction of ischemic damage in NGF-transgenic mice: correlation with enhancement of antioxidant enzyme activities. | If permanent focal ischemia is induced by middle cerebral artery occlusion (MCAO), neurons within the infarcted territory die by necrosis and apoptosis (or programmed cell death). We have previously shown, using a mouse strain transgenic (tg) for the nerve growth factor (NGF) gene, that tg mice have consistently smaller infarcted areas than wild-type (wt) animals, correlated with upregulated NGF synthesis and impaired apoptotic cell death. We studied, in wt and tg mice subjected to MCAO, the activities of several antioxidant enzymes and the synthesis of the proteins of the Bcl-2 family. Our results show that the antiapoptotic Bcl-2 protein and glutathione peroxidase are recruited after MCAO. NGF-tg mice also had an intrinsic resistance to oxidative stress because their basal copper zinc superoxide dismutase (SOD) and glutathione transferase activities were high. Additionally, manganese SOD activity increased in NGF-tg mice after MCAO, correlating strongly with the resistance of these mice to apoptosis. | [
{
"begin_idx": "13",
"end_idx": "28",
"entity_id": "D002545",
"entity_type": "Disease",
"text_name": "ischemic damage"
},
{
"begin_idx": "135",
"end_idx": "143",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
},
{
"begin_idx": "245",
"end_idx": "253",
"entity_id": "D009336",
"entity_type": "Disease",
"text_name": "necrosis"
},
{
"begin_idx": "158",
"end_idx": "190",
"entity_id": "D020244",
"entity_type": "Disease",
"text_name": "middle cerebral artery occlusion"
},
{
"begin_idx": "192",
"end_idx": "196",
"entity_id": "D020244",
"entity_type": "Disease",
"text_name": "MCAO"
},
{
"begin_idx": "603",
"end_idx": "607",
"entity_id": "D020244",
"entity_type": "Disease",
"text_name": "MCAO"
},
{
"begin_idx": "811",
"end_idx": "815",
"entity_id": "D020244",
"entity_type": "Disease",
"text_name": "MCAO"
},
{
"begin_idx": "1059",
"end_idx": "1063",
"entity_id": "D020244",
"entity_type": "Disease",
"text_name": "MCAO"
},
{
"begin_idx": "32",
"end_idx": "35",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "NGF"
},
{
"begin_idx": "367",
"end_idx": "386",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "nerve growth factor"
},
{
"begin_idx": "388",
"end_idx": "391",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "NGF"
},
{
"begin_idx": "511",
"end_idx": "514",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "NGF"
},
{
"begin_idx": "817",
"end_idx": "820",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "NGF"
},
{
"begin_idx": "1041",
"end_idx": "1044",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "NGF"
},
{
"begin_idx": "696",
"end_idx": "701",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
},
{
"begin_idx": "750",
"end_idx": "755",
"entity_id": "596",
"entity_type": "Gene",
"text_name": "Bcl-2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "367",
"end_idx": "386",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "nerve growth factor"
},
{
"begin_idx": "388",
"end_idx": "391",
"entity_id": "4803",
"entity_type": "Gene",
"text_name": "NGF"
}
] | [
{
"begin_idx": "158",
"end_idx": "190",
"entity_id": "D020244",
"entity_type": "Disease",
"text_name": "middle cerebral artery occlusion"
},
{
"begin_idx": "135",
"end_idx": "143",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
}
] | [
"nerve growth factor",
"NGF"
] | [
"middle cerebral artery occlusion",
"ischemia"
] |
10408973 | The CTLA-4 gene is associated with multiple sclerosis. | We have investigated whether three intragenic polymorphisms of the CTLA-4 gene, a C/T base exchange in the promoter (p.-318), an A/G substitution in exon 1 (p.49) and a dinucleotide repeat polymorphism in exon 4 (p.642), were associated with genetic susceptibility to multiple sclerosis (MS). We observed a significant association (p < 0.05) for homozygosity for the G49 allele in a case-control analysis of 378 MS patients and 237 controls, and a transmission disequilibrium (p < 0.02) for the G49 allele in 31 MS families. This was further corroborated by evidence for linkage by the affected pedigree member (APM) analysis (p < 0.0002) and a transmission distortion (p < 0.05) of the exon 4(642) polymorphism. Sequencing of the promoter, the first and second exons and the parts of the first intron revealed no further polymorphisms. Our results suggest that a dysregulation of CTLA-4-driven downregulation of T-cell activation could be involved in the pathogenesis of MS. | [
{
"begin_idx": "35",
"end_idx": "53",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "323",
"end_idx": "341",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "343",
"end_idx": "345",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "467",
"end_idx": "469",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "567",
"end_idx": "569",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1027",
"end_idx": "1029",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "4",
"end_idx": "10",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "122",
"end_idx": "128",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
},
{
"begin_idx": "936",
"end_idx": "942",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "4",
"end_idx": "10",
"entity_id": "1493",
"entity_type": "Gene",
"text_name": "CTLA-4"
}
] | [
{
"begin_idx": "35",
"end_idx": "53",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
}
] | [
"CTLA-4"
] | [
"multiple sclerosis"
] |
10411504 | An allele of COL9A2 associated with intervertebral disc disease. | Intervertebral disc disease is one of the most common musculoskeletal disorders. A number of environmental and anthropometric risk factors may contribute to it, and recent reports have suggested the importance of genetic factors as well. The COL9A2 gene, which codes for one of the polypeptide chains of collagen IX that is expressed in the intervertebral disc, was screened for sequence variations in individuals with intervertebral disc disease. The analysis identified a putative disease-causing sequence variation that converted a codon for glutamine to one for tryptophan in six out of the 157 individuals but in none of 174 controls. The tryptophan allele cosegregated with the disease phenotype in the four families studied, giving a lod score (logarithm of odds ratio) for linkage of 4.5, and subsequent linkage disequilibrium analysis conditional on linkage gave an additional lod score of 7.1. | [
{
"begin_idx": "36",
"end_idx": "63",
"entity_id": "C535531",
"entity_type": "Disease",
"text_name": "intervertebral disc disease"
},
{
"begin_idx": "65",
"end_idx": "92",
"entity_id": "C535531",
"entity_type": "Disease",
"text_name": "Intervertebral disc disease"
},
{
"begin_idx": "484",
"end_idx": "511",
"entity_id": "C535531",
"entity_type": "Disease",
"text_name": "intervertebral disc disease"
},
{
"begin_idx": "119",
"end_idx": "144",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "musculoskeletal disorders"
},
{
"begin_idx": "13",
"end_idx": "19",
"entity_id": "1298",
"entity_type": "Gene",
"text_name": "COL9A2"
},
{
"begin_idx": "307",
"end_idx": "313",
"entity_id": "1298",
"entity_type": "Gene",
"text_name": "COL9A2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "13",
"end_idx": "19",
"entity_id": "1298",
"entity_type": "Gene",
"text_name": "COL9A2"
},
{
"begin_idx": "307",
"end_idx": "313",
"entity_id": "1298",
"entity_type": "Gene",
"text_name": "COL9A2"
}
] | [
{
"begin_idx": "36",
"end_idx": "63",
"entity_id": "C535531",
"entity_type": "Disease",
"text_name": "intervertebral disc disease"
},
{
"begin_idx": "119",
"end_idx": "144",
"entity_id": "D009140",
"entity_type": "Disease",
"text_name": "musculoskeletal disorders"
}
] | [
"COL9A2",
"COL9A2"
] | [
"intervertebral disc disease",
"musculoskeletal disorders"
] |
10417275 | Identification of a mutation cluster in mevalonate kinase deficiency, including a new mutation in a patient of Mennonite ancestry. | Mevalonate kinase (MKase) deficiency (MKD) is a rare autosomal recessive disorder in the pathway of cholesterol and nonsterol isoprenoid biosynthesis. Thus far, two disease-causing missense alleles have been identified, N301T and A334T. We report four additional mutations associated with MKD: L264F, T243I, L265P, and I268T, the last found in a patient of Mennonite ancestry. Electrophoretic analysis of bacterially expressed wild-type and mutant MKase indicated that I268T and T243I mutants produced normal or somewhat reduced amounts of MKase protein; conversely, L264F and L265P mutations resulted in considerably decreased, or absent, MKase protein. Immunoblot analysis of MKase from all patients suggested that the MKase polypeptide was grossly intact and produced in amounts comparable to control levels. Three mutations resulted in significantly diminished MKase enzyme activity (<2%), whereas the I268T allele yielded approximately 20% residual enzyme activity. Our results should allow more-accurate identification of carriers and indicate a mutation "cluster" within amino acids 240-270 of the mature MKase polypeptide. | [
{
"begin_idx": "184",
"end_idx": "212",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "40",
"end_idx": "68",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "mevalonate kinase deficiency"
},
{
"begin_idx": "131",
"end_idx": "167",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "Mevalonate kinase (MKase) deficiency"
},
{
"begin_idx": "150",
"end_idx": "155",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "579",
"end_idx": "584",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "671",
"end_idx": "676",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "771",
"end_idx": "776",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "809",
"end_idx": "814",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "852",
"end_idx": "857",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "996",
"end_idx": "1001",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "1243",
"end_idx": "1248",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "150",
"end_idx": "155",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
},
{
"begin_idx": "1243",
"end_idx": "1248",
"entity_id": "4598",
"entity_type": "Gene",
"text_name": "MKase"
}
] | [
{
"begin_idx": "131",
"end_idx": "167",
"entity_id": "D054078",
"entity_type": "Disease",
"text_name": "Mevalonate kinase (MKase) deficiency"
},
{
"begin_idx": "184",
"end_idx": "212",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
}
] | [
"MKase",
"MKase"
] | [
"Mevalonate kinase (MKase) deficiency",
"autosomal recessive disorder"
] |
10418172 | Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer. | BACKGROUND: We previously found that the majority (9/11) of p53 tumor suppressor gene mutations in 60 lung cancer patients in Taiwan were small intragenic deletions and nonsense mutations. To gain insights into the possible etiologic factors involved in these mutations and the prognostic significance of p53 gene mutations in lung cancer in Taiwan, we investigated the influence of polymorphism at p53, cytochrome p450 1A1 (CYP1A1) and glutathione S-transferase M1 (GSTM1) loci on p53 gene mutation, and the association of p53 gene mutation with prognosis in these lung cancer patients. METHODS: The polymorphism of these genes was determined by polymerase chain reaction followed by restriction enzyme digestion. The Pearson chi 2 test was used to compare allelic distributions between lung cancer patients and controls. The log-rank test was used to assess the significance of the survival differences between patients with and without p53 mutations. RESULTS: There was no significant difference with respect to the genotype distribution of p53, CYP1A1 and GSTM1 polymorphisms between patients with and without p53 mutations, although a tendency toward increasing frequency of the wild-type homozygote genotype of p53 polymorphism was noted in lung cancer patients containing p53 mutations. We further analyzed the association of p53 mutation with prognoses in lung cancer patients for whom postoperative survival data were available. The estimated median survival times for patients with and without p53 mutation were 25 and 28 months, respectively. There was no significant correlation between p53 mutation and survival. CONCLUSIONS: Our data suggest that p53 gene mutation may not be associated with polymorphisms of p53, CYP1A1 and GSTM1 genes, and it may have no significant effect on the prognosis of lung cancer patients in Taiwan. | [
{
"begin_idx": "122",
"end_idx": "133",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "237",
"end_idx": "248",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "462",
"end_idx": "473",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "701",
"end_idx": "712",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "923",
"end_idx": "934",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "1382",
"end_idx": "1393",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "1499",
"end_idx": "1510",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "1945",
"end_idx": "1956",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "199",
"end_idx": "204",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "34",
"end_idx": "40",
"entity_id": "1543",
"entity_type": "Gene",
"text_name": "CYP1A1"
},
{
"begin_idx": "539",
"end_idx": "558",
"entity_id": "1543",
"entity_type": "Gene",
"text_name": "cytochrome p450 1A1"
},
{
"begin_idx": "560",
"end_idx": "566",
"entity_id": "1543",
"entity_type": "Gene",
"text_name": "CYP1A1"
},
{
"begin_idx": "1184",
"end_idx": "1190",
"entity_id": "1543",
"entity_type": "Gene",
"text_name": "CYP1A1"
},
{
"begin_idx": "1863",
"end_idx": "1869",
"entity_id": "1543",
"entity_type": "Gene",
"text_name": "CYP1A1"
},
{
"begin_idx": "45",
"end_idx": "50",
"entity_id": "2944",
"entity_type": "Gene",
"text_name": "GSTM1"
},
{
"begin_idx": "572",
"end_idx": "600",
"entity_id": "2944",
"entity_type": "Gene",
"text_name": "glutathione S-transferase M1"
},
{
"begin_idx": "602",
"end_idx": "607",
"entity_id": "2944",
"entity_type": "Gene",
"text_name": "GSTM1"
},
{
"begin_idx": "1195",
"end_idx": "1200",
"entity_id": "2944",
"entity_type": "Gene",
"text_name": "GSTM1"
},
{
"begin_idx": "1874",
"end_idx": "1879",
"entity_id": "2944",
"entity_type": "Gene",
"text_name": "GSTM1"
},
{
"begin_idx": "29",
"end_idx": "32",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "59",
"end_idx": "62",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "91",
"end_idx": "94",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "195",
"end_idx": "198",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "440",
"end_idx": "443",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "534",
"end_idx": "537",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "617",
"end_idx": "620",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "659",
"end_idx": "662",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1074",
"end_idx": "1077",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1179",
"end_idx": "1182",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1249",
"end_idx": "1252",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1352",
"end_idx": "1355",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1414",
"end_idx": "1417",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1468",
"end_idx": "1471",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1639",
"end_idx": "1642",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1734",
"end_idx": "1737",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1796",
"end_idx": "1799",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1858",
"end_idx": "1861",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "539",
"end_idx": "558",
"entity_id": "1543",
"entity_type": "Gene",
"text_name": "cytochrome p450 1A1"
},
{
"begin_idx": "659",
"end_idx": "662",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
}
] | [
{
"begin_idx": "122",
"end_idx": "133",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "1382",
"end_idx": "1393",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
}
] | [
"cytochrome p450 1A1",
"p53"
] | [
"lung cancer",
"lung cancer"
] |
10421657 | Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. | In Crigler-Najjar type II patients and, recently, in Crigler-Najjar type I patients treated with human hepatocyte cell therapy, phenobarbital has been used for reducing the serum bilirubin load. Its effect is attributed to induction of the enzyme required for hepatic bilirubin elimination, UDP-glucuronosyltransferase, UGT1A1. This study investigated the expression and inducibility of UGT1A1 in human donor livers and their corresponding primary hepatocyte cultures. Immunoblot analysis using a specific antibody directed against the amino terminal of the human UGT1A1 isoform showed that 5 hepatocyte donors exhibited a >50-fold difference in UGT1A1 level. UGT1A1 protein level correlated strongly with both liver microsomal bilirubin UGT activity and liver UGT1A1 mRNA level (r(2) =.82 and.72, respectively). Of the 4 patients with the lowest UGT1A1 levels, 3 were homozygotes for the UGT1A1 promoter variant sequence associated with Gilbert's syndrome, and the fourth was a heterozygote. The 3 donors with the highest levels had a history of phenytoin exposure. Hepatocytes isolated from the phenytoin-exposed donors exhibited marked declines in UGT1A1 mRNA levels during culturing. Induction studies using hepatocytes treated for 48 hours with phenobarbital (2 mmol/L), oltipraz (50 micromol/L), or 3-methylcholanthrene (2.5 micromol/L) revealed UGT1A1-inducing effects of phenobarbital, oltipraz, and, in particular, 3-methylcholanthrene. Our data suggest that both genetic and environmental factors play an important role in the marked interindividual variability in UGT1A1 expression. An understanding of these mechanisms could lead to advances in the pharmacological therapy of life-threatening unconjugated hyperbilirubinemia. | [
{
"begin_idx": "188",
"end_idx": "210",
"entity_id": "C536213",
"entity_type": "Disease",
"text_name": "Crigler-Najjar type II"
},
{
"begin_idx": "238",
"end_idx": "259",
"entity_id": "D003414",
"entity_type": "Disease",
"text_name": "Crigler-Najjar type I"
},
{
"begin_idx": "1123",
"end_idx": "1141",
"entity_id": "D005878",
"entity_type": "Disease",
"text_name": "Gilbert's syndrome"
},
{
"begin_idx": "1903",
"end_idx": "1921",
"entity_id": "D006932",
"entity_type": "Disease",
"text_name": "hyperbilirubinemia"
},
{
"begin_idx": "79",
"end_idx": "85",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "505",
"end_idx": "511",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "572",
"end_idx": "578",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "749",
"end_idx": "755",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "831",
"end_idx": "837",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "845",
"end_idx": "851",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "946",
"end_idx": "952",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "1032",
"end_idx": "1038",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "1074",
"end_idx": "1080",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "1336",
"end_idx": "1342",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "1537",
"end_idx": "1543",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "1760",
"end_idx": "1766",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "79",
"end_idx": "85",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
},
{
"begin_idx": "1032",
"end_idx": "1038",
"entity_id": "54658",
"entity_type": "Gene",
"text_name": "UGT1A1"
}
] | [
{
"begin_idx": "1123",
"end_idx": "1141",
"entity_id": "D005878",
"entity_type": "Disease",
"text_name": "Gilbert's syndrome"
},
{
"begin_idx": "1903",
"end_idx": "1921",
"entity_id": "D006932",
"entity_type": "Disease",
"text_name": "hyperbilirubinemia"
}
] | [
"UGT1A1",
"UGT1A1"
] | [
"Gilbert's syndrome",
"hyperbilirubinemia"
] |
10422803 | An individual with a healthy phenotype in spite of a pathogenic LDL receptor mutation (C240F). | Familial hypercholesterolemia (FH) is caused by a defect in the function of the low density lipoprotein (LDL) receptor and inherited in an autosomal, codominant way. In this study we present a 13-year-old girl, compound heterozygote for the LDL receptor mutations C240F and Y167X. Fibroblasts from the patient showed very low cholesterol esterification rate, LDL uptake, and degradation compared to normal fibroblasts (< 2%, 8%, and < 2%, respectively). The C240F mutant was expressed in LDL receptor deficient CHOMldlA7 cells. Analysis of cell extracts by immunoblotting demonstrated delayed processing of the mutated LDL receptor, which was accumulated as a precursor protein of normal size. A high molecular weight form of the receptor was also detectable in these cells, which probably reflects cross-linking through the unpaired cysteine residue in the binding domain. Cells expressing the C240F mutant protein were unable to mediate uptake and degradation of LDL. The two siblings of the index case also carried the C240F mutation, but surprisingly one of them (a 17-year-old brother) showed no signs of hypercholesterolemia. This observation is consistent with the view that there may be cholesterol lowering mechanisms that can be activated, perhaps by mutations in known or hitherto unknown genes. | [
{
"begin_idx": "1205",
"end_idx": "1225",
"entity_id": "D006937",
"entity_type": "Disease",
"text_name": "hypercholesterolemia"
},
{
"begin_idx": "95",
"end_idx": "124",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "Familial hypercholesterolemia"
},
{
"begin_idx": "126",
"end_idx": "128",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "FH"
},
{
"begin_idx": "64",
"end_idx": "76",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
},
{
"begin_idx": "175",
"end_idx": "213",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "low density lipoprotein (LDL) receptor"
},
{
"begin_idx": "336",
"end_idx": "348",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
},
{
"begin_idx": "583",
"end_idx": "595",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
},
{
"begin_idx": "714",
"end_idx": "726",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "175",
"end_idx": "213",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "low density lipoprotein (LDL) receptor"
},
{
"begin_idx": "714",
"end_idx": "726",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
}
] | [
{
"begin_idx": "95",
"end_idx": "124",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "Familial hypercholesterolemia"
},
{
"begin_idx": "1205",
"end_idx": "1225",
"entity_id": "D006937",
"entity_type": "Disease",
"text_name": "hypercholesterolemia"
}
] | [
"low density lipoprotein (LDL) receptor",
"LDL receptor"
] | [
"Familial hypercholesterolemia",
"hypercholesterolemia"
] |
10425041 | Identification of 9 novel FBN1 mutations in German patients with Marfan syndrome. | We report 9 new mutations in German patients presenting with classical Marfan syndrome. All mutations occur in exons with calcium-binding (cb) epidermal growth factor-like (EGF) domains. Five mutations are missense involving exons 12, 27, 30, 44, and 52 with the resultant substitution of cysteine by phenylalanine (C504F), cysteine by tyrosine (C1129Y), tyrosine by cysteine (Y1261C), cysteine by serine (C1833S), and cysteine by tyrosine (C2142Y), respectively. The other four mutations are single base deletions in exons 39, 43, 48, and 58, at nucleotide A4826, C5311, T6018, and A7291, respectively, each resulting in frameshift with premature termination. Four mutations were detected in sporadic cases and are likely to be de novo. | [
{
"begin_idx": "65",
"end_idx": "80",
"entity_id": "D008382",
"entity_type": "Disease",
"text_name": "Marfan syndrome"
},
{
"begin_idx": "153",
"end_idx": "168",
"entity_id": "D008382",
"entity_type": "Disease",
"text_name": "Marfan syndrome"
},
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "2200",
"entity_type": "Gene",
"text_name": "FBN1"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "2200",
"entity_type": "Gene",
"text_name": "FBN1"
}
] | [
{
"begin_idx": "65",
"end_idx": "80",
"entity_id": "D008382",
"entity_type": "Disease",
"text_name": "Marfan syndrome"
}
] | [
"FBN1"
] | [
"Marfan syndrome"
] |
10428046 | Induction of the manganese superoxide dismutase gene by sphingomyelinase and ceramide. | The present study reports the effect of ceramide generated by hydrolysis of membrane sphingomyelin with bacterial sphingomyelinase (SMase) and of cell-permeable ceramide analogues on the expression of manganese superoxide dismutase (MnSOD). Incubation of the rat primary astrocytes with SMase led to a time- and dose-dependent increase in MnSOD activity. The increase in MnSOD activity was accompanied by an increase in MnSOD protein and mRNA. A similar effect on the expression of MnSOD was observed with the addition of cell-permeable ceramide analogues (C2 and C6). On the other hand, C2-dihydroceramide (N-acetylsphinganine), which lacks the functional critical double bond, was ineffective in inducing the expression of MnSOD. Nuclear run-on analysis showed that SMase and ceramide increased the rate of transcription of the MnSOD gene. Besides astrocytes, SMase was also found to induce the expression of MnSOD in rat mesangial cells, C6 glial cells, PC12 cells, and human skin fibroblasts. Markedly higher expression of mRNA, protein, and activity of MnSOD in skin fibroblasts from patients with Farber disease, a human disorder with pathognomonic accumulation of ceramide due to a deficiency of ceramidase, than in normal skin fibroblasts indicate that ceramide may act as a physiological inducer of MnSOD gene expression. However, stimulation of ceramide-mediated DNA fragmentation by antisense knockdown of MnSOD suggests that induction of MnSOD by ceramide is a protective response of the cell. | [
{
"begin_idx": "1190",
"end_idx": "1204",
"entity_id": "D055577",
"entity_type": "Disease",
"text_name": "Farber disease"
},
{
"begin_idx": "1276",
"end_idx": "1300",
"entity_id": "D055577",
"entity_type": "Disease",
"text_name": "deficiency of ceramidase"
},
{
"begin_idx": "17",
"end_idx": "47",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "manganese superoxide dismutase"
},
{
"begin_idx": "288",
"end_idx": "318",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "manganese superoxide dismutase"
},
{
"begin_idx": "320",
"end_idx": "325",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "426",
"end_idx": "431",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "458",
"end_idx": "463",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "507",
"end_idx": "512",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "569",
"end_idx": "574",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "812",
"end_idx": "817",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "917",
"end_idx": "922",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "998",
"end_idx": "1003",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "1145",
"end_idx": "1150",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "1395",
"end_idx": "1400",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "1504",
"end_idx": "1509",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
},
{
"begin_idx": "1537",
"end_idx": "1542",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "MnSOD"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "17",
"end_idx": "47",
"entity_id": "6648",
"entity_type": "Gene",
"text_name": "manganese superoxide dismutase"
}
] | [
{
"begin_idx": "1276",
"end_idx": "1300",
"entity_id": "D055577",
"entity_type": "Disease",
"text_name": "deficiency of ceramidase"
}
] | [
"manganese superoxide dismutase"
] | [
"deficiency of ceramidase"
] |
10431237 | The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. | Tangier disease (TD) is an autosomal recessive disorder of lipid metabolism. It is characterized by absence of plasma high-density lipoprotein (HDL) and deposition of cholesteryl esters in the reticulo-endothelial system with splenomegaly and enlargement of tonsils and lymph nodes. Although low HDL cholesterol is associated with an increased risk for coronary artery disease, this condition is not consistently found in TD pedigrees. Metabolic studies in TD patients have revealed a rapid catabolism of HDL and its precursors. In contrast to normal mononuclear phagocytes (MNP), MNP from TD individuals degrade internalized HDL in unusual lysosomes, indicating a defect in cellular lipid metabolism. HDL-mediated cholesterol efflux and intracellular lipid trafficking and turnover are abnormal in TD fibroblasts, which have a reduced in vitro growth rate. The TD locus has been mapped to chromosome 9q31. Here we present evidence that TD is caused by mutations in ABC1, encoding a member of the ATP-binding cassette (ABC) transporter family, located on chromosome 9q22-31. We have analysed five kindreds with TD and identified seven different mutations, including three that are expected to impair the function of the gene product. The identification of ABC1 as the TD locus has implications for the understanding of cellular HDL metabolism and reverse cholesterol transport, and its association with premature cardiovascular disease. | [
{
"begin_idx": "1497",
"end_idx": "1519",
"entity_id": "D002318",
"entity_type": "Disease",
"text_name": "cardiovascular disease"
},
{
"begin_idx": "437",
"end_idx": "460",
"entity_id": "D003324",
"entity_type": "Disease",
"text_name": "coronary artery disease"
},
{
"begin_idx": "310",
"end_idx": "322",
"entity_id": "D013163",
"entity_type": "Disease",
"text_name": "splenomegaly"
},
{
"begin_idx": "67",
"end_idx": "82",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "Tangier disease"
},
{
"begin_idx": "84",
"end_idx": "99",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "Tangier disease"
},
{
"begin_idx": "101",
"end_idx": "103",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "506",
"end_idx": "508",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "541",
"end_idx": "543",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "674",
"end_idx": "676",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "883",
"end_idx": "885",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "946",
"end_idx": "948",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "1021",
"end_idx": "1023",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "1195",
"end_idx": "1197",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "1352",
"end_idx": "1354",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "327",
"end_idx": "365",
"entity_id": "D014388",
"entity_type": "Disease",
"text_name": "enlargement of tonsils and lymph nodes"
},
{
"begin_idx": "111",
"end_idx": "159",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder of lipid metabolism"
},
{
"begin_idx": "1050",
"end_idx": "1054",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "1340",
"end_idx": "1344",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "1050",
"end_idx": "1054",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "1050",
"end_idx": "1054",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
}
] | [
{
"begin_idx": "67",
"end_idx": "82",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "Tangier disease"
},
{
"begin_idx": "111",
"end_idx": "159",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder of lipid metabolism"
}
] | [
"ABC1",
"ABC1"
] | [
"Tangier disease",
"autosomal recessive disorder of lipid metabolism"
] |
10433912 | Dlx5 regulates regional development of the branchial arches and sensory capsules. | We report the generation and analysis of mice homozygous for a targeted deletion of the Dlx5 homeobox gene. Dlx5 mutant mice have multiple defects in craniofacial structures, including their ears, noses, mandibles and calvaria, and die shortly after birth. A subset (28%) exhibit exencephaly. Ectodermal expression of Dlx5 is required for the development of olfactory and otic placode-derived epithelia and surrounding capsules. The nasal capsules are hypoplastic (e.g. lacking turbinates) and, in most cases, the right side is more severely affected than the left. Dorsal otic vesicle derivatives (e. g. semicircular canals and endolymphatic duct) and the surrounding capsule, are more severely affected than ventral (cochlear) structures. Dlx5 is also required in mandibular arch ectomesenchyme, as the proximal mandibular arch skeleton is dysmorphic. Dlx5 may control craniofacial development in part through the regulation of the goosecoid homeobox gene. goosecoid expression is greatly reduced in Dlx5 mutants, and both goosecoid and Dlx5 mutants share a number of similar craniofacial malformations. Dlx5 may perform a general role in skeletal differentiation, as exemplified by hypomineralization within the calvaria. The distinct focal defects within the branchial arches of the Dlx1, Dlx2 and Dlx5 mutants, along with the nested expression of their RNAs, support a model in which these genes have both redundant and unique functions in the regulation of regional patterning of the craniofacial ectomesenchyme. | [
{
"begin_idx": "1173",
"end_idx": "1186",
"entity_id": "D000014",
"entity_type": "Disease",
"text_name": "malformations"
},
{
"begin_idx": "43",
"end_idx": "59",
"entity_id": "D006053",
"entity_type": "Disease",
"text_name": "branchial arches"
},
{
"begin_idx": "1345",
"end_idx": "1361",
"entity_id": "D006053",
"entity_type": "Disease",
"text_name": "branchial arches"
},
{
"begin_idx": "362",
"end_idx": "373",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "exencephaly"
},
{
"begin_idx": "232",
"end_idx": "255",
"entity_id": "D019465",
"entity_type": "Disease",
"text_name": "craniofacial structures"
},
{
"begin_idx": "1369",
"end_idx": "1373",
"entity_id": "1745",
"entity_type": "Gene",
"text_name": "Dlx1"
},
{
"begin_idx": "1375",
"end_idx": "1379",
"entity_id": "1746",
"entity_type": "Gene",
"text_name": "Dlx2"
},
{
"begin_idx": "0",
"end_idx": "4",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "170",
"end_idx": "174",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "190",
"end_idx": "194",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "400",
"end_idx": "404",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "823",
"end_idx": "827",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "936",
"end_idx": "940",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "1084",
"end_idx": "1088",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "1121",
"end_idx": "1125",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "1188",
"end_idx": "1192",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "1384",
"end_idx": "1388",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "0",
"end_idx": "4",
"entity_id": "1749",
"entity_type": "Gene",
"text_name": "Dlx5"
},
{
"begin_idx": "1375",
"end_idx": "1379",
"entity_id": "1746",
"entity_type": "Gene",
"text_name": "Dlx2"
}
] | [
{
"begin_idx": "232",
"end_idx": "255",
"entity_id": "D019465",
"entity_type": "Disease",
"text_name": "craniofacial structures"
},
{
"begin_idx": "43",
"end_idx": "59",
"entity_id": "D006053",
"entity_type": "Disease",
"text_name": "branchial arches"
}
] | [
"Dlx5",
"Dlx2"
] | [
"craniofacial structures",
"branchial arches"
] |
10436404 | Association between vitamin D receptor gene polymorphism and nephrolithiasis. | AIMS: To study the distribution of vitamin D receptor (VDR) gene alleles in hypercalciuric and nonhypercalciuric nephrolithiasis patients, hypothesizing that distinct biochemical parameters would be associated with different VDR genotypes. METHODS: 12 hypercalciuric, 15 normocalciuric nephrolithiasis patients, and 150 healthy subjects were recruited. The individual genetic pattern for VDR was evaluated by DNA extraction followed by polymerase chain reaction amplification of the VDR gene and digestion with the restriction enzyme BsmI. RESULTS: In the hypercalciuric group, Bb patients represented 50% (6/12); bb patients 33% (4/12), and BB cases were 16% (2/12). The VDR frequency distribution was not statistically different in hypercalciuric patients and controls (Bb 72%; bb 16%; BB 12%). In the nonhypercalciuric group, the prevalence of the bb genotype (7/15; 47%) was thrice the percentage of control subjects, while the percentage of BB patients was similar to that of the control group (2/15; 13%). Patients with the bb haplotype exhibited a higher daily urinary calcium excretion. Among hypercalciuric patients, after a calcium-restricted diet, bb patients showed a 39% reduction in daily urinary calcium excretion in comparison with a nonsignificant 13% reduction observed in BB subjects (p = 0.004). CONCLUSIONS: The effects of VDR gene polymorphism on calcium metabolism contribute to the understanding of the pathogenesis of urinary calculi. | [
{
"begin_idx": "154",
"end_idx": "168",
"entity_id": "C562793",
"entity_type": "Disease",
"text_name": "hypercalciuric"
},
{
"begin_idx": "330",
"end_idx": "344",
"entity_id": "C562793",
"entity_type": "Disease",
"text_name": "hypercalciuric"
},
{
"begin_idx": "634",
"end_idx": "648",
"entity_id": "C562793",
"entity_type": "Disease",
"text_name": "hypercalciuric"
},
{
"begin_idx": "812",
"end_idx": "826",
"entity_id": "C562793",
"entity_type": "Disease",
"text_name": "hypercalciuric"
},
{
"begin_idx": "1179",
"end_idx": "1193",
"entity_id": "C562793",
"entity_type": "Disease",
"text_name": "hypercalciuric"
},
{
"begin_idx": "61",
"end_idx": "76",
"entity_id": "D053040",
"entity_type": "Disease",
"text_name": "nephrolithiasis"
},
{
"begin_idx": "191",
"end_idx": "206",
"entity_id": "D053040",
"entity_type": "Disease",
"text_name": "nephrolithiasis"
},
{
"begin_idx": "364",
"end_idx": "379",
"entity_id": "D053040",
"entity_type": "Disease",
"text_name": "nephrolithiasis"
},
{
"begin_idx": "20",
"end_idx": "38",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "113",
"end_idx": "131",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "133",
"end_idx": "136",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "303",
"end_idx": "306",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "466",
"end_idx": "469",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "561",
"end_idx": "564",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "750",
"end_idx": "753",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
},
{
"begin_idx": "1422",
"end_idx": "1425",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "20",
"end_idx": "38",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "561",
"end_idx": "564",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
}
] | [
{
"begin_idx": "61",
"end_idx": "76",
"entity_id": "D053040",
"entity_type": "Disease",
"text_name": "nephrolithiasis"
},
{
"begin_idx": "1179",
"end_idx": "1193",
"entity_id": "C562793",
"entity_type": "Disease",
"text_name": "hypercalciuric"
}
] | [
"vitamin D receptor",
"VDR"
] | [
"nephrolithiasis",
"hypercalciuric"
] |
10441340 | Subcortical band heterotopia in rare affected males can be caused by missense mutations in DCX (XLIS) or LIS1. | Subcortical band heterotopia (SBH) are bilateral and symmetric ribbons of gray matter found in the central white matter between the cortex and the ventricular surface, which comprises the less severe end of the lissencephaly (agyria-pachygyria-band) spectrum of malformations. Mutations in DCX (also known as XLIS ) have previously been described in females with SBH. We have now identified mutations in either the DCX or LIS1 gene in three of 11 boys studied, demonstrating for the first time that mutations of either DCX or LIS1 can cause SBH or mixed pachygyria-SBH (PCH-SBH) in males. All three changes detected are missense mutations, predicted to be of germline origin. They include a missense mutation in exon 4 of DCX in a boy with PCH-SBH (R78H), a different missense mutation in exon 4 of DCX in a boy with mild SBH and in his mildly affected mother (R89G) and a missense mutation in exon 6 of LIS1 in a boy with SBH (S169P). The missense mutations probably account for the less severe brain malformations, although other patients with missense mutations in the same exons have had diffuse lissencephaly. Therefore, it appears likely that the effect of the specific amino acid change on the protein determines the severity of the phenotype, with some mutations enabling residual protein function and allowing normal migration in a larger proportion of neurons. However, we expect that somatic mosaic mutations of both LIS1 and DCX will also prove to be an important mechanism in causing SBH in males. | [
{
"begin_idx": "373",
"end_idx": "386",
"entity_id": "D000014",
"entity_type": "Disease",
"text_name": "malformations"
},
{
"begin_idx": "1107",
"end_idx": "1126",
"entity_id": "D001927",
"entity_type": "Disease",
"text_name": "brain malformations"
},
{
"begin_idx": "105",
"end_idx": "109",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "LIS1"
},
{
"begin_idx": "322",
"end_idx": "335",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "lissencephaly"
},
{
"begin_idx": "337",
"end_idx": "343",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "agyria"
},
{
"begin_idx": "344",
"end_idx": "354",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "pachygyria"
},
{
"begin_idx": "533",
"end_idx": "537",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "LIS1"
},
{
"begin_idx": "637",
"end_idx": "641",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "LIS1"
},
{
"begin_idx": "1015",
"end_idx": "1019",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "LIS1"
},
{
"begin_idx": "1211",
"end_idx": "1224",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "lissencephaly"
},
{
"begin_idx": "1539",
"end_idx": "1543",
"entity_id": "D054082",
"entity_type": "Disease",
"text_name": "LIS1"
},
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "Subcortical band heterotopia"
},
{
"begin_idx": "96",
"end_idx": "100",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "XLIS"
},
{
"begin_idx": "111",
"end_idx": "139",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "Subcortical band heterotopia"
},
{
"begin_idx": "141",
"end_idx": "144",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "SBH"
},
{
"begin_idx": "420",
"end_idx": "424",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "XLIS"
},
{
"begin_idx": "474",
"end_idx": "477",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "SBH"
},
{
"begin_idx": "652",
"end_idx": "655",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "SBH"
},
{
"begin_idx": "665",
"end_idx": "679",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "pachygyria-SBH"
},
{
"begin_idx": "681",
"end_idx": "688",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "PCH-SBH"
},
{
"begin_idx": "851",
"end_idx": "858",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "PCH-SBH"
},
{
"begin_idx": "933",
"end_idx": "936",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "SBH"
},
{
"begin_idx": "1034",
"end_idx": "1037",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "SBH"
},
{
"begin_idx": "1608",
"end_idx": "1611",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "SBH"
},
{
"begin_idx": "91",
"end_idx": "94",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "96",
"end_idx": "100",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "XLIS"
},
{
"begin_idx": "401",
"end_idx": "404",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "420",
"end_idx": "424",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "XLIS"
},
{
"begin_idx": "526",
"end_idx": "529",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "630",
"end_idx": "633",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "833",
"end_idx": "836",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "910",
"end_idx": "913",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "1548",
"end_idx": "1551",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "DCX"
},
{
"begin_idx": "105",
"end_idx": "109",
"entity_id": "5048",
"entity_type": "Gene",
"text_name": "LIS1"
},
{
"begin_idx": "533",
"end_idx": "537",
"entity_id": "5048",
"entity_type": "Gene",
"text_name": "LIS1"
},
{
"begin_idx": "637",
"end_idx": "641",
"entity_id": "5048",
"entity_type": "Gene",
"text_name": "LIS1"
},
{
"begin_idx": "1015",
"end_idx": "1019",
"entity_id": "5048",
"entity_type": "Gene",
"text_name": "LIS1"
},
{
"begin_idx": "1539",
"end_idx": "1543",
"entity_id": "5048",
"entity_type": "Gene",
"text_name": "LIS1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "105",
"end_idx": "109",
"entity_id": "5048",
"entity_type": "Gene",
"text_name": "LIS1"
},
{
"begin_idx": "96",
"end_idx": "100",
"entity_id": "1641",
"entity_type": "Gene",
"text_name": "XLIS"
}
] | [
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "Subcortical band heterotopia"
},
{
"begin_idx": "420",
"end_idx": "424",
"entity_id": "D054221",
"entity_type": "Disease",
"text_name": "XLIS"
}
] | [
"LIS1",
"XLIS"
] | [
"Subcortical band heterotopia",
"XLIS"
] |
10441342 | Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome. | Greig cephalopolysyndactyly syndrome, characterized by craniofacial and limb anomalies (GCPS; MIM 175700), previously has been demonstrated to be associated with translocations as well as point mutations affecting one allele of the zinc finger gene GLI3. In addition to GCPS, Pallister-Hall syndrome (PHS; MIM 146510) and post-axial polydactyly type A (PAP-A; MIM 174200), two other disorders of human development, are caused by GLI3 mutations. In order to gain more insight into the mutational spectrum associated with a single phenotype, we report here the extension of the GLI3 mutation analysis to 24 new GCPS cases. We report the identification of 15 novel mutations present in one of the patient's GLI3 alleles. The mutations map throughout the coding gene regions. The majority are truncating mutations (nine of 15) that engender prematurely terminated protein products mostly but not exclusively N-terminally to or within the central region encoding the DNA-binding domain. Two missense and two splicing mutations mapping within the zinc finger motifs presumably also interfere with DNA binding. The five mutations identified within the protein regions C-terminal to the zinc fingers putatively affect additional functional properties of GLI3. In cell transfection experiments using fusions of the DNA-binding domain of yeast GAL4 to different segments of GLI3, transactivating capacity was assigned to two adjacent independent domains (TA(1)and TA(2)) in the C-terminal third of GLI3. Since these are the only functional domains affected by three C-terminally truncating mutations, we postulate that GCPS may be due either to haploinsufficiency resulting from the complete loss of one gene copy or to functional haploinsufficiency related to compromised properties of this transcription factor such as DNA binding and transactivation. | [
{
"begin_idx": "47",
"end_idx": "83",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "Greig cephalopolysyndactyly syndrome"
},
{
"begin_idx": "85",
"end_idx": "121",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "Greig cephalopolysyndactyly syndrome"
},
{
"begin_idx": "173",
"end_idx": "177",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "GCPS"
},
{
"begin_idx": "355",
"end_idx": "359",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "GCPS"
},
{
"begin_idx": "694",
"end_idx": "698",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "GCPS"
},
{
"begin_idx": "1694",
"end_idx": "1698",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "GCPS"
},
{
"begin_idx": "157",
"end_idx": "171",
"entity_id": "D017880",
"entity_type": "Disease",
"text_name": "limb anomalies"
},
{
"begin_idx": "361",
"end_idx": "384",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "Pallister-Hall syndrome"
},
{
"begin_idx": "386",
"end_idx": "389",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "PHS"
},
{
"begin_idx": "31",
"end_idx": "35",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "334",
"end_idx": "338",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "514",
"end_idx": "518",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "661",
"end_idx": "665",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "789",
"end_idx": "793",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1331",
"end_idx": "1335",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1449",
"end_idx": "1453",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1573",
"end_idx": "1577",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "407",
"end_idx": "436",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "post-axial polydactyly type A"
},
{
"begin_idx": "438",
"end_idx": "443",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "PAP-A"
},
{
"begin_idx": "1419",
"end_idx": "1423",
"entity_id": "855828",
"entity_type": "Gene",
"text_name": "GAL4"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "31",
"end_idx": "35",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1419",
"end_idx": "1423",
"entity_id": "855828",
"entity_type": "Gene",
"text_name": "GAL4"
}
] | [
{
"begin_idx": "47",
"end_idx": "83",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "Greig cephalopolysyndactyly syndrome"
},
{
"begin_idx": "1694",
"end_idx": "1698",
"entity_id": "C537300",
"entity_type": "Disease",
"text_name": "GCPS"
}
] | [
"GLI3",
"GAL4"
] | [
"Greig cephalopolysyndactyly syndrome",
"GCPS"
] |
10441482 | CYP2A6 gene deletion reduces susceptibility to lung cancer. | CYP2A6 is an enzyme with a high ability to activate a nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), to its potent and ultimate carcinogen. In the present study, we investigated the relationship between genetic polymorphism of CYP2A6 and lung cancer risk in a case-control study of Japanese subjects. Genotyping of the CYP2A6 gene in both healthy volunteers and lung cancer patients was conducted. The frequency with which the subjects carried homozygotes of the CYP2A6 gene deletion-type mutation (deletion), which causes lack of the enzyme activity, was lower in the lung cancer patients than in the healthy control subjects. The odds ratio (OR) of the group homozygous for the deletion was significantly lower and calculated to be 0.25 (95% CI; 0.08-0.83) when the OR for the population with homozygotes of the CYP2A6 wild-type gene was defined as 1.00. In the allelic-base analysis, there was also a significant decrease in the OR for the deletion allele. These data suggest that deficient CYP2A6 activity due to genetic polymorphism reduces lung cancer risk. | [
{
"begin_idx": "47",
"end_idx": "58",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "318",
"end_idx": "329",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "442",
"end_idx": "453",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "649",
"end_idx": "660",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung cancer"
},
{
"begin_idx": "1118",
"end_idx": "1137",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "reduces lung cancer"
},
{
"begin_idx": "0",
"end_idx": "6",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
},
{
"begin_idx": "60",
"end_idx": "66",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
},
{
"begin_idx": "307",
"end_idx": "313",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
},
{
"begin_idx": "399",
"end_idx": "405",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
},
{
"begin_idx": "543",
"end_idx": "549",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
},
{
"begin_idx": "894",
"end_idx": "900",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
},
{
"begin_idx": "1074",
"end_idx": "1080",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "0",
"end_idx": "6",
"entity_id": "1548",
"entity_type": "Gene",
"text_name": "CYP2A6"
}
] | [
{
"begin_idx": "1118",
"end_idx": "1137",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "reduces lung cancer"
}
] | [
"CYP2A6"
] | [
"reduces lung cancer"
] |
10441570 | The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations. | Functional characterization of a gene often requires the discovery of the full spectrum of its associated phenotypes. Mutations in the human GLI3 gene have been identified in Greig cepalopolysyndactyly, Pallister-Hall syndrome (PHS), and postaxial polydactyly type-A (PAP-A). We studied the involvement of GLI3 in additional phenotypes of digital abnormalities in one family (UR003) with preaxial polydactyly type-IV (PPD-IV), three families (UR014, UR015, and UR016) with dominant PAP-A/B (with PPD-A and -B in the same family), and one family with PHS. Linkage analysis showed no recombination with GLI3-linked polymorphisms. Family UR003 had a 1-nt frameshift insertion, resulting in a truncated protein of 1,245 amino acids. A frameshift mutation due to a 1-nt deletion was found in family UR014, resulting in a truncated protein of 1,280 amino acids. Family UR015 had a nonsense mutation, R643X, and family UR016 had a missense mutation, G727R, in a highly conserved amino acid of domain 3. The patient with PHS had a nonsense mutation, E1147X. These results add two phenotypes to the phenotypic spectrum caused by GLI3 mutations: the combined PAP-A/B and PPD-IV. These mutations do not support the suggested association between the mutations in GLI3 and the resulting phenotypes. We propose that all phenotypes associated with GLI3 mutations be called "GLI3 morphopathies," since the phenotypic borders of the resulting syndromes are not well defined and there is no apparent genotype-phenotype correlation. | [
{
"begin_idx": "107",
"end_idx": "135",
"entity_id": "C562429",
"entity_type": "Disease",
"text_name": "postaxial polydactyly type-A"
},
{
"begin_idx": "438",
"end_idx": "466",
"entity_id": "C562429",
"entity_type": "Disease",
"text_name": "postaxial polydactyly type-A"
},
{
"begin_idx": "539",
"end_idx": "560",
"entity_id": "D018376",
"entity_type": "Disease",
"text_name": "digital abnormalities"
},
{
"begin_idx": "403",
"end_idx": "426",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "Pallister-Hall syndrome"
},
{
"begin_idx": "428",
"end_idx": "431",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "PHS"
},
{
"begin_idx": "750",
"end_idx": "753",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "PHS"
},
{
"begin_idx": "1213",
"end_idx": "1216",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "PHS"
},
{
"begin_idx": "27",
"end_idx": "31",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "184",
"end_idx": "188",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "341",
"end_idx": "345",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "506",
"end_idx": "510",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "682",
"end_idx": "689",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "PAP-A/B"
},
{
"begin_idx": "801",
"end_idx": "805",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1320",
"end_idx": "1324",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1451",
"end_idx": "1455",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1533",
"end_idx": "1537",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "1559",
"end_idx": "1563",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
},
{
"begin_idx": "117",
"end_idx": "135",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "polydactyly type-A"
},
{
"begin_idx": "448",
"end_idx": "466",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "polydactyly type-A"
},
{
"begin_idx": "468",
"end_idx": "473",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "PAP-A"
},
{
"begin_idx": "682",
"end_idx": "689",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "PAP-A/B"
},
{
"begin_idx": "1349",
"end_idx": "1354",
"entity_id": "5069",
"entity_type": "Gene",
"text_name": "PAP-A"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "682",
"end_idx": "689",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "PAP-A/B"
},
{
"begin_idx": "184",
"end_idx": "188",
"entity_id": "2737",
"entity_type": "Gene",
"text_name": "GLI3"
}
] | [
{
"begin_idx": "107",
"end_idx": "135",
"entity_id": "C562429",
"entity_type": "Disease",
"text_name": "postaxial polydactyly type-A"
},
{
"begin_idx": "750",
"end_idx": "753",
"entity_id": "D054975",
"entity_type": "Disease",
"text_name": "PHS"
}
] | [
"PAP-A/B",
"GLI3"
] | [
"postaxial polydactyly type-A",
"PHS"
] |
10441571 | Missense mutation in the alternative splice region of the PAX6 gene in eye anomalies. | The PAX6 gene is involved in ocular morphogenesis, and PAX6 mutations have been detected in various types of ocular anomalies, including aniridia, Peters anomaly, corneal dystrophy, congenital cataract, and foveal hypoplasia. The gene encodes a transcriptional regulator that recognizes target genes through its paired-type DNA-binding domain. The paired domain is composed of two distinct DNA-binding subdomains, the N-terminal subdomain (NTS) and the C-terminal subdomain (CTS), which bind respective consensus DNA sequences. The human PAX6 gene produces two alternative splice isoforms that have the distinct structure of the paired domain. The insertion, into the NTS, of 14 additional amino acids encoded by exon 5a abolishes the DNA-binding activity of the NTS and unmasks the DNA-binding ability of the CTS. Thus, exon 5a appears to function as a molecular switch that specifies target genes. We ascertained a novel missense mutation in four pedigrees with Peters anomaly, congenital cataract, Axenfeldt anomaly, and/or foveal hypoplasia, which, to our knowledge, is the first mutation identified in the splice-variant region. A T-->A transition at the 20th nucleotide position of exon 5a results in a Val-->Asp (GTC-->GAC) substitution at the 7th codon of the alternative splice region. Functional analyses demonstrated that the V54D mutation slightly increased NTS binding and decreased CTS transactivation activity to almost half. | [
{
"begin_idx": "293",
"end_idx": "310",
"entity_id": "C537858",
"entity_type": "Disease",
"text_name": "foveal hypoplasia"
},
{
"begin_idx": "1113",
"end_idx": "1130",
"entity_id": "C537858",
"entity_type": "Disease",
"text_name": "foveal hypoplasia"
},
{
"begin_idx": "233",
"end_idx": "247",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters anomaly"
},
{
"begin_idx": "1050",
"end_idx": "1064",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters anomaly"
},
{
"begin_idx": "1087",
"end_idx": "1104",
"entity_id": "D000013",
"entity_type": "Disease",
"text_name": "Axenfeldt anomaly"
},
{
"begin_idx": "268",
"end_idx": "287",
"entity_id": "D002386",
"entity_type": "Disease",
"text_name": "congenital cataract"
},
{
"begin_idx": "1066",
"end_idx": "1085",
"entity_id": "D002386",
"entity_type": "Disease",
"text_name": "congenital cataract"
},
{
"begin_idx": "249",
"end_idx": "266",
"entity_id": "D003317",
"entity_type": "Disease",
"text_name": "corneal dystrophy"
},
{
"begin_idx": "71",
"end_idx": "84",
"entity_id": "D005124",
"entity_type": "Disease",
"text_name": "eye anomalies"
},
{
"begin_idx": "195",
"end_idx": "211",
"entity_id": "D005124",
"entity_type": "Disease",
"text_name": "ocular anomalies"
},
{
"begin_idx": "223",
"end_idx": "231",
"entity_id": "D015783",
"entity_type": "Disease",
"text_name": "aniridia"
},
{
"begin_idx": "58",
"end_idx": "62",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX6"
},
{
"begin_idx": "90",
"end_idx": "94",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX6"
},
{
"begin_idx": "141",
"end_idx": "145",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX6"
},
{
"begin_idx": "624",
"end_idx": "628",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX6"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "58",
"end_idx": "62",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX6"
},
{
"begin_idx": "141",
"end_idx": "145",
"entity_id": "5080",
"entity_type": "Gene",
"text_name": "PAX6"
}
] | [
{
"begin_idx": "233",
"end_idx": "247",
"entity_id": "C537884",
"entity_type": "Disease",
"text_name": "Peters anomaly"
},
{
"begin_idx": "293",
"end_idx": "310",
"entity_id": "C537858",
"entity_type": "Disease",
"text_name": "foveal hypoplasia"
}
] | [
"PAX6",
"PAX6"
] | [
"Peters anomaly",
"foveal hypoplasia"
] |
10441575 | EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. | Osteochondromas occur as sporadic solitary lesions or as multiple lesions, characterizing the hereditary multiple exostoses syndrome (EXT). Approximately 15% of all chondrosarcomas arise within the cartilaginous cap of an osteochondroma. EXT is genetically heterogeneous, and two genes, EXT1 and EXT2, located on 8q24 and 11p11-p12, respectively, have been cloned. It is still unclear whether osteochondroma is a developmental disorder or a true neoplasm. Furthermore, it is unclear whether inactivation of both alleles of an EXT gene, according to the tumor-suppressor model, is required for osteochondroma development, or whether a single EXT germline mutation acts in a dominant negative way. We therefore studied loss of heterozygosity and DNA ploidy in eight sporadic and six hereditary osteochondromas. EXT1- and EXT2-mutation analysis was performed in a total of 34 sporadic and hereditary osteochondromas and secondary peripheral chondrosarcomas. We demonstrated osteochondroma to be a true neoplasm, since aneuploidy was found in 4 of 10 osteochondromas. Furthermore, LOH was almost exclusively found at the EXT1 locus in 5 of 14 osteochondromas. Four novel constitutional cDNA alterations were detected in exon 1 of EXT1. Two patients with multiple osteochondromas demonstrated a germline mutation combined with loss of the remaining wild-type allele in three osteochondromas, indicating that, in cartilaginous cells of the growth plate, inactivation of both copies of the EXT1 gene is required for osteochondroma formation in hereditary cases. In contrast, no somatic EXT1 cDNA alterations were found in sporadic osteochondromas. No mutations were found in the EXT2 gene. | [
{
"begin_idx": "1138",
"end_idx": "1148",
"entity_id": "D000782",
"entity_type": "Disease",
"text_name": "aneuploidy"
},
{
"begin_idx": "536",
"end_idx": "558",
"entity_id": "D002658",
"entity_type": "Disease",
"text_name": "developmental disorder"
},
{
"begin_idx": "96",
"end_idx": "121",
"entity_id": "D002813",
"entity_type": "Disease",
"text_name": "secondary chondrosarcomas"
},
{
"begin_idx": "288",
"end_idx": "303",
"entity_id": "D002813",
"entity_type": "Disease",
"text_name": "chondrosarcomas"
},
{
"begin_idx": "1061",
"end_idx": "1076",
"entity_id": "D002813",
"entity_type": "Disease",
"text_name": "chondrosarcomas"
},
{
"begin_idx": "0",
"end_idx": "3",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
},
{
"begin_idx": "257",
"end_idx": "260",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
},
{
"begin_idx": "361",
"end_idx": "364",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
},
{
"begin_idx": "649",
"end_idx": "652",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
},
{
"begin_idx": "764",
"end_idx": "767",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
},
{
"begin_idx": "217",
"end_idx": "255",
"entity_id": "D005097",
"entity_type": "Disease",
"text_name": "hereditary multiple exostoses syndrome"
},
{
"begin_idx": "1373",
"end_idx": "1397",
"entity_id": "D005097",
"entity_type": "Disease",
"text_name": "multiple osteochondromas"
},
{
"begin_idx": "569",
"end_idx": "577",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasm"
},
{
"begin_idx": "1122",
"end_idx": "1130",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasm"
},
{
"begin_idx": "345",
"end_idx": "359",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondroma"
},
{
"begin_idx": "516",
"end_idx": "530",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondroma"
},
{
"begin_idx": "716",
"end_idx": "730",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondroma"
},
{
"begin_idx": "1094",
"end_idx": "1108",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondroma"
},
{
"begin_idx": "1170",
"end_idx": "1185",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondromas"
},
{
"begin_idx": "1262",
"end_idx": "1277",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondromas"
},
{
"begin_idx": "1493",
"end_idx": "1508",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondromas"
},
{
"begin_idx": "1632",
"end_idx": "1646",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "osteochondroma"
},
{
"begin_idx": "1738",
"end_idx": "1762",
"entity_id": "D015831",
"entity_type": "Disease",
"text_name": "sporadic osteochondromas"
},
{
"begin_idx": "65",
"end_idx": "91",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary osteochondromas"
},
{
"begin_idx": "904",
"end_idx": "930",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary osteochondromas"
},
{
"begin_idx": "1009",
"end_idx": "1035",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary osteochondromas"
},
{
"begin_idx": "410",
"end_idx": "414",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "932",
"end_idx": "936",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "1240",
"end_idx": "1244",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "1349",
"end_idx": "1353",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "1606",
"end_idx": "1610",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "1702",
"end_idx": "1706",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "419",
"end_idx": "423",
"entity_id": "2132",
"entity_type": "Gene",
"text_name": "EXT2"
},
{
"begin_idx": "942",
"end_idx": "946",
"entity_id": "2132",
"entity_type": "Gene",
"text_name": "EXT2"
},
{
"begin_idx": "1795",
"end_idx": "1799",
"entity_id": "2132",
"entity_type": "Gene",
"text_name": "EXT2"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
false,
false,
false
] | [
{
"begin_idx": "410",
"end_idx": "414",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "410",
"end_idx": "414",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "1240",
"end_idx": "1244",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
},
{
"begin_idx": "1349",
"end_idx": "1353",
"entity_id": "2131",
"entity_type": "Gene",
"text_name": "EXT1"
}
] | [
{
"begin_idx": "217",
"end_idx": "255",
"entity_id": "D005097",
"entity_type": "Disease",
"text_name": "hereditary multiple exostoses syndrome"
},
{
"begin_idx": "96",
"end_idx": "121",
"entity_id": "D002813",
"entity_type": "Disease",
"text_name": "secondary chondrosarcomas"
},
{
"begin_idx": "764",
"end_idx": "767",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
},
{
"begin_idx": "361",
"end_idx": "364",
"entity_id": "D005096",
"entity_type": "Disease",
"text_name": "EXT"
}
] | [
"EXT1",
"EXT1",
"EXT1",
"EXT1"
] | [
"hereditary multiple exostoses syndrome",
"secondary chondrosarcomas",
"EXT",
"EXT"
] |
10443546 | Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain. | The expression of mRNA coding for prepro-thyrotropin releasing hormone (preproTRH) was estimated in the rat brain in two animal models of limbic seizures, evoked by systemic administration of pilocarpine (400 mg/kg ip) or kainate (12 mg/kg ip). As shown by an in situ hybridization study, after 24h both pilocarpine- and kainate-induced seizures profoundly increased the preproTRH mRNA level in the dentate gyrus. After 72h, the preproTRH mRNA level was back to control values. Kainate-treated rats showed an elevated level of TRH in the hippocampus, septum, frontal and occipital cortex after 24 and 72h, whereas in the striatum and amygdala the TRH level was raised after 72h only. In the hypothalamus, TRH levels was lowered after 3 and 24h, and returned to the control after 72h. Pilocarpine-induced seizures also elevated the TRH level after 72h in the majority of the above structures, except for the hypothalamus and amygdala where no changes were found at any time point. A radioreceptor assay showed that kainate decreased the Bmax value of TRH receptors in the striatum and hippocampus after 3 and 24h, respectively, and had no effect on the Kd values. In contrast, pilocarpine-induced seizures lowered the Bmax of TRH receptors in the striatum, hippocampus and piriform cortex after 72h only, and decreased Kd values in the striatum, amygdala and frontal cortex. These data showed that pilocarpine- and kainate-induced seizures enhanced likewise preproTRH mRNA in the dentate gyrus; on the other hand, they differed with respect to time- and structure-related changes in TRH tissue levels and TRH receptors. These differences may have functional significance in TRH-dependent control mechanism of the seizure activity in these two models of limbic epilepsy. | [
{
"begin_idx": "1883",
"end_idx": "1898",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "limbic epilepsy"
},
{
"begin_idx": "44",
"end_idx": "52",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "276",
"end_idx": "284",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "468",
"end_idx": "476",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "935",
"end_idx": "943",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "1327",
"end_idx": "1335",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "1561",
"end_idx": "1569",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "1843",
"end_idx": "1850",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizure"
},
{
"begin_idx": "56",
"end_idx": "85",
"entity_id": "7200",
"entity_type": "Gene",
"text_name": "thyrotropin-releasing hormone"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "56",
"end_idx": "85",
"entity_id": "7200",
"entity_type": "Gene",
"text_name": "thyrotropin-releasing hormone"
},
{
"begin_idx": "56",
"end_idx": "85",
"entity_id": "7200",
"entity_type": "Gene",
"text_name": "thyrotropin-releasing hormone"
}
] | [
{
"begin_idx": "44",
"end_idx": "52",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "1883",
"end_idx": "1898",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "limbic epilepsy"
}
] | [
"thyrotropin-releasing hormone",
"thyrotropin-releasing hormone"
] | [
"seizures",
"limbic epilepsy"
] |
10443650 | Progressive decline in insulin levels in Rabson-Mendenhall syndrome. | Mutations in the insulin receptor gene cause the severe insulin-resistant syndromes leprechaunism and Rabson-Mendenhall syndrome, whose metabolic features include fasting hypoglycemia, post-prandial hyperglycemia, and extremely elevated insulin levels. Patients with Rabson-Mendenhall syndrome have a protracted course and eventually develop ketoacidosis. To determine the mechanism causing this progression and the paradoxical fasting hypoglycemia, we conducted a retrospective study in a patient with Rabson-Mendenhall syndrome, who was a compound heterozygous for two missense mutations affecting the kinase domain of the insulin receptor beta-subunit (I1115T and R1131W). At birth, the patient had fasting hypoglycemia and postprandial hyperglycemia. This was followed at approximately 3 yr of age by constant hyperglycemia and, at 6 yr of age, by constant ketoacidosis. Urinary organic acids during ketoacidosis resembled those of patients with type 1 diabetes. Plasma glucose levels increased (r2 = 0.31; P < 0.01), whereas insulin levels decreased with age (r2 = 0.51; P < 0.01). During periods ofhypoglycemia and hyperglycemia (0-1 yr of age), constant hyperglycemia (3-4 yr of age), and hyperglycemia with ketoacidosis (6-7 yr of age), insulin levels were significantly correlated with plasma glucose levels (P < 0.05). However, the slope of the regression and the predicted insulin level at zero glucose decreased with increasing age. When insulin levels were normalized for the plasma glucose concentrations, an exponential decrease in the insulin/glucose ratio was observed (r2 = 0.92; P < 0.01), with most of the decline occurring before 2 yr of age. These results indicate that the paradoxical fasting hypoglycemia of patients with Rabson-Mendenhall syndrome is associated with severely increased levels of circulating insulin and that the progression of this disease is due to a decline in insulin levels. | [
{
"begin_idx": "1026",
"end_idx": "1034",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "268",
"end_idx": "281",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "809",
"end_idx": "822",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "883",
"end_idx": "896",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "1190",
"end_idx": "1203",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "1230",
"end_idx": "1243",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "1265",
"end_idx": "1278",
"entity_id": "D006943",
"entity_type": "Disease",
"text_name": "hyperglycemia"
},
{
"begin_idx": "240",
"end_idx": "252",
"entity_id": "D007003",
"entity_type": "Disease",
"text_name": "hypoglycemia"
},
{
"begin_idx": "505",
"end_idx": "517",
"entity_id": "D007003",
"entity_type": "Disease",
"text_name": "hypoglycemia"
},
{
"begin_idx": "779",
"end_idx": "791",
"entity_id": "D007003",
"entity_type": "Disease",
"text_name": "hypoglycemia"
},
{
"begin_idx": "1785",
"end_idx": "1797",
"entity_id": "D007003",
"entity_type": "Disease",
"text_name": "hypoglycemia"
},
{
"begin_idx": "125",
"end_idx": "166",
"entity_id": "D007333",
"entity_type": "Disease",
"text_name": "insulin-resistant syndromes leprechaunism"
},
{
"begin_idx": "411",
"end_idx": "423",
"entity_id": "D007662",
"entity_type": "Disease",
"text_name": "ketoacidosis"
},
{
"begin_idx": "930",
"end_idx": "942",
"entity_id": "D007662",
"entity_type": "Disease",
"text_name": "ketoacidosis"
},
{
"begin_idx": "973",
"end_idx": "985",
"entity_id": "D007662",
"entity_type": "Disease",
"text_name": "ketoacidosis"
},
{
"begin_idx": "1284",
"end_idx": "1296",
"entity_id": "D007662",
"entity_type": "Disease",
"text_name": "ketoacidosis"
},
{
"begin_idx": "41",
"end_idx": "67",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
},
{
"begin_idx": "171",
"end_idx": "197",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
},
{
"begin_idx": "336",
"end_idx": "362",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
},
{
"begin_idx": "572",
"end_idx": "598",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
},
{
"begin_idx": "1815",
"end_idx": "1841",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
},
{
"begin_idx": "23",
"end_idx": "30",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "306",
"end_idx": "313",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "694",
"end_idx": "701",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1099",
"end_idx": "1106",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1314",
"end_idx": "1321",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1453",
"end_idx": "1460",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1519",
"end_idx": "1526",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1620",
"end_idx": "1627",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1902",
"end_idx": "1909",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "1974",
"end_idx": "1981",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
},
{
"begin_idx": "86",
"end_idx": "102",
"entity_id": "3643",
"entity_type": "Gene",
"text_name": "insulin receptor"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "86",
"end_idx": "102",
"entity_id": "3643",
"entity_type": "Gene",
"text_name": "insulin receptor"
},
{
"begin_idx": "1974",
"end_idx": "1981",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
}
] | [
{
"begin_idx": "41",
"end_idx": "67",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
},
{
"begin_idx": "572",
"end_idx": "598",
"entity_id": "D056731",
"entity_type": "Disease",
"text_name": "Rabson-Mendenhall syndrome"
}
] | [
"insulin receptor",
"insulin"
] | [
"Rabson-Mendenhall syndrome",
"Rabson-Mendenhall syndrome"
] |
10443997 | Association between drinking-related antisocial behavior and a polymorphism in the serotonin transporter gene in a Japanese population. | BACKGROUND: Involvement of the serotoninergic system (S/S) in alcoholism has been suggested in both mice and humans. Previous studies have suggested the S/S genotype of the serotonin transporter gene promoter polymorphism to be associated with severe alcohol dependence marked by severe withdrawal symptoms. It has also been associated with alcoholics who exhibit a dissocial personality disorder. METHODS: We examined the polymorphism in 166 Japanese alcoholics who experienced withdrawal seizure or delirium and 290 Japanese controls. RESULTS: The S/S genotype was not increased in the patients. Exploratory analyses showed significantly less frequent S allele and S/S genotype frequencies in the alcoholics with a history of drinking-related arrests than in the controls (p = 0.009 and p = 0.03, respectively), perhaps reflecting previously reported harm avoidance personality traits associated with S/S. Alcoholics with the L allele had a significantly earlier onset of alcohol dependence than those with the S/S genotype (p = 0.01). CONCLUSIONS: The present study failed to provide supportive evidence for an association of the S/S genotype with severe alcoholism marked by physical withdrawal symptoms or with antisocial behaviors among the Japanese. Although our data support involvement of the central serotoninergic system in some types of alcoholism, the potential association findings of this study emerged as only exploratory and, therefore, should be understood as tentative until replicated in other studies. | [
{
"begin_idx": "198",
"end_idx": "208",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "387",
"end_idx": "405",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "1110",
"end_idx": "1128",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "1294",
"end_idx": "1304",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1485",
"end_idx": "1495",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "37",
"end_idx": "56",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behavior"
},
{
"begin_idx": "1352",
"end_idx": "1372",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behaviors"
},
{
"begin_idx": "637",
"end_idx": "645",
"entity_id": "D003693",
"entity_type": "Disease",
"text_name": "delirium"
},
{
"begin_idx": "502",
"end_idx": "532",
"entity_id": "D010554",
"entity_type": "Disease",
"text_name": "dissocial personality disorder"
},
{
"begin_idx": "626",
"end_idx": "633",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizure"
},
{
"begin_idx": "423",
"end_idx": "442",
"entity_id": "D013375",
"entity_type": "Disease",
"text_name": "withdrawal symptoms"
},
{
"begin_idx": "1324",
"end_idx": "1343",
"entity_id": "D013375",
"entity_type": "Disease",
"text_name": "withdrawal symptoms"
},
{
"begin_idx": "83",
"end_idx": "104",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
},
{
"begin_idx": "309",
"end_idx": "330",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "83",
"end_idx": "104",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
},
{
"begin_idx": "309",
"end_idx": "330",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
}
] | [
{
"begin_idx": "387",
"end_idx": "405",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "1352",
"end_idx": "1372",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behaviors"
}
] | [
"serotonin transporter",
"serotonin transporter"
] | [
"alcohol dependence",
"antisocial behaviors"
] |
10445756 | Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. | The mechanisms underlying phenacetin-induced toxicity and carcinogenicity are not clear. In particular, it is not known whether these effects are mediated by metabolic activation of the drug. CYP1A2 is known to metabolize phenacetin in vitro. To determine the role of this enzyme in vivo, the toxicity and carcinogenicity of phenacetin was examined in Cyp1a2-null mice (that lack CYP1A2). Six- to 8-week-old wild type (+/+) or null (-/-) mice were fed either a control diet, or one containing 1.25% phenacetin, ad libitum for up to 67 weeks. Representative groups of mice were examined for phenacetin-induced toxicity and carcinogenicity after 36, 48, 58, or 67 weeks of feeding. Consistent with the known role of CYP1A2 in phenacetin metabolism, plasma levels of phenacetin were higher and acetaminophen levels lower in the (-/-) mice fed phenacetin compared to phenacetin-fed (+/+) controls. Weight gain was significantly depressed in both groups of phenacetin-fed mice after 4 weeks of feeding, and continued to be lower for the remainder of the experiment, compared to controls. Hepatomegaly and splenomegaly were more severe in (-/-) mice but present in both genotypes fed phenacetin at all time points assessed. Histological analysis of liver, kidney, spleen, and urogenital tract also revealed a differential response in the (-/-) mice fed phenacetin compared to (+/+) mice fed the same diet. Further, mortality was the most severe in the (-/-) mice fed phenacetin than in all other groups. Despite significant toxicity in (-/-) mice fed phenacetin, only one renal carcinoma was found among them. Results from this work demonstrate that, in the absence of CYP1A2, phenacetin is more toxic than in controls. This provides evidence that metabolism of phenacetin by CYP1A2 alters toxicity in vivo, and suggests that alternate CYP1A2-independent metabolic pathways contribute to its toxicity. | [
{
"begin_idx": "1155",
"end_idx": "1167",
"entity_id": "D006529",
"entity_type": "Disease",
"text_name": "Hepatomegaly"
},
{
"begin_idx": "1638",
"end_idx": "1653",
"entity_id": "D007680",
"entity_type": "Disease",
"text_name": "renal carcinoma"
},
{
"begin_idx": "1172",
"end_idx": "1184",
"entity_id": "D013163",
"entity_type": "Disease",
"text_name": "splenomegaly"
},
{
"begin_idx": "22",
"end_idx": "30",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "117",
"end_idx": "125",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "365",
"end_idx": "373",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "681",
"end_idx": "689",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "1590",
"end_idx": "1598",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "1856",
"end_idx": "1864",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "1958",
"end_idx": "1966",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "8",
"end_idx": "14",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "264",
"end_idx": "270",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "424",
"end_idx": "430",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "Cyp1a2"
},
{
"begin_idx": "452",
"end_idx": "458",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "786",
"end_idx": "792",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "1735",
"end_idx": "1741",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "1842",
"end_idx": "1848",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "1902",
"end_idx": "1908",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
}
] | [
"Yes",
"Yes",
"Yes",
"No",
"No",
"No"
] | [
false,
true,
false,
false,
false,
false
] | [
{
"begin_idx": "8",
"end_idx": "14",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "8",
"end_idx": "14",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "8",
"end_idx": "14",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "1902",
"end_idx": "1908",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "264",
"end_idx": "270",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "CYP1A2"
},
{
"begin_idx": "424",
"end_idx": "430",
"entity_id": "1544",
"entity_type": "Gene",
"text_name": "Cyp1a2"
}
] | [
{
"begin_idx": "1172",
"end_idx": "1184",
"entity_id": "D013163",
"entity_type": "Disease",
"text_name": "splenomegaly"
},
{
"begin_idx": "22",
"end_idx": "30",
"entity_id": "D064420",
"entity_type": "Disease",
"text_name": "toxicity"
},
{
"begin_idx": "1155",
"end_idx": "1167",
"entity_id": "D006529",
"entity_type": "Disease",
"text_name": "Hepatomegaly"
},
{
"begin_idx": "1638",
"end_idx": "1653",
"entity_id": "D007680",
"entity_type": "Disease",
"text_name": "renal carcinoma"
},
{
"begin_idx": "1638",
"end_idx": "1653",
"entity_id": "D007680",
"entity_type": "Disease",
"text_name": "renal carcinoma"
},
{
"begin_idx": "1638",
"end_idx": "1653",
"entity_id": "D007680",
"entity_type": "Disease",
"text_name": "renal carcinoma"
}
] | [
"CYP1A2",
"CYP1A2",
"CYP1A2",
"CYP1A2",
"CYP1A2",
"Cyp1a2"
] | [
"splenomegaly",
"toxicity",
"Hepatomegaly",
"renal carcinoma",
"renal carcinoma",
"renal carcinoma"
] |
10446171 | Functional and structural studies of wild type SOX9 and mutations causing campomelic dysplasia. | In humans, mutations in SOX9 result in a skeletal malformation syndrome, campomelic dysplasia (CD). The present study investigated two major classes of CD mutations: 1) point mutations in the high mobility group (HMG) domain and 2) truncations and frameshifts that alter the C terminus of the protein. We analyzed the effect of one novel mutation and three other point mutations in the HMG domain of SOX9 on the DNA binding and DNA bending properties of the protein. The F12L mutant HMG domain shows negligible DNA binding, the H65Y mutant shows minimal DNA binding, whereas the A19V mutant shows near wild type DNA binding and bends DNA normally. Interestingly, the P70R mutant has altered DNA binding specificity, but also bends DNA normally. The effects of the point mutations were interpreted using a molecular model of the SOX9 HMG domain. We analyzed the effects upon transcription of mutations resembling the truncation and frameshift mutations in CD patients, and found that progressive deletion of the C terminus causes progressive loss of transactivation. Maximal transactivation by SOX9 requires both the C-terminal domain rich in proline, glutamine, and serine and the adjacent domain composed entirely of proline, glutamine, and alanine. Thus, CD arises by mutations that interfere with DNA binding by SOX9 or truncate the C-terminal transactivation domain and thereby impede the ability of SOX9 to activate target genes during organ development. | [
{
"begin_idx": "137",
"end_idx": "167",
"entity_id": "D000014",
"entity_type": "Disease",
"text_name": "skeletal malformation syndrome"
},
{
"begin_idx": "74",
"end_idx": "94",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "campomelic dysplasia"
},
{
"begin_idx": "169",
"end_idx": "189",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "campomelic dysplasia"
},
{
"begin_idx": "191",
"end_idx": "193",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "248",
"end_idx": "250",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1051",
"end_idx": "1053",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1353",
"end_idx": "1355",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "47",
"end_idx": "51",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "120",
"end_idx": "124",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "496",
"end_idx": "500",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "924",
"end_idx": "928",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "1189",
"end_idx": "1193",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "1411",
"end_idx": "1415",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "1500",
"end_idx": "1504",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "47",
"end_idx": "51",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
},
{
"begin_idx": "1411",
"end_idx": "1415",
"entity_id": "6662",
"entity_type": "Gene",
"text_name": "SOX9"
}
] | [
{
"begin_idx": "74",
"end_idx": "94",
"entity_id": "D055036",
"entity_type": "Disease",
"text_name": "campomelic dysplasia"
},
{
"begin_idx": "137",
"end_idx": "167",
"entity_id": "D000014",
"entity_type": "Disease",
"text_name": "skeletal malformation syndrome"
}
] | [
"SOX9",
"SOX9"
] | [
"campomelic dysplasia",
"skeletal malformation syndrome"
] |
10447258 | Identification of a common PEX1 mutation in Zellweger syndrome. | The Zellweger spectrum of disease, encompassing Zellweger syndrome and the progressively milder phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease, is due to a failure to form functional peroxisomes. Cell fusion complementation studies demonstrated that these diseases are genetically heterogeneous, with two-thirds of all patients lying within a single complementation group, CG1. Molecular genetic and cell biology studies have shown that PEX1 is deficient in many CG1 patients. However, previous studies have focused on mildly affected patients and there is still no report of two mutant PEX1 alleles in any Zellweger syndrome patient. Furthermore, mutations in the PMP70 gene have also been identified in two Zellweger syndrome patients from CG1, raising the possibility that CG1 patients may represent a mixture of PEX1-deficient and PMP70-deficient individuals. To address the molecular basis of disease in Zellweger syndrome patients from CG1, we examined all 24 PEX1 exons in four patients, including both patients that have mutations in PMP70. PEX1 mutations were detected in all four patients, including a 1-bp insertion (c.2097insT) in exon 13 that was present in three of the four patients. Subsequent studies demonstrated that this mutation is present in one-half of all CG1 patients and correlates with the Zellweger syndrome phenotype. As this mutation leads to a loss of protein function its frequency makes it the most common cause of Zellweger syndrome, helping to explain the high percentage of patients that belong to CG1. | [
{
"begin_idx": "174",
"end_idx": "203",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "neonatal adrenoleukodystrophy"
},
{
"begin_idx": "44",
"end_idx": "62",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "68",
"end_idx": "97",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger spectrum of disease"
},
{
"begin_idx": "112",
"end_idx": "130",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "697",
"end_idx": "715",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "799",
"end_idx": "817",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "999",
"end_idx": "1017",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "1407",
"end_idx": "1425",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "1538",
"end_idx": "1556",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
},
{
"begin_idx": "208",
"end_idx": "232",
"entity_id": "D052919",
"entity_type": "Disease",
"text_name": "infantile Refsum disease"
},
{
"begin_idx": "463",
"end_idx": "466",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "553",
"end_idx": "556",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "832",
"end_idx": "835",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "866",
"end_idx": "869",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "1032",
"end_idx": "1035",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "1370",
"end_idx": "1373",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "1624",
"end_idx": "1627",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
},
{
"begin_idx": "27",
"end_idx": "31",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "527",
"end_idx": "531",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "677",
"end_idx": "681",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "906",
"end_idx": "910",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "1056",
"end_idx": "1060",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "1139",
"end_idx": "1143",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "755",
"end_idx": "760",
"entity_id": "5825",
"entity_type": "Gene",
"text_name": "PMP70"
},
{
"begin_idx": "925",
"end_idx": "930",
"entity_id": "5825",
"entity_type": "Gene",
"text_name": "PMP70"
},
{
"begin_idx": "1132",
"end_idx": "1137",
"entity_id": "5825",
"entity_type": "Gene",
"text_name": "PMP70"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "27",
"end_idx": "31",
"entity_id": "5189",
"entity_type": "Gene",
"text_name": "PEX1"
},
{
"begin_idx": "1370",
"end_idx": "1373",
"entity_id": "3895",
"entity_type": "Gene",
"text_name": "CG1"
}
] | [
{
"begin_idx": "68",
"end_idx": "97",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger spectrum of disease"
},
{
"begin_idx": "112",
"end_idx": "130",
"entity_id": "D015211",
"entity_type": "Disease",
"text_name": "Zellweger syndrome"
}
] | [
"PEX1",
"CG1"
] | [
"Zellweger spectrum of disease",
"Zellweger syndrome"
] |
10447259 | Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. | Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections, and caused by mutations in the WAS protein (WASP) gene. WASP contains several functional domains through which it interacts with proteins involved in intracellular signaling and regulation of the actin cytoskeleton. In this report, 17 WASP gene mutations were identified, 12 of which are novel. DNA of affected males and obligate carriers was PCR amplified and analyzed by SSCA, heteroduplex analysis, and direct sequencing. The effects of the mutations at the mRNA and protein level were ascertained by RT-PCR and Western blot analyses. All missense mutations were located in exons 1-4. Most of the nonsense, frameshift and splice site mutations were found in exons 6-11. Mutations that alter splice sites led to the synthesis of several types of mRNAs, a fraction of which represented the normally spliced product. The presence of normally spliced transcripts was correlated with a milder phenotype. When one such case was studied by Western blotting, reduced amounts of normal-size WASP were present. In other cases as well, a correlation was found between the amount of normal or mutant WASP present and the phenotypes of the affected individuals. No protein was detected in two individuals with severe WAS. Reduced levels of a normal-size WASP with a missense mutation were seen in two individuals with XLT. It is concluded that mutation analysis at the DNA level is not sufficient for predicting clinical course. Studies at the transcript and protein level are needed for a better assessment. | [
{
"begin_idx": "1589",
"end_idx": "1592",
"entity_id": "C564052",
"entity_type": "Disease",
"text_name": "XLT"
},
{
"begin_idx": "247",
"end_idx": "253",
"entity_id": "D004485",
"entity_type": "Disease",
"text_name": "eczema"
},
{
"begin_idx": "229",
"end_idx": "245",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "thrombocytopenia"
},
{
"begin_idx": "23",
"end_idx": "47",
"entity_id": "D014923",
"entity_type": "Disease",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "139",
"end_idx": "163",
"entity_id": "D014923",
"entity_type": "Disease",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "165",
"end_idx": "168",
"entity_id": "D014923",
"entity_type": "Disease",
"text_name": "WAS"
},
{
"begin_idx": "1488",
"end_idx": "1491",
"entity_id": "D014923",
"entity_type": "Disease",
"text_name": "WAS"
},
{
"begin_idx": "176",
"end_idx": "211",
"entity_id": "D053632",
"entity_type": "Disease",
"text_name": "X-linked recessive immunodeficiency"
},
{
"begin_idx": "23",
"end_idx": "47",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "139",
"end_idx": "163",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "312",
"end_idx": "323",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WAS protein"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
},
{
"begin_idx": "337",
"end_idx": "341",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
},
{
"begin_idx": "516",
"end_idx": "520",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
},
{
"begin_idx": "1266",
"end_idx": "1270",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
},
{
"begin_idx": "1372",
"end_idx": "1376",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
},
{
"begin_idx": "1525",
"end_idx": "1529",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
true,
true,
true
] | [
{
"begin_idx": "23",
"end_idx": "47",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "23",
"end_idx": "47",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "516",
"end_idx": "520",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "WASP"
},
{
"begin_idx": "139",
"end_idx": "163",
"entity_id": "7454",
"entity_type": "Gene",
"text_name": "Wiskott-Aldrich syndrome"
}
] | [
{
"begin_idx": "23",
"end_idx": "47",
"entity_id": "D014923",
"entity_type": "Disease",
"text_name": "Wiskott-Aldrich syndrome"
},
{
"begin_idx": "1589",
"end_idx": "1592",
"entity_id": "C564052",
"entity_type": "Disease",
"text_name": "XLT"
},
{
"begin_idx": "229",
"end_idx": "245",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "thrombocytopenia"
},
{
"begin_idx": "176",
"end_idx": "211",
"entity_id": "D053632",
"entity_type": "Disease",
"text_name": "X-linked recessive immunodeficiency"
}
] | [
"Wiskott-Aldrich syndrome",
"Wiskott-Aldrich syndrome",
"WASP",
"Wiskott-Aldrich syndrome"
] | [
"Wiskott-Aldrich syndrome",
"XLT",
"thrombocytopenia",
"X-linked recessive immunodeficiency"
] |
10447263 | Identification of recurrent and novel mutations in the LDL receptor gene in Japanese familial hypercholesterolemia. Mutation in brief no. 248. Online. | We used the denaturing gradient gel electrophoresis (DGGE) method to investigate 120 Japanese patients with familial hypercholesterolemia (FH) for mutations in the promoter region and the 18 exons and their flanking intron sequence of the low density lipoprotein (LDL) receptor gene. Fourteen aberrant DGGE patterns were found, and the underlying mutations were characterized by DNA sequencing. Five novel missense mutations (C317S, F382L A410T, L547V, and E693K), two nonsense mutations (W512X and K790X), four frameshift mutation (355del7, 1246ins5, 1687ins1, and 2035ins1), one splicing mutation (1845+2 T-->C), and two inframe mutations (661ins21 and 1115del9/ins6) were identified. Six of these mutations (L547V, E693K, W512X, 355del7, 1687ins1, and 20354ins1) have not been described before in FH. These newly identified mutations cosegregated in their family members with defective LDL receptor activity and hypercholesterolemia, and are thought to be causal for the FH phenotype. These results demonstrate that there is a broad spectrum of mutations in the LDL receptor gene in the Japanese population. | [
{
"begin_idx": "1066",
"end_idx": "1086",
"entity_id": "D006937",
"entity_type": "Disease",
"text_name": "hypercholesterolemia"
},
{
"begin_idx": "85",
"end_idx": "114",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "259",
"end_idx": "288",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "290",
"end_idx": "292",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "FH"
},
{
"begin_idx": "951",
"end_idx": "953",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "FH"
},
{
"begin_idx": "1125",
"end_idx": "1127",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "FH"
},
{
"begin_idx": "55",
"end_idx": "67",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
},
{
"begin_idx": "85",
"end_idx": "114",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "259",
"end_idx": "288",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "290",
"end_idx": "292",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "FH"
},
{
"begin_idx": "390",
"end_idx": "428",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "low density lipoprotein (LDL) receptor"
},
{
"begin_idx": "951",
"end_idx": "953",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "FH"
},
{
"begin_idx": "1040",
"end_idx": "1052",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
},
{
"begin_idx": "1125",
"end_idx": "1127",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "FH"
},
{
"begin_idx": "1216",
"end_idx": "1228",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "LDL receptor"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "390",
"end_idx": "428",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "low density lipoprotein (LDL) receptor"
},
{
"begin_idx": "1125",
"end_idx": "1127",
"entity_id": "3949",
"entity_type": "Gene",
"text_name": "FH"
}
] | [
{
"begin_idx": "85",
"end_idx": "114",
"entity_id": "D006938",
"entity_type": "Disease",
"text_name": "familial hypercholesterolemia"
},
{
"begin_idx": "1066",
"end_idx": "1086",
"entity_id": "D006937",
"entity_type": "Disease",
"text_name": "hypercholesterolemia"
}
] | [
"low density lipoprotein (LDL) receptor",
"FH"
] | [
"familial hypercholesterolemia",
"hypercholesterolemia"
] |
10447264 | Mutation analysis of iduronate-2-sulphatase gene in 24 patients with Hunter syndrome: characterisation of 6 novel mutations. Mutation in brief no. 249. Online. | Hunter syndrome is a rare, X-linked, recessively inherited disease affecting approximately 1 in 132,000 males. The disease is caused by the inability to degrade dermatan sulphate and heparan sulphate due to mutations in the iduronate-2-sulphatase gene (IDS). The mutations causing the disorder are heterogeneous, ranging from small micro-lesions to gross deletions and inversions. We have screened DNA samples from a panel of 24 unrelated Hunter syndrome patients and have identified mutations in 16 individuals. Six mutations represent novel changes in the gene and these include two single base deletions (1264DC and 1632/3DT); two single base insertions (776/8insC and 1082insT); and two missense mutations--Y264N (914T-->G) and Q465P (1518A-->C). An additional two missense mutations and one splice site alteration identified in this study have been described previously. Southern analysis revealed complete or partial gene deletions in a further 7 patients. | [
{
"begin_idx": "69",
"end_idx": "84",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Hunter syndrome"
},
{
"begin_idx": "160",
"end_idx": "175",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Hunter syndrome"
},
{
"begin_idx": "599",
"end_idx": "614",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Hunter syndrome"
},
{
"begin_idx": "209",
"end_idx": "226",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited disease"
},
{
"begin_idx": "413",
"end_idx": "416",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "413",
"end_idx": "416",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
},
{
"begin_idx": "413",
"end_idx": "416",
"entity_id": "3423",
"entity_type": "Gene",
"text_name": "IDS"
}
] | [
{
"begin_idx": "69",
"end_idx": "84",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "Hunter syndrome"
},
{
"begin_idx": "209",
"end_idx": "226",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited disease"
}
] | [
"IDS",
"IDS"
] | [
"Hunter syndrome",
"inherited disease"
] |
10447266 | Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec[1263del55;1342G>C]] in Spanish Gaucher disease patients. Mutation in brief no. 251. Online. | To study glucocerebrosidase mutations causing Gaucher disease, we have screened 30 apparently unrelated patients for the presence of 7 previous described mutations. N370S (1226A>G) was the most common mutation (43%), followed by L444P (1448T>C) (23%). To identify the other unknown mutations, we screened regions of the glucocerebrosidase gene (GBA), by SSCP and sequencing. These analyses allowed identification of one novel G195W (700G>T), and two rare T134P (517A>C) and G377S (1246G>A) missense mutations. Mutation T134P (517A>C) was present in a type I patient, while G195W (700G>T), was encountered in two patients (types I, and III). The prevalence of mutation G377S (1246G>A), previously undetected in Spain, was found to be high (8%) making it a good candidate for routine genetic screening in patients from Spanish descent. Two null mutations have been identified as well Rec[1263del55;1342G>C], and 1451delAC). The Rec[1263del55;1342G>C] is a novel chimeric allele in which the gene sequence between nucleotides 5878-6272 [sequence numbering according to Horowitz et al.(1989)] has been replaced by the homologous region of the pseudogene, and consequently it carries the 1263del55 and D409H (1342G>C) mutations. The functional equivalence of this allele to a 1263del55 allele previously described, suggest the potencial existence of a group of four distinct 55 bp deletion harboring alleles with identical clinical consequences. | [
{
"begin_idx": "124",
"end_idx": "139",
"entity_id": "D005776",
"entity_type": "Disease",
"text_name": "Gaucher disease"
},
{
"begin_idx": "231",
"end_idx": "246",
"entity_id": "D005776",
"entity_type": "Disease",
"text_name": "Gaucher disease"
},
{
"begin_idx": "530",
"end_idx": "533",
"entity_id": "2629",
"entity_type": "Gene",
"text_name": "GBA"
}
] | [
"Yes"
] | [
false
] | [
{
"begin_idx": "530",
"end_idx": "533",
"entity_id": "2629",
"entity_type": "Gene",
"text_name": "GBA"
}
] | [
{
"begin_idx": "124",
"end_idx": "139",
"entity_id": "D005776",
"entity_type": "Disease",
"text_name": "Gaucher disease"
}
] | [
"GBA"
] | [
"Gaucher disease"
] |
10447268 | Identification of novel mutations in the PCCB gene in European propionic acidemia patients. Mutation in brief no. 253. Online. | Propionyl-CoA carboxylase (PCC) is a biotin-dependent enzyme located in the mitochondrial matrix. Mutations in the PCCA and PCCB genes, which encode the a and b subunits of this heteropolymer, result in propionic acidemia (PA). We report the molecular analysis of b-deficient patients from Spain and Austria. Subjects were screened for defects affecting the PCCB gene by direct sequencing from genomic PCR products, restriction digests and mRNA analysis by RT-PCR. Study by western blot of the presence of immunoreactive b-PCC protein was also performed. A total of four novel sequence variations were found including the point mutations V205D, and M442T, and the frameshift mutation 790-791insG. Additionally, a new point change, L17M, was identified on the same allele as 790-791insG. The missense changes described above were not found in at least 40 control chromosomes analyzed. The Austrian patients were homozygous for V205D. One of the Spanish subjects was heterozygous for M442T and the known mutation c1170insT. The other Spanish patient carried L17M+790-791insG on one allele, and the described mutation E168K on the other mutant chromosome. The mutations V205D and M442T were confirmed at RNA level and also we have detected the presence of immunoreactive b-PCC protein translated from these mutant alleles. The patient having L17M+790-791insG and E168K also presented immunoreactive b-PCC protein. However, no cDNA product was obtained from the chromosome carrying L17M+790-791insG. We propose that 790-791insG, which causes a frameshift and a premature stop codon, is responsible for this finding. In any case, the translation from this mutant cDNA would produce a severity truncated peptide and, in consequence, a non-functional protein. Expression analysis of all these changes will help us to clarify their structural/functional consequences. | [
{
"begin_idx": "391",
"end_idx": "402",
"entity_id": "C535600",
"entity_type": "Disease",
"text_name": "b-deficient"
},
{
"begin_idx": "63",
"end_idx": "81",
"entity_id": "D056693",
"entity_type": "Disease",
"text_name": "propionic acidemia"
},
{
"begin_idx": "330",
"end_idx": "348",
"entity_id": "D056693",
"entity_type": "Disease",
"text_name": "propionic acidemia"
},
{
"begin_idx": "350",
"end_idx": "352",
"entity_id": "D056693",
"entity_type": "Disease",
"text_name": "PA"
},
{
"begin_idx": "242",
"end_idx": "246",
"entity_id": "5095",
"entity_type": "Gene",
"text_name": "PCCA"
},
{
"begin_idx": "41",
"end_idx": "45",
"entity_id": "5096",
"entity_type": "Gene",
"text_name": "PCCB"
},
{
"begin_idx": "251",
"end_idx": "255",
"entity_id": "5096",
"entity_type": "Gene",
"text_name": "PCCB"
},
{
"begin_idx": "485",
"end_idx": "489",
"entity_id": "5096",
"entity_type": "Gene",
"text_name": "PCCB"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "41",
"end_idx": "45",
"entity_id": "5096",
"entity_type": "Gene",
"text_name": "PCCB"
},
{
"begin_idx": "242",
"end_idx": "246",
"entity_id": "5095",
"entity_type": "Gene",
"text_name": "PCCA"
}
] | [
{
"begin_idx": "63",
"end_idx": "81",
"entity_id": "D056693",
"entity_type": "Disease",
"text_name": "propionic acidemia"
},
{
"begin_idx": "63",
"end_idx": "81",
"entity_id": "D056693",
"entity_type": "Disease",
"text_name": "propionic acidemia"
}
] | [
"PCCB",
"PCCA"
] | [
"propionic acidemia",
"propionic acidemia"
] |
10447527 | A paired-sibling analysis of the XbaI polymorphism in the muscle glycogen synthase gene. | AIMS/HYPOTHESIS: We have previously shown an association between a XbaI polymorphism in the muscle glycogen synthase gene (GYS1) and both Type II (non-insulin-dependent) diabetes mellitus and hypertension. Association studies are, however, hampered by the selection of the control group. To circumvent these problems we addressed the same question using a novel genotype discordant paired-sibling approach. METHODS: We identified 122 sex-matched sib-pairs discordant for the Xba1 polymorphism among a new set of 743 Finnish subjects from 227 families with Type II diabetes and paired analyses were done by McNemar test of symmetry and by permutation tests. RESULTS: Paired analysis showed that siblings with the A2 variant had more hypertension (p = 0.0067), obesity (p = 0.033) and microalbuminuria (p = 0.031) but not significantly more Type II diabetes (p = 0.27) than siblings with the A1 variant. Siblings with the A2 variant were more often treated by insulin (p = 0.050) or anti-hypertensive medication (p = 0.0060) or both. Diabetic A2 variant carriers had higher triglyceride (p = 0.023) and lower HDL cholesterol (p = 0.0059) concentrations and an earlier age at onset of diabetes (p = 0.022) than diabetic siblings with the A1 variant. In non-diabetic sib-pairs the presence of the A2 variant was associated with higher diastolic (p = 0.0014) blood pressure. Finally, the allele frequency of the XbaI polymorphism differed between 216 randomly chosen unrelated Type II diabetic patients and 115 unrelated healthy control spouses without a family history of Type II diabetes (12.7 vs. 6.5 %, p = 0.013). CONCLUSION/INTERPRETATION: The A2 allele of the XbaI polymorphism in the GYS1 confers an increased susceptibility to different features of the metabolic syndrome and Type II diabetes. | [
{
"begin_idx": "1121",
"end_idx": "1132",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "Diabetic A2"
},
{
"begin_idx": "1271",
"end_idx": "1279",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetes"
},
{
"begin_idx": "1297",
"end_idx": "1305",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
},
{
"begin_idx": "1343",
"end_idx": "1351",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
},
{
"begin_idx": "1569",
"end_idx": "1577",
"entity_id": "D003920",
"entity_type": "Disease",
"text_name": "diabetic"
},
{
"begin_idx": "227",
"end_idx": "276",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II (non-insulin-dependent) diabetes mellitus"
},
{
"begin_idx": "645",
"end_idx": "661",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "928",
"end_idx": "944",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "1657",
"end_idx": "1673",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "1869",
"end_idx": "1885",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II diabetes"
},
{
"begin_idx": "281",
"end_idx": "293",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "821",
"end_idx": "833",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "1075",
"end_idx": "1087",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "1846",
"end_idx": "1864",
"entity_id": "D008659",
"entity_type": "Disease",
"text_name": "metabolic syndrome"
},
{
"begin_idx": "848",
"end_idx": "855",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obesity"
},
{
"begin_idx": "212",
"end_idx": "216",
"entity_id": "2997",
"entity_type": "Gene",
"text_name": "GYS1"
},
{
"begin_idx": "1776",
"end_idx": "1780",
"entity_id": "2997",
"entity_type": "Gene",
"text_name": "GYS1"
},
{
"begin_idx": "1047",
"end_idx": "1054",
"entity_id": "3630",
"entity_type": "Gene",
"text_name": "insulin"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "212",
"end_idx": "216",
"entity_id": "2997",
"entity_type": "Gene",
"text_name": "GYS1"
},
{
"begin_idx": "1776",
"end_idx": "1780",
"entity_id": "2997",
"entity_type": "Gene",
"text_name": "GYS1"
}
] | [
{
"begin_idx": "227",
"end_idx": "276",
"entity_id": "D003924",
"entity_type": "Disease",
"text_name": "Type II (non-insulin-dependent) diabetes mellitus"
},
{
"begin_idx": "848",
"end_idx": "855",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obesity"
}
] | [
"GYS1",
"GYS1"
] | [
"Type II (non-insulin-dependent) diabetes mellitus",
"obesity"
] |
10447650 | Leber's hereditary optic neuropathy: clinical and molecular genetic findings in a patient with a new mutation in the ND6 gene. | BACKGROUND: Leber's hereditary optic neuropathy (LHON) is a maternally inherited ocular disease associated with mutations in the mitochondrial DNA (mtDNA). We describe the clinical and molecular genetic findings in a LHON patient and his family with a new mtDNA mutation at np14568 in the ND6 gene. METHODS: Ophthalmological examination was performed in one affected male and two maternal relatives. Direct sequence analysis of the complete mtDNA protein coding region was initiated in the affected patient. Four unaffected maternal relatives also underwent molecular genetic evaluation. RESULTS: Clinical examination of the affected male showed typical features of LHON. In his unaffected mother slight peripapillary microangiopathy was found. Molecular analysis did not show any of the common LHON mutations. A nucleotide exchange was detected at position 14568 replacing a glycine by serine in the ND6 gene. This mutation was the only new mutation found within the entire protein and tRNA coding region of the patient's mitochondrial genome. This novel mutation was also present in four non-affected maternal family members, but absent in 60 other LHON lineages and 175 unrelated controls. CONCLUSION: The new mutation at nucleotide position 14568 lies in the close vicinity of other LHON-related mutations (np14459, np14484, np14498, np14596) within the evolutionarily most conserved region of the ND6 gene. Since no other mutation was detected throughout the mtDNA coding region and the new alteration was excluded in controls, our clinical and molecular genetic findings suggest that the novel point mutation at np14568 is responsible for LHON in this family. | [
{
"begin_idx": "208",
"end_idx": "222",
"entity_id": "D005128",
"entity_type": "Disease",
"text_name": "ocular disease"
},
{
"begin_idx": "831",
"end_idx": "860",
"entity_id": "D014652",
"entity_type": "Disease",
"text_name": "peripapillary microangiopathy"
},
{
"begin_idx": "0",
"end_idx": "35",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "Leber's hereditary optic neuropathy"
},
{
"begin_idx": "139",
"end_idx": "174",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "Leber's hereditary optic neuropathy"
},
{
"begin_idx": "176",
"end_idx": "180",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "344",
"end_idx": "348",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "793",
"end_idx": "797",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "922",
"end_idx": "926",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "1278",
"end_idx": "1282",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "1414",
"end_idx": "1418",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "1772",
"end_idx": "1776",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "LHON"
},
{
"begin_idx": "117",
"end_idx": "120",
"entity_id": "4541",
"entity_type": "Gene",
"text_name": "ND6"
},
{
"begin_idx": "416",
"end_idx": "419",
"entity_id": "4541",
"entity_type": "Gene",
"text_name": "ND6"
},
{
"begin_idx": "1028",
"end_idx": "1031",
"entity_id": "4541",
"entity_type": "Gene",
"text_name": "ND6"
},
{
"begin_idx": "1529",
"end_idx": "1532",
"entity_id": "4541",
"entity_type": "Gene",
"text_name": "ND6"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "117",
"end_idx": "120",
"entity_id": "4541",
"entity_type": "Gene",
"text_name": "ND6"
},
{
"begin_idx": "416",
"end_idx": "419",
"entity_id": "4541",
"entity_type": "Gene",
"text_name": "ND6"
}
] | [
{
"begin_idx": "0",
"end_idx": "35",
"entity_id": "D029242",
"entity_type": "Disease",
"text_name": "Leber's hereditary optic neuropathy"
},
{
"begin_idx": "208",
"end_idx": "222",
"entity_id": "D005128",
"entity_type": "Disease",
"text_name": "ocular disease"
}
] | [
"ND6",
"ND6"
] | [
"Leber's hereditary optic neuropathy",
"ocular disease"
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.